



(51) International Patent Classification:

C07D 213/74 (2006.01) *C07D 231/12* (2006.01)
C07D 239/42 (2006.01) *A61K 31/44* (2006.01)
C07D 249/06 (2006.01) *A61K 31/506* (2006.01)
C07D 271/07 (2006.01) *A61P 25/18* (2006.01)

(21) International Application Number:

PCT/GB2015/050480

(22) International Filing Date:

19 February 2015 (19.02.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

14156011.0 20 February 2014 (20.02.2014) EP

(71) Applicant (for MG only): **TAKEDA CAMBRIDGE LIMITED** [GB/GB]; 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0PA (GB).

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-Chome, Chou-Ku, Osaka-Shi, Osaka 541-0045 (JP).

(72) Inventors: **FIELDHOUSE, Charlotte**; c/o Takeda Cambridge Limited, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0PA (GB). **GLEN, Angela**; c/o Takeda Cambridge Limited, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0PA (GB). **MAINE, Stephanie**; c/o Takeda Cambridge Limited, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0PA (GB). **FUJIMOTO, Tatsuhiko**; c/o Takeda Pharmaceutical Company Limited, Shonan Research Center, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555 (JP). **ROBINSON, John Stephen**; c/o Takeda Cambridge

Limited, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0PA (GB).

(74) Agents: **JOHNSON, Stephen** et al.; Venner Shipley LLP, Byron House, Cambridge Business Park, Cowley Road, Cambridge Cambridgeshire CB4 0WZ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS



(57) Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L, X, R^a, R^b, R¹, R² and R³ are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to amide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

The orexin peptides (orexin A and orexin B, OxA and OxB), also known as hypocretins, were discovered in 1998 by two groups (Sakurai *et al.*, *Cell*, **1998**, 92, 573 and De Lecea *et al.*, *Proc. Nat. Acad. Sci.*, **1998**, 95, 322). These neuropeptides are both derived from the common precursor pre-pro-orexin and are produced in the lateral hypothalamus. OxA is a 33 amino acid residue which has similar potency at both the Ox1R (orexin 1 receptors) and Ox2R (orexin 2 receptors) whereas OxB is made up of 28 amino acids and binds selectively to the Ox2R.


Orexin receptors are believed to be implicated in both feeding behaviour (Sakurai *et al.*, *Cell*, **1998**, 92, 573) and also in regulating sleep architecture (Chemelli *et al.*, *Cell*, **1999**, 98, 437). More recently, it has been shown that orexin receptors are implicated in arousal, reward, learning and memory (Harris *et al.*, *Trends Neurosci.*, **2006**, 29, 571).

WO 2003/099276 describes a broad class of compounds, including certain amides, which are useful as factor Xa inhibitors for treating thromboembolic disorders.

We have now discovered a class of compounds that are orexin receptor antagonists.

Furthermore, certain compounds of the invention show selectivity for the orexin 1 receptor over the orexin 2 receptor.

In accordance with the present invention, there is therefore provided a compound of formula



wherein

R^1 represents a 5- or 6-membered heteroaryl group optionally substituted by at least one substituent independently selected from halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkoxycarbonyl, C₁-C₃ alkoxycarbonylamino, C₁-C₃ haloalkyl, C₁-C₃ haloalkoxy, -NR⁴R⁵, C₃-C₆ cycloalkylamino, C₁-C₃ alkylcarbonyloxy, C₁-C₃ alkylcarbonylamino, sulphonamido (-SO₂NH₂), C₁-C₃ alkylsulphonyl, C₁-C₃ alkylsulphonylamino and -C(O)NR⁶R⁷;

L represents a bond, CH₂, O or NR¹²;

R^a represents a hydrogen atom or a C₁-C₃ alkyl or C₁-C₃ haloalkyl group;

R^b represents a hydrogen atom or a C₁-C₃ alkyl or C₁-C₃ haloalkyl group;

X represents CH₂, CHF or CF₂;

R^2 represents a hydrogen atom or a C₁-C₆ alkyl or C₃-C₆ cycloalkyl group;

R^3 represents a phenyl group or a 5- or 6-membered heteroaryl group, all optionally substituted by at least one substituent independently selected from halogen, hydroxyl, cyano, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ hydroxyalkyl, C₁-C₃ alkoxy, C₁-C₃ haloalkoxy, C₂-C₄ alkenyl, C₁-C₃ alkylcarbonyloxy, C₁-C₃ alkoxycarbonyl, -NR⁸R⁹, -C(O)NR¹⁰R¹¹, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyloxy,

C₃-C₆ cycloalkylmethyl or a 5- or 6-membered heteroaryl group, the heteroaryl group itself being optionally substituted by at least one substituent independently selected from C₁-C₆ alkyl, C₁-C₆ alkoxy and C₁-C₆ haloalkoxy;

R^4 and R^5 each independently represent a hydrogen atom or a C_1 - C_3 alkyl or C_3 - C_6 cycloalkyl group, or R^4 and R^5 may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring optionally substituted by at least one substituent independently selected from halogen, hydroxyl and C_1 - C_3 alkoxy;

5 R^6 and R^7 each independently represent a hydrogen atom or a C_1 - C_3 alkyl or C_3 - C_6 cycloalkyl group, or R^6 and R^7 may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring optionally substituted by at least one substituent independently selected from halogen and hydroxyl;

R^8 and R^9 each independently represent a hydrogen atom or a C_1 - C_3 alkyl or C_3 - C_6 cycloalkyl group, or R^8 and R^9 may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring optionally substituted by at least one substituent independently selected from halogen, hydroxyl and C_1 - C_3 alkoxy;

10 R^{10} and R^{11} each independently represent a hydrogen atom or a C_1 - C_3 alkyl or C_3 - C_6 cycloalkyl group, or R^{10} and R^{11} may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring optionally substituted by at least one substituent independently selected from halogen and hydroxyl; and

R^{12} represents a hydrogen atom, methyl group or a C_2 - C_3 alkylene chain that links to R^1 to form a 5- or 6-membered ring;

20 or a pharmaceutically acceptable salt thereof.

In the context of the present specification, unless otherwise stated, an "alkyl" substituent group or an alkyl moiety in a substituent group may be linear or branched. Examples of C_1 - C_8 alkyl groups/moieties include methyl, ethyl, propyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-

butyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl and n-octyl.

An “alkenyl” substituent group or an alkenyl moiety in a substituent group refers to an unsaturated alkyl group having one or more double bonds. Examples of C₂-C₆ alkenyl groups/moieties include ethenyl, propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 1-hexenyl, 1,3-butadienyl, 1,3-pentadienyl, 1,4-pentadienyl and 1,4-hexadienyl.

A “cycloalkyl” substituent group/moiety is a saturated hydrocarbyl ring containing, for example, from 3 to 8 carbon atoms, examples of which include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

A “haloalkyl” or “haloalkoxy” substituent group/moiety comprises at least one halogen atom, e.g. one, two, three, four or five halogen atoms. Examples of C₁-C₆ haloalkyl and C₁-C₆ haloalkoxy groups/moieties include fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, fluoromethoxy, difluoromethoxy and trifluoromethoxy.

It will be understood that if R⁴ and R⁵ together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring, the heterocyclic ring may contain one or more (e.g. one or two) further ring heteroatoms (e.g. nitrogen, oxygen or sulphur atoms) in addition to the nitrogen atom to which R⁴ and R⁵ are attached.

However, it will be appreciated that the invention does not encompass any unstable ring structures or any O-O, O-S or S-S bonds. If a substituent is present on the ring, it may be attached to any suitable ring atom. Examples of such heterocyclic rings include azetidiny, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, 1,4-azathianyl, azepanyl and 1,4-oxaazepanyl moieties. Similar comments apply with respect to R⁶ and R⁷, R⁸ and R⁹, and R¹⁰ and R¹¹ when they form a 4- to 7-membered saturated heterocyclic ring.

A "heteroaryl" group is a 5- or 6-membered aryl group in which from 1 to 4 ring carbon atoms are replaced by heteroatoms independently selected from nitrogen, oxygen and sulphur. The heteroaryl group can be bonded at any suitable ring atom (i.e. at any carbon or heteroatom of the heteroaryl ring system).

5

When any chemical moiety or group in formula (I) is described as being optionally substituted, it will be appreciated that the moiety or group may be either unsubstituted or substituted by one or more of the specified substituents. It will be appreciated that the number and nature of substituents will be selected so as to avoid sterically undesirable combinations.

10

R^1 represents a 5- or 6-membered heteroaryl group optionally substituted by at least one substituent, e.g. one, two, three or four substituents, independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), cyano, hydroxyl, C_3 - C_6 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), C_1 , C_2 or C_3 alkyl, C_1 , C_2 or C_3 alkoxy, C_1 , C_2 or C_3 alkoxycarbonyl, C_1 , C_2 or C_3 alkoxycarbonylamino, C_1 , C_2 or C_3 haloalkyl, C_1 , C_2 or C_3 haloalkoxy, $-NR^4R^5$, C_3 - C_6 cycloalkylamino (cyclopropylamino, cyclobutylamino, cyclopentylamino or cyclohexylamino), C_1 , C_2 or C_3 alkylcarbonyloxy, C_1 , C_2 or C_3 alkylcarbonylamino, sulphonamido, C_1 , C_2 or C_3 alkylsulphonyl, C_1 , C_2 or C_3 alkylsulphonylamino and $-C(O)NR^6R^7$.

15

20

R^1 represents a 5- or 6-membered heteroaryl group. This R^1 heteroaryl group comprises one or more, e.g. one, two, three or four, ring heteroatoms independently selected from nitrogen, oxygen and sulphur. Examples of such 5- or 6-membered monocyclic heteroaromatic groups include pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furyl, furazanyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl and tetrazinyl.

25

In an embodiment of the invention, R^1 represents a 5- or 6-membered heteroaryl group containing one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur (such as pyridinyl, pyrimidinyl and pyrazinyl), the heteroaryl group being optionally substituted by at least one substituent, e.g. one, two, three or four substituents, independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), cyano, hydroxyl, C₃-C₆ cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), C₁, C₂ or C₃ alkyl, C₁, C₂ or C₃ alkoxy, C₁, C₂ or C₃ alkoxycarbonyl, C₁, C₂ or C₃ alkoxycarbonylamino, C₁, C₂ or C₃ haloalkyl, C₁, C₂ or C₃ haloalkoxy, $-NR^4R^5$, C₃-C₆ cycloalkylamino (cyclopropylamino, cyclobutylamino, cyclopentylamino or cyclohexylamino), C₁, C₂ or C₃ alkylcarbonyloxy, C₁, C₂ or C₃ alkylcarbonylamino, sulphonamido, C₁, C₂ or C₃ alkylsulphonyl, C₁, C₂ or C₃ alkylsulphonylamino and $-C(O)NR^6R^7$.

In another embodiment, R^1 represents a 5- or 6-membered heteroaryl group containing one or two ring heteroatoms independently selected from nitrogen and oxygen (such as pyridinyl, pyrimidinyl and pyrazinyl), the heteroaryl group being optionally substituted by one, two, three or four substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁, C₂ or C₃ alkyl, C₁, C₂ or C₃ alkoxy, C₁, C₂ or C₃ alkoxycarbonyl, C₁, C₂ or C₃ alkoxycarbonylamino, C₁, C₂ or C₃ haloalkyl, C₁, C₂ or C₃ haloalkoxy, $-NR^4R^5$, C₅-C₆ cycloalkylamino, C₁, C₂ or C₃ alkylcarbonyloxy, C₁, C₂ or C₃ alkylcarbonylamino, sulphonamido, C₁, C₂ or C₃ alkylsulphonyl, C₁, C₂ or C₃ alkylsulphonylamino and $-C(O)NR^6R^7$.

In a further embodiment, R^1 represents a 6-membered heteroaryl group containing as the only ring heteroatoms one or two ring nitrogen atoms (such as pyridinyl, pyrimidinyl and pyrazinyl), the heteroaryl group being optionally substituted by one, two, three or four (particularly one or two) substituents independently selected from halogen (particularly

fluorine, chlorine and bromine), cyclopropyl, C₁, C₂ or C₃ alkyl (particularly methyl, ethyl and isopropyl), C₁, C₂ or C₃ alkoxy (particularly methoxy), C₁, C₂ or C₃ haloalkyl (particularly trifluoromethyl) and C₁, C₂ or C₃ haloalkoxy (particularly trifluoromethoxy).

- 5 In a still further embodiment, R¹ represents any one of the following moieties or is selected from a group containing two or more of such moieties in any combination:
- (i) 4-(trifluoromethyl)pyridin-2-yl,
 - (ii) 5-(trifluoromethyl)pyridin-2-yl,
 - (iii) 5-(trifluoromethoxy)pyridin-2-yl,
 - 10 (iv) 6-(trifluoromethyl)pyridin-2-yl,
 - (v) 6-(trifluoromethyl)pyridin-3-yl,
 - (vi) 5-chloropyridin-2-yl,
 - (vii) 5-bromopyridin-2-yl,
 - (viii) 3-fluoro-5-(trifluoromethyl)pyridin-2-yl,
 - 15 (ix) 3-chloro-5-(trifluoromethyl)pyridin-2-yl,
 - (x) 3-bromo-5-(trifluoromethyl)pyridin-2-yl,
 - (xi) 5-bromo-3-methoxypyridin-2-yl,
 - (xii) 3-methyl-5-(trifluoromethyl)pyridin-2-yl,
 - (xiii) 5-(trifluoromethyl)pyrimidin-2-yl,
 - 20 (xiv) 5-ethylpyrimidin-2-yl,
 - (xv) 5-(trifluoromethyl)pyrazin-2-yl,
 - (xvi) 5-chloropyrazin-2-yl,
 - (xvii) 5-(ethyl)pyrazin-2-yl,
 - (xviii) 5-(cyclopropyl)pyrazin-2-yl,
 - 25 (xix) 5-(isopropyl)pyrazin-2-yl,
 - (xx) 3-methyl-5-(trifluoromethyl)pyrazin-2-yl,
 - (xxi) 3-ethyl-5-(trifluoromethyl)pyrazin-2-yl,
 - (xxii) 3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl, and
 - (xxiii) 3-isopropyl-5-(trifluoromethyl)pyrazin-2-yl.

In one embodiment, R^1 represents a mono-substituted 6-membered heteroaryl group, the substituent being preferably attached in the para-position relative to the point of attachment of the moiety -L-, or, the five-membered ring in the case where the moiety -L- represents a bond.

5

In an embodiment of the invention, L represents CH_2 , O or NR^{12} .

In a further embodiment, L represents NR^{12} .

10 R^a and R^b each independently represent a hydrogen atom or a C_1 , C_2 or C_3 alkyl or C_1 , C_2 or C_3 haloalkyl group.

In one embodiment, R^a and R^b each represent a hydrogen atom.

15 In another embodiment, one of R^a and R^b represents a hydrogen atom and the other of R^a and R^b represents a C_1 alkyl (i.e. methyl) or haloalkyl (e.g. trifluoromethyl) group.

In a further embodiment, R^a represents a hydrogen atom or a methyl group and R^b represents a hydrogen atom.

20

X represents CH_2 , CHF or CF_2 .

In one embodiment, X represents CH_2 .

25 R^2 represents a hydrogen atom or a C_1 - C_6 , or C_1 - C_4 , or C_1 - C_2 alkyl or C_3 - C_6 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) group.

In one embodiment, R^2 represents a hydrogen atom or C_3 - C_6 cycloalkyl group.

In another embodiment, R^2 represents a hydrogen atom.

R^3 represents a phenyl group or a 5- or 6-membered heteroaryl group, all optionally

- 5 substituted by at least one substituent, e.g. one, two, three or four substituents, independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, cyano, C_1 , C_2 or C_3 alkyl, C_1 , C_2 or C_3 haloalkyl, C_1 , C_2 or C_3 hydroxyalkyl, C_1 , C_2 or C_3 alkoxy, C_1 , C_2 or C_3 haloalkoxy, C_2 , C_3 or C_4 alkenyl, C_1 , C_2 or C_3 alkylcarbonyloxy, C_1 , C_2 or C_3 alkoxycarbonyl, $-NR^8R^9$, $-C(O)NR^{10}R^{11}$,
 10 C_3 - C_6 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), C_3 - C_6 cycloalkyloxy (cyclopropyloxy, cyclobutyloxy, cyclopentyloxy or cyclohexyloxy), C_3 - C_6 cycloalkylmethyl (cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl or cyclohexylmethyl) or a 5- or 6-membered heteroaryl group, the heteroaryl group itself being optionally substituted by at least one substituent, e.g. one, two, three or four
 15 substituents, independently selected from C_1 - C_6 , or C_1 - C_4 , or C_1 - C_2 alkyl, C_1 - C_6 , or C_1 - C_4 , or C_1 - C_2 alkoxy and C_1 - C_6 , or C_1 - C_4 , or C_1 - C_2 haloalkoxy.

- R^3 represents a phenyl group or a 5- or 6-membered heteroaryl group. This R^3 heteroaryl group comprises one or more, e.g. one, two, three or four, ring heteroatoms independently
 20 selected from nitrogen, oxygen and sulphur. Examples of such 5- or 6-membered heteroaryl groups include pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furyl, furazanyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl and tetrazinyl.

- 25 The R^3 phenyl or heteroaryl group may optionally be substituted with at least one 5- or 6-membered heteroaryl substituent group. The “heteroaryl” substituent group, as used in this context, comprises a total of 5 or 6 ring atoms, of which one, two, three or four ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulphur atoms.

Examples of such heteroaryl substituent groups include pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furyl, furazanyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl and tetrazinyl.

5

In an embodiment of the invention, R^3 represents a phenyl group or a 5- or 6-membered heteroaryl group containing one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur (such as pyridinyl, pyrimidinyl and pyrazinyl), all optionally substituted by at least one substituent, e.g. one, two, three or four substituents,

10

independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, cyano, C_1 , C_2 or C_3 alkyl, C_1 , C_2 or C_3 haloalkyl, C_1 , C_2 or

C_3 hydroxyalkyl, C_1 , C_2 or C_3 alkoxy, C_1 , C_2 or C_3 haloalkoxy, C_2 , C_3 or C_4 alkenyl,

C_1 , C_2 or C_3 alkylcarbonyloxy, C_1 , C_2 or C_3 alkoxycarbonyl, $-NR^8R^9$, $-C(O)NR^{10}R^{11}$,

C_3 - C_5 cycloalkyl, C_3 - C_5 cycloalkyloxy, C_3 - C_5 cycloalkylmethyl or a 5- or 6-membered

15

heteroaryl group (such as triazolyl, pyrazolyl, oxadiazolyl, pyrimidinyl and imidazolyl), the heteroaryl group itself being optionally substituted by at least one substituent, e.g. one, two, three or four substituents, independently selected from C_1 - C_6 , or C_1 - C_4 , or

C_1 - C_2 alkyl, C_1 - C_6 , or C_1 - C_4 , or C_1 - C_2 alkoxy and C_1 - C_6 , or C_1 - C_4 , or

C_1 - C_2 haloalkoxy.

20

In another embodiment, R^3 represents a phenyl group or a 5- or 6-membered heteroaryl group containing one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur (such as pyridinyl, pyrimidinyl and pyrazinyl), all optionally substituted by at least one substituent, e.g. one, two, three or four substituents,

25

independently selected from fluorine, chlorine, bromine, C_1 , C_2 or C_3 alkyl, C_1 , C_2 or C_3 haloalkyl, C_1 , C_2 or C_3 alkoxy, C_1 , C_2 or C_3 haloalkoxy, cyclopropyl, $-NR^8R^9$ (e.g. piperidinyl), or a 5- or 6-membered heteroaryl group (such as triazolyl, pyrazolyl, oxadiazolyl, pyrimidinyl and imidazolyl), the heteroaryl group itself being optionally

substituted by at least one substituent, e.g. one, two, three or four substituents,
independently selected from C₁-C₂ alkyl, C₁-C₂ alkoxy and C₁-C₂ haloalkoxy.

In a further embodiment, R³ represents a phenyl group optionally substituted by one, two
5 or three (particularly one or two) substituents independently selected from fluorine,
chlorine, C₁, C₂ or C₃ alkyl, C₁, C₂ or C₃ alkoxy or a 5- or 6-membered heteroaryl
group (such as triazolyl, pyrazolyl, oxadiazolyl and pyrimidinyl), the heteroaryl group
itself being optionally substituted by one or two substituents independently selected from
C₁-C₂ alkyl, C₁-C₂ alkoxy and C₁-C₂ haloalkoxy, preferably methyl.

10 In a still further embodiment, R³ represents any one of the following moieties or is selected
from a group containing two or more of such moieties in any combination:

- (i) 2-fluorophenyl,
- (ii) 2-chlorophenyl,
- 15 (iii) 2-methylphenyl,
- (iv) 2-cyclopropylphenyl,
- (v) 2-methoxyphenyl,
- (vi) 2-ethoxyphenyl,
- (vii) 2-(difluoromethoxy)phenyl,
- 20 (viii) 3-methylphenyl,
- (ix) 3-methoxyphenyl,
- (x) 2,6-difluorophenyl,
- (xi) 2,6-dichlorophenyl,
- (xii) 2,6-dimethoxyphenyl,
- 25 (xiii) 2,6-diethoxyphenyl,
- (xiv) 2-ethoxy-5-methylphenyl,
- (xv) 2,5-dimethoxyphenyl,
- (xvi) 2-fluoro-6-methoxyphenyl,
- (xvii) 5-fluoro-2-methoxyphenyl,
- 30 (xviii) 3-fluoro-2-methoxyphenyl,
- (xix) 2-(1*H*-1,2,4-triazol-1-yl)phenyl,

- (xx) 2-(2*H*-1,2,3-triazol-2-yl)phenyl,
(xxi) 5-methyl-2-(1*H*-1,2,3-triazol-1-yl)phenyl,
(xxii) 5-methyl-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
(xxiii) 5-fluoro-2-(1*H*-1,2,3-triazol-1-yl)phenyl,
5 (xxiv) 5-fluoro-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
(xxv) 2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl,
(xxvi) 2-(pyrimidin-2-yl)phenyl,
(xxvii) 5-fluoro-2-(pyrimidin-2-yl)phenyl,
(xxviii) 2-(1*H*-pyrazol-1-yl)phenyl,
10 (xxix) 2-(1*H*-imidazol-1-yl)phenyl,
(xxx) 2-(1*H*-1,2,3-triazol-1-yl)phenyl,
(xxxi) 2-(pyrimidin-2-yl)-5-fluorophenyl,
(xxxii) 2-fluoro-6-(2*H*-1,2,3-triazol-2-yl)phenyl,
(xxxiii) 2-methoxy-5-methylphenyl,
15 (xxxiv) 2-chloro-6-(2*H*-1,2,3-triazol-2-yl)phenyl,
(xxxv) 2-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl,
(xxxvi) 5-trifluoromethyl-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
(xxxvii) 2-fluoro-6-(pyrazol-1-yl)phenyl,
(xxxviii) 5-fluoro-2-(pyrazol-1-yl)phenyl,
20 (xxxix) 5-methyl-2-(pyrazol-1-yl)phenyl,
(xl) 2-bromo-6-methoxyphenyl,
(xli) 2-methoxy-6-(pyrazol-1-yl)phenyl,
(xlii) 5-chloro-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
(xliii) 3-fluoro-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
25 (xliv) 5-trifluoromethyl-2-(1*H*-1,2,3-triazol-1-yl)phenyl,
(xlv) 5-chloro-2-(1*H*-1,2,3-triazol-1-yl)phenyl,
(xlvi) 2,3-difluoro-6-(2*H*-1,2,3-triazol-2-yl)phenyl,
(xlvii) 5-cyclopropyl-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
(xlviii) 5-chloro-2-(pyrazol-1-yl)phenyl,
30 (xlix) 3,5-difluoro-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
(l) 2-(difluoromethyl)phenyl,
(li) 2-(trifluoromethyl)phenyl,

- (lii) 3,6-difluoro-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
- (liii) 2-cyclopropyl-6-fluorophenyl,
- (liv) 2-(5-ethoxypyrimidin-2-yl)phenyl,
- (lv) 3-(pyrimidin-2-yl)pyridin-2-yl,
- 5 (lvi) 3-ethoxy-6-methylpyridin-2-yl,
- (lvii) 3-(pyrazol-1-yl)pyridin-2-yl,
- (lviii) 3-(piperidin-1-yl)pyridin-2-yl,
- (lix) 3-(trifluoromethoxy)pyridin-2-yl,
- (lx) 3-(ethoxy)pyridin-2-yl,
- 10 (lxi) 3-(cyclopropyl)pyridin-2-yl,
- (lxii) 3-chloropyridin-2-yl,
- (lxiii) 3-bromopyridin-2-yl,
- (lxiv) 3-methoxypyridin-2-yl,
- (lxv) 3-(propan-2-yloxy)pyridin-2-yl,
- 15 (lxvi) 6-bromo-3-methoxypyridin-2-yl,
- (lxvii) 3-methoxy-6-methylpyridin-2-yl, and
- (lxviii) 3-(2*H*-1,2,3-triazol-2-yl)pyridin-2-yl.

- In a still further embodiment, when R³ represents a substituted phenyl group or a
- 20 substituted 5- or 6-membered heteroaryl group (such as pyridinyl, pyrimidinyl and pyrazinyl), the substituent(s) is/are independently any one of the following moieties or is/are independently selected from a group containing two or more of such moieties in any combination:
- (i) methyl,
 - 25 (ii) methoxy,
 - (iii) ethoxy,
 - (iv) isopropyloxy,
 - (v) difluoromethoxy,
 - (vi) trifluoromethoxy,
 - 30 (vii) fluorine,
 - (viii) chlorine,
 - (ix) bromine,

- (x) difluoromethyl,
- (xi) trifluoromethyl,
- (xii) piperidinyl (e.g. piperidin-1-yl),
- (xiii) triazolyl (e.g. 1,2,3-triazol-2-yl, 1,2,3-triazol-1-yl or 1,2,4-triazol-1-yl),
- 5 (xiv) pyrazolyl (e.g. pyrazol-1-yl),
- (xv) oxadiazolyl,
- (xvi) 3-methyl-1,2,4-oxadiazol-5-yl,
- (xvii) 5-methyl-1,3,4-oxadiazol-2-yl,
- (xviii) pyrimidinyl (e.g. pyrimidin-2-yl),
- 10 (xix) 5-ethoxypyrimidin-2-yl,
- (xx) imidazolyl (e.g. imidazol-1-yl), and
- (xxi) cyclopropyl.

When R^3 represents a substituted phenyl group or a substituted 6-membered heteroaryl group, the substituent(s) is/are preferably attached in the ortho- and/or meta-positions relative to the point of attachment of the amide moiety, $-NR^2C(O)-$.

R^4 and R^5 each independently represent a hydrogen atom or a C_1 , C_2 or C_3 alkyl or C_3 - C_6 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) group, or R^4 and R^5 may together with the nitrogen atom to which they are attached form a 4-, 5-, 6- or 7-membered saturated heterocyclic ring optionally substituted by at least one substituent, e.g. one or two substituents independently, selected from halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl and C_1 , C_2 or C_3 alkoxy.

In one aspect, the saturated heterocyclic ring may contain a single ring heteroatom (being the nitrogen atom to which R^4 and R^5 are attached).

In an alternative aspect, the saturated heterocyclic ring may contain a second ring heteroatom selected from a nitrogen or oxygen atom.

In one embodiment, R^4 and R^5 each independently represent a hydrogen atom or a C_1 , C_2 or C_3 alkyl or C_3 - C_6 or C_3 - C_5 or C_5 - C_6 cycloalkyl, particularly cyclopropyl, group, or R^4 and R^5 may together with the nitrogen atom to which they are attached form a 4- or 5-membered saturated heterocyclic ring optionally substituted by one or two substituents independently selected from fluorine, chlorine, bromine, hydroxyl and methoxy.

In a second embodiment, R^4 and R^5 each represent a hydrogen atom.

10 In a third embodiment, R^4 and R^5 each represent a C_1 - C_3 alkyl group.

In a fourth embodiment, one of R^4 and R^5 represents a hydrogen atom and the other of R^4 and R^5 represents a C_1 - C_3 alkyl group.

15 In a fifth embodiment, one of R^4 and R^5 represents a cyclopropyl group and the other of R^4 and R^5 represents a C_1 - C_3 alkyl group.

In a sixth embodiment, R^4 and R^5 together with the nitrogen atom to which they are attached form an azetidiny or pyrrolidinyl ring optionally substituted by one or two substituents independently selected from fluorine, hydroxyl and methoxy.

20

R^6 and R^7 each independently represent a hydrogen atom or a C_1 , C_2 or C_3 alkyl or C_3 - C_6 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) group, or R^6 and R^7 may together with the nitrogen atom to which they are attached form a 4-, 5-, 6- or 7-membered saturated heterocyclic ring optionally substituted by at least one substituent, e.g. one or two substituents, independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine) and hydroxyl.

25

In one aspect, the saturated heterocyclic ring may contain a single ring heteroatom (being the nitrogen atom to which R^6 and R^7 are attached).

5 In an alternative aspect, the saturated heterocyclic ring may contain a second ring heteroatom selected from a nitrogen or oxygen atom.

In one embodiment, R^6 and R^7 each independently represent a hydrogen atom or a C_1 , C_2 or C_3 alkyl or C_3 - C_6 or C_3 - C_5 or C_5 - C_6 cycloalkyl, particularly cyclopropyl, group, or R^6 and R^7 may together with the nitrogen atom to which they are attached form a
10 4- or 5-membered saturated heterocyclic ring optionally substituted by one or two substituents independently selected from fluorine, chlorine, bromine and hydroxyl.

In a second embodiment, R^6 and R^7 each represent a hydrogen atom.

15 In a third embodiment, R^6 and R^7 each represent a C_1 - C_3 alkyl group.

In a fourth embodiment, one of R^6 and R^7 represents a hydrogen atom and the other of R^6 and R^7 represents a C_1 - C_3 alkyl group.


20 In a fifth embodiment, one of R^6 and R^7 represents a cyclopropyl group and the other of R^6 and R^7 represents a C_1 - C_3 alkyl group.

In a sixth embodiment, R^6 and R^7 together with the nitrogen atom to which they are attached form an azetidiny or pyrrolidinyl ring optionally substituted by one or two
25 substituents independently selected from fluorine and hydroxyl.

R^8 and R^9 are defined as for R^4 and R^5 above.

R^{10} and R^{11} are defined as for R^6 and R^7 above.

R^{12} represents a hydrogen atom, methyl group or a C_2 - C_3 alkylene chain that links to R^1 to form a 5- or 6-membered ring. Thus, for example, the following moiety may be formed
 5 when R^{12} represents a C_3 alkylene chain and R^1 represents a pyridin-2-yl group:



In an embodiment of the invention, R^{12} represents a hydrogen atom or methyl group.

10 In another embodiment, R^{12} represents a hydrogen atom.

In a preferred embodiment of the invention,

R^1 represents a 5- or 6-membered heteroaryl group optionally substituted by at least one substituent independently selected from halogen, cyclopropyl, C_1 - C_3 alkyl, C_1 -
 15 C_3 alkoxy, C_1 - C_3 haloalkyl and C_1 - C_3 haloalkoxy;

L represents CH_2 , O or NR^{12} ;

R^a represents a hydrogen atom or a methyl group;

R^b represents a hydrogen atom;


X represents CH_2 or CF_2 ;

20 R^2 represents a hydrogen atom or cyclobutyl group;

R^3 represents a phenyl or pyridinyl group optionally substituted by at least one substituent independently selected from fluorine, chlorine, bromine, C_1 - C_3 alkyl, C_1 - C_3 haloalkyl, C_1 - C_3 alkoxy, C_1 - C_3 haloalkoxy, cyclopropyl, piperidinyl, or a 5- or

6-membered heteroaryl group, the heteroaryl group itself being optionally substituted by at least one C₁-C₂ alkyl or C₁-C₂ alkoxy group.

In another preferred embodiment, the invention provides compounds of formula



wherein

R¹ as as defined above;

R^{a1} represents a hydrogen atom or methyl group; and

R^{3a} represents 5- or 6-membered heteroaryl group.

In one aspect, R^{3a} in formula (Ia) represents a triazolyl (e.g. 1,2,3-triazol-2-yl) or pyrimidinyl (e.g. pyrimidin-2-yl) group.

Examples of compounds of the invention include:

2,6-Dimethoxy-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

2,6-Dimethoxy-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;

5-Methyl-2-(2*H*-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;

N-[(1*S*,2*S*)-2-[(5-Ethylpyrimidin-2-yl)amino]cyclopentyl]-5-methyl-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

N-[(1*S*,2*S*)-2-[(5-Chloropyridin-2-yl)amino]cyclopentyl]-5-methyl-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

5-Methyl-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

5-Methyl-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5 2-(3-Methyl-1,2,4-oxadiazol-5-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

N-[(*1S*,2*S*)-2-[(5-Chloropyrazin-2-yl)amino]cyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

10 5-Fluoro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

2-(1H-Pyrazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

2-(2H-1,2,3-Triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

15 2-(Pyrimidin-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

5-Fluoro-2-(pyrimidin-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

20 2-(3-Methyl-1,2,4-oxadiazol-5-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-(3-Methyl-1,2,4-oxadiazol-5-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;

2-(2H-1,2,3-Triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

25 2-(2H-1,2,3-Triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;

2-(2H-1,2,3-Triazol-2-yl)-*N*-[(*1S*,2*R*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]oxy}cyclopentyl]benzamide;

30 2-(2H-1,2,3-Triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopentyl]benzamide;

2,6-Dimethoxy-*N*-[(*1S*,2*S*)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopentyl]benzamide;

2-(2H-1,2,3-Triazol-2-yl)-*N*-(2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide;

2-(2H-1,2,3-Triazol-2-yl)-*N*-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide;

5 5-Methyl-2-(2H-1,2,3-triazol-2-yl)-*N*-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide;

2,6-Dimethoxy-*N*-[(*1S*,2*S*)-2-{[6-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

10 3-Bromo-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

2-Ethoxy-5-methyl-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

3-Ethoxy-6-methyl-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

15 2-(1H-Pyrazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-Fluoro-6-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

20 2,6-Difluoro-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2,6-Dimethoxy-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-(1H-1,2,3-Triazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

25 5-Fluoro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-Methoxy-5-methyl-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

30 2-(Pyrimidin-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5-Fluoro-2-(pyrimidin-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-Chloro-6-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5-Fluoro-2-(1H-1,2,3-triazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5 5-Methyl-2-(1H-1,2,3-triazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

3-(1H-Pyrazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

10 2-(5-Methyl-1,3,4-oxadiazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-Fluoro-6-(1H-pyrazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

15 5-Fluoro-2-(1H-pyrazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5-Methyl-2-(1H-pyrazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

20 2-Bromo-6-methoxy-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-Methoxy-6-(1H-pyrazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

3-(Piperidin-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

25 5-Chloro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

3-Fluoro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

30 2-(1H-1,2,3-Triazol-1-yl)-5-(trifluoromethyl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5-Chloro-2-(1H-1,2,3-triazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2,3-Difluoro-6-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5-Cyclopropyl-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5 3-(Trifluoromethoxy)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

5-Chloro-2-(1H-pyrazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

10 3-Ethoxy-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

3,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-(Trifluoromethyl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

15 3-Cyclopropyl-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

3,6-Difluoro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

20 2-(Difluoromethyl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-Cyclopropyl-6-fluoro-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5-Methyl-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[6-(trifluoromethyl)pyridin-3-yl]amino}cyclopentyl]benzamide;

25 *N*-Cyclobutyl-2,6-dimethoxy-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

2-Chloro-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

30 2-Chloro-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;

2-Fluoro-6-methoxy-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

2,6-Difluoro-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

N-[(*1S,2S*)-2-{Methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

5 5-Fluoro-*N*-[(*1S,2S*)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

2-Fluoro-*N*-[(*1S,2S*)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-6-(2H-1,2,3-triazol-2-yl)benzamide;

10 *N*-[(*1S,2S*)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

N-[(*1S,2S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

N-[(*1S,2S*)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

15 *N*-[(*1S,2S*)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;

5-Fluoro-*N*-[(*1S,2S*)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;

20 *N*-[(*1S,2S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-(2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-[(*1R,2R*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

25 5-Fluoro-*N*-[(*1S,2S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-[(*1S,2S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(1H-pyrazol-1-yl)pyridine-2-carboxamide;

30 3-Ethoxy-*N*-[(*1S,2S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide,

2-Chloro-*N*-[(*1S,2S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-6-(2H-1,2,3-triazol-2-yl)benzamide;

2,6-Difluoro-*N*-[(*1S,2S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

3-Cyclopropyl-*N*-[(*1S,2S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

5 *N*-[(*1S,2S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(trifluoromethoxy)pyridine-2-carboxamide;

N-[(*1S,2S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;

10 5-Chloro-*N*-[(*1S,2S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;

15 *N*-(2-Methyl-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;

5-Chloro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

20 3-Fluoro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

3,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

3-(2H-1,2,3-Triazol-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

25 3-(1H-Pyrazol-1-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

2-Fluoro-6-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

30 *N*-(2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopentyl)-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

N-[(*1S,2S*)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-[(1*S*,2*S*)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

N-[(1*S*,2*S*)-2-{[3-Bromo-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

5 *N*-[(1*S*,2*S*)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

N-[(1*S*,2*S*)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

10 *N*-[(1*S*,2*S*)-2-{[3-(Propan-2-yl)-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

N-[(1*S*,2*S*)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

N-[(1*S*,2*S*)-2-[(5-Cyclopropylpyrazin-2-yl)amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

15 *N*-[(1*S*,2*S*)-2-{[5-(Propan-2-yl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

N-[(1*S*,2*S*)-2-[(5-Ethylpyrazin-2-yl)amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

20 2-(2*H*-1,2,3-Triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]benzamide;

5-Chloro-2-(2*H*-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]benzamide;

N-[(1*S*,2*S*)-2-[(5-Bromopyridin-2-yl)amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

25 *N*-[(1*S*,2*S*)-2-[(5-Bromo-3-methoxypyridin-2-yl)amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

2-(2*H*-1,2,3-Triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[4-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

30 *N*-[(1*S*,2*S*)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

5 *N*-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

10 *N*-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

N-[(1*S*,2*S*)-4,4-Difluoro-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

N-[(1*S*,2*S*)-4,4-Difluoro-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

15 2-(5-Ethoxypyrimidin-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-Fluoro-6-methoxy-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

20 *N*-[(1*S*,2*S*)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;

5-Fluoro-*N*-[(1*S*,2*S*)-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;

25 *N*-[(1*S*,2*S*)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide;

2-(3-Methyl-1,2,4-oxadiazol-5-yl)-*N*-[(1*S*,2*S*)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

30 *N*-[(1*S*,2*S*)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

2-(3-Methyl-1,2,4-oxadiazol-5-yl)-*N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5 *N*-(2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

10 *N*-[(1*S*,2*S*)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide;

N-[(1*S*,2*S*)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

15 *N*-[(1*S*,2*S*)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;

N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

20 *N*-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

25 *N*-[(1*S*,2*S*)-2-{[5-(Difluoromethoxy)pyridin-2-yl]amino}-4,4-difluorocyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

N-[(1*S*,2*S*)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-5-fluoro-2-(pyrimidin-2-yl)benzamide;

30 *N*-[(1*S*,2*S*)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

2-(5-Methyl-1,3,4-oxadiazol-2-yl)-*N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;


enantiomers thereof and pharmaceutically acceptable salts of any of the foregoing.

It should be noted that each of the chemical compounds listed above represents a particular and independent aspect of the invention.

5


The present invention further provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above which comprises

(i) reacting a compound of formula



10


wherein L, X, R^a , R^b , R^1 and R^2 are as defined in formula (I), with a compound of formula



wherein R^{20} represents a halogen atom (e.g. chlorine atom) or a hydroxyl group and R^3 is as defined in formula (I), or a salt (e.g. hydrochloride salt) thereof; or

15

(ii) when L represents NH or N(CH₃), reacting a compound of formula



wherein R^{25} represents a hydrogen atom or methyl group and X, R^a , R^b , R^2 and R^3 are as defined in formula (I), with a compound of formula (V), $R^1 - LG^1$, wherein LG^1 represents a leaving group (e.g. a halogen atom) and R^1 is as defined in formula (I);

5 and optionally thereafter carrying out one or more of the following procedures:

- converting a compound of formula (I) into another compound of formula (I)
- removing any protecting groups
- forming a pharmaceutically acceptable salt.

10 Process (i) may conveniently be carried out by combining the amine of formula (II) with an acid chloride of formula (III) in the presence of a base such as triethyl amine or DIPEA (*N,N*-diisopropylethylamine) in a solvent such as dichloromethane. Alternatively the reaction can be carried out from the amine of formula (II) and a carboxylic acid of formula (III) using any of the known coupling reagents such as EDC (1-ethyl-3-(3-

15 dimethylaminopropyl)carbodiimide) and HOAt (7-aza-1-hydroxybenzotriazole), with or HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) with a base such as DIPEA. Another method is to activate the carboxylic acid to the corresponding acid chloride *in situ* for example with oxalyl chloride in the presence of a catalytic amount of DMF.

20

Process (ii) may conveniently be carried out by mixing the compound of formula (IV) with the compound of formula (V) in a solvent such as DMSO, acetonitrile or toluene and optionally in the presence of a base such as DIPEA, and heating conventionally or using microwave irradiation.


25

Compounds of formula (II) in which L represents CH_2 , X represents CH_2 and R^a and R^b are each hydrogen may be prepared according to the scheme below. The heterocyclic bromomethylene compound is likely to be commercially available or can be prepared by bromination of the corresponding heterocyclic methyl compound using, for example, *N*-bromosuccinimide and benzoyl peroxide in carbon tetrachloride at elevated temperature.

30 Reaction of the heterocyclic bromomethylene compound with triphenylphosphine in


toluene at raised temperature will afford the corresponding phosphonium bromide which on treatment with a base such as *n*-butyl lithium in the presence of the Boc-protected cyclic ketone will afford the corresponding alkene. The alkene can be reduced by hydrogenation using hydrogen gas in the presence of a catalyst such as palladium on carbon. Finally, the

5 Boc protecting group can be removed using methods known to those skilled in the art, e.g. acid hydrolysis.



Boc = *tert*-butoxycarbonyl


- 10 Compounds of formula (II) in which L represents an oxygen atom may be prepared by reacting a compound of formula



wherein X, R^a, R^b and R² is as defined in formula (II), with a compound of formula (V) as defined above, in the presence of a base such as sodium hydride.

15

Compounds of formula (II) in which L represents NH or N(CH₃) may be prepared by reacting a compound of formula



in which LG^2 represents a protecting group such as a *tert*-butoxycarbonyl group, and X, R^a , R^b , R^2 and R^{25} are as defined in formula (IV) above, with a compound of formula (V) as defined above.

Compounds of formula (IV) may be prepared by reacting a compound of formula (VII) with a compound of formula (III) followed by removal of the protecting group, LG^2 , by acid treatment using, for example, an acid such as hydrochloric acid.

Compounds of formulae (III), (V), (VI) and (VII) are either commercially available, are well known in the literature or may be prepared using known techniques.

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as phenol, hydroxyl or amino groups in the reagents may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the introduction and/or removal of one or more protecting groups.

The protection and deprotection of functional groups is described in 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 3rd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1999).

The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt thereof, preferably an acid addition salt such as a formate, hemi-formate, hydrochloride, hydrobromide, benzenesulphonate (besylate), saccharin (e.g. monosaccharin), trifluoroacetate, sulphate, nitrate, phosphate, acetate, fumarate, maleate,

tartrate, lactate, citrate, pyruvate, succinate, valerate, propanoate, butanoate, malonate, oxalate, 1-hydroxy-2-naphthoate (xinafoate), methanesulphonate or *p*-toluenesulphonate salt.

5 In one aspect of the invention, compounds of formula (I) may bear one or more radiolabels. Such radiolabels may be introduced by using radiolabel-containing reagents in the synthesis of the compounds of formula (I), or may be introduced by coupling the compounds of formula (I) to chelating moieties capable of binding to a radioactive metal atom. Such radiolabeled versions of the compounds may be used, for example, in
10 diagnostic imaging studies.

Unless stated otherwise, any atom specified herein may also be an isotope of said atom. For example, the term “hydrogen” encompasses ^1H , ^2H and ^3H . Similarly carbon atoms are to be understood to include ^{12}C , ^{13}C and ^{14}C , nitrogen atoms are to be understood to
15 include ^{14}N and ^{15}N , and oxygen atoms are to be understood to include ^{16}O , ^{17}O and ^{18}O .

In a further aspect of the invention, compounds of formula (I) may be isotopically labelled. As used herein, an “isotopically labelled” compound is one in which the abundance of a particular nuclide at a particular atomic position within the molecule is increased above the
20 level at which it occurs in nature.

Compounds of formula (I) and their salts may be in the form of hydrates or solvates which form an aspect of the present invention. Such solvates may be formed with common organic solvents, including but not limited to, alcoholic solvents e.g. methanol, ethanol or
25 isopropanol.

Where compounds of formula (I) are capable of existing in stereoisomeric forms, it will be understood that the invention encompasses the use of all geometric and optical isomers (including atropisomers) of the compounds of formula (I) and mixtures thereof including
30 racemates. The use of tautomers and mixtures thereof also forms an aspect of the present invention. Enantiomerically pure forms are particularly desired.

Compounds of formula (I) and their salts may be amorphous or in a polymorphic form or a mixture of any of these, each of which forms an aspect of the present invention.

The compounds of formula (I) and their pharmaceutically acceptable salts have activity as
5 pharmaceuticals, in particular as orexin receptor antagonists, and may be used in the
treatment of **schizophrenia and other psychotic disorders** (e.g., psychotic disorder,
psychosis or schizoaffective disorder); **dementia and other cognitive disorders**; **anxiety**
disorders (e.g., generalized anxiety disorder, post-traumatic stress disorder, panic
disorders, acute stress disorder, social anxiety disorder, phobias including agoraphobia,
10 obsessive compulsive disorder, trichotillomania or body dysmorphic disorder);
mood disorders (e.g., depressive disorders, major depressive disorders, bipolar disorders
including bipolar I and II, bipolar mania, bipolar depression); **addiction** including
substance dependence (e.g. cocaine, opiates, cannabis or prescription drug dependence),
alcohol dependence, nicotine dependence or gambling disorder; **eating disorders** (e.g.
15 binge eating, bulimia nervosa, anorexia nervosa or obesity); **sleep disorders** (e.g. rapid eye
movement sleep disorder); **disorders usually first diagnosed in infancy, childhood, or**
adolescence (e.g., attention-deficit disorder, autistic spectrum disorders, Rett syndrome,
Fragile X syndrome, Asperger syndrome and disruptive behaviour disorders); **restless leg**
syndrome; **pain** (e.g. neuropathic pain including chemotherapy induced pain or migraine);
20 and **neurodegenerative disorders** (e.g. Parkinson's or Alzheimer's disease).

Thus, the present invention provides a compound of formula (I) or a pharmaceutically
acceptable salt thereof as hereinbefore defined for use in therapy, in particular for the
treatment of conditions whose development or symptoms are linked to orexin receptor
25 activity.

The present invention also provides the use of a compound of formula (I) or a
pharmaceutically acceptable salt thereof as hereinbefore defined for the preparation of a
medicament for the treatment of conditions whose development or symptoms are linked to
30 orexin receptor activity.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

5 Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disorder or condition in question. Persons at risk of developing a particular disorder or condition generally include those having a family history of the disorder or condition, or those who have been identified by genetic testing or screening to be particularly
10 susceptible to developing the disorder or condition or those in the prodromal phase of a disorder.

In particular, the compounds of the invention (including pharmaceutically acceptable salts) may be used in the treatment of the positive symptoms of schizophrenia, schizophreniform
15 disorder or schizoaffective disorder (e.g. voices or hallucinations), cognitive disorders (such as dementia and impaired learning), anxiety disorders (such as post-traumatic stress disorder or panic disorders), or addiction.

The invention also provides a method of treating at least one symptom or condition
20 associated with schizophrenia and other psychotic disorders (e.g., psychotic disorder, psychosis or schizoaffective disorder); dementia and other cognitive disorders; anxiety disorders (e.g., generalized anxiety disorder, post-traumatic stress disorder, panic disorders, acute stress disorder, social anxiety disorder, phobias including agoraphobia, obsessive compulsive disorder, trichotillomania or body dysmorphic disorder); mood
25 disorders (e.g., depressive disorders, major depressive disorders, bipolar disorders including bipolar I and II, bipolar mania, bipolar depression); addiction including substance dependence (e.g. cocaine, opiates, cannabis or prescription drug dependence), alcohol dependence, nicotine dependence or gambling disorder; eating disorders (e.g. binge eating, bulimia nervosa, anorexia nervosa or obesity); sleep disorders (e.g. rapid eye
30 movement sleep disorder); disorders usually first diagnosed in infancy, childhood, or adolescence (e.g., attention-deficit disorder, autistic spectrum disorders, Rett syndrome, Fragile X syndrome, Asperger syndrome and disruptive behaviour disorders); restless leg

syndrome; pain (e.g. neuropathic pain including chemotherapy induced pain or migraine); and neurodegenerative disorders (e.g. Parkinson's or Alzheimer's disease) which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore
5 defined.

Such symptoms and conditions include, but are not limited to, anxiety, agitation, hostility, panic, an eating disorder, an affective symptom, a mood symptom, a negative and positive psychotic symptom commonly associated with psychosis and neurodegenerative disorder.

10 For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. For example, the daily dosage of the compound of the invention, if inhaled, may be in the range from 0.05 micrograms per kilogram body weight ($\mu\text{g/kg}$) to
15 100 micrograms per kilogram body weight ($\mu\text{g/kg}$). Alternatively, if the compound is administered orally, then the daily dosage of the compound of the invention may be in the range from 0.01 micrograms per kilogram body weight ($\mu\text{g/kg}$) to 100 milligrams per kilogram body weight (mg/kg).

20 The compounds of formula (I) and pharmaceutically acceptable salts thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

25 Therefore the present invention further provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The invention still further provides a process for the preparation of a pharmaceutical
30 composition of the invention which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined with a pharmaceutically acceptable adjuvant, diluent or carrier.

Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceutics - The Science of Dosage Form Design", M. E. Aulton, Churchill Livingstone, 1988.

5

Pharmaceutically acceptable adjuvants, diluents or carriers that may be used in the pharmaceutical compositions of the invention are those conventionally employed in the field of pharmaceutical formulation, and include, but are not limited to, sugars, sugar alcohols, starches, ion exchangers, alumina, aluminium stearate, lecithin, serum proteins
10 such as human serum albumin, buffer substances such as phosphates, glycerine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulphate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium
15 carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

The pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, rectally, nasally, buccally, vaginally or via an implanted
20 reservoir. Oral administration is preferred. The pharmaceutical compositions of the invention may contain any conventional non-toxic pharmaceutically acceptable adjuvants, diluents or carriers. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

25

The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. The suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable
30 preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable diluents and solvents that may be employed are mannitol, water,

Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are
5 natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant.

The pharmaceutical compositions of this invention may be orally administered in any
10 orally acceptable dosage form including, but not limited to, capsules, tablets, powders, granules, and aqueous suspensions and solutions. These dosage forms are prepared according to techniques well-known in the art of pharmaceutical formulation. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral
15 administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavouring and/or colouring agents may be added.

The pharmaceutical compositions of the invention may also be administered in the form of
20 suppositories for rectal administration. These compositions can be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active ingredient. Such materials include, but are not limited to, cocoa butter, beeswax and
25 polyethylene glycols.

The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing
30 benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilising or dispersing agents known in the art.

Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The compounds of the invention (that is, compounds of formula (I) and pharmaceutically acceptable salts thereof) may also be administered in conjunction with other compounds used for the treatment of the above conditions.

The invention therefore further relates to combination therapies wherein a compound of the invention or a pharmaceutical composition or formulation comprising a compound of the invention is administered with another therapeutic agent or agents for the treatment of one or more of the conditions previously indicated. Such therapeutic agents may be selected from the following:

(i) **antidepressants** such as, for example, amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, duloxetine, elzasonan, escitalopram, fluvoxamine, fluoxetine, gepirone, imipramine, ipsapirone, maprotiline, nortriptyline, nefazodone, paroxetine, phenelzine, protriptyline, reboxetine, robaizotan, sertraline, sibutramine, tianeptine, thionisoxetine, tranilcypromaine, trazodone, trimipramine, venlafaxine, vortioxetine and equivalents and pharmaceutically active isomer(s) and/or metabolite(s) thereof;

(ii) **antipsychotics** including, for example, amisulpride, aripiprazole, asenapine, benisoxidil, bifeprunox, brexpiprazole, carbamazepine, cariprazine, clozapine, chlorpromazine, debenzapine, divalproex, duloxetine, eszopiclone, haloperidol, iloperidone, lamotrigine, loxapine, lurasidone, mesoridazine, olanzapine, paliperidone, perlapine, perphenazine, phenothiazine, phenylbutylpiperidine, pimozide, prochlorperazine, quetiapine, risperidone, sertindole, sulpiride, suproclonidine, suriclone, thioridazine, trifluoperazine, trimetozine, valproate, valproic acid, zopiclone, zotepine, ziconapine, ziprasidone, and equivalents and pharmaceutically active isomer(s) and/or

metabolite(s) thereof;

(iii) **anxiolytics** including, for example, alnespirone, azapirones, benzodiazepines, barbiturates, and equivalents and pharmaceutically active isomer(s) and/or metabolite(s) thereof. Example anxiolytics include adinazolam, alprazolam, balezepam, bentazepam, 5 bromazepam, brotizolam, buspirone, clonazepam, clorazepate, chlordiazepoxide, cyprazepam, diazepam, diphenhydramine, estazolam, fenobam, flunitrazepam, flurazepam, fosazepam, lorazepam, lormetazepam, meprobamate, midazolam, nitrazepam, oxazepam, prazepam, quazepam, reclazepam, tracazolate, trepipam, temazepam, triazolam, 10 uldazepam, and zolazepam; and equivalents and pharmaceutically active isomer(s) and/or metabolite(s) thereof;

(iv) **anticonvulsants** including, for example, carbamazepine, valproate, lamotrigine, levetiracetam and gabapentin, and equivalents and pharmaceutically active isomer(s) 15 and/or metabolite(s) thereof;

(v) **Alzheimer's therapies** including, for example, donepezil, galantamine, memantine, rivastigmine, tacrine, and equivalents and pharmaceutically active isomer(s) and/or metabolite(s) thereof;

20 (vi) **Parkinson's therapies** including, for example, L-dopa, ropinirole, pramipexole, monoamine oxidase type B (MAO-B) inhibitors such as deprenyl, selegiline and rasagiline, catechol-O-methyl transferase (COMT) inhibitors such as entacapone or tolcapone, adenosine A-2 inhibitors, dopamine re-uptake inhibitors, NMDA antagonists, Nicotine 25 agonists, and Dopamine agonists and inhibitors of neuronal nitric oxide synthase, and equivalents and pharmaceutically active isomer(s) and/or metabolite(s) thereof;

(vii) **migraine therapies** including, for example, almotriptan, amantadine, botulinum toxin A, bromocriptine, butalbital, cabergoline, dichloralphenazone, dihydroergotamine, 30 eletriptan, frovatriptan, lisuride, naratriptan, pergolide, pramipexole, rizatriptan, ropinirole, sumatriptan, topiramate, zolmitriptan, and zomitriptan, and equivalents and pharmaceutically active isomer(s) and/or metabolite(s) thereof;

(viii) **stroke therapies** including, for example, abciximab, activase, citicoline, desmoteplase, , and equivalents and pharmaceutically active isomer(s) and/or metabolite(s) thereof;

5

(ix) **urinary incontinence therapies** including, for example, darafenacin, duloxetine, falvoxate, mirabegron, oxybutynin, propiverine, robalzotan, solifenacin, and tolterodine, and equivalents and pharmaceutically active isomer(s) and/or metabolite(s) thereof;

10 (x) **neuropathic pain therapies** including, for example, capsaicin, gabapentin, lidoderm, and pregabalin, and equivalents and pharmaceutically active isomer(s) and/or metabolite(s) thereof;

(xi) **nociceptive pain therapies** such as, for example, celecoxib, etoricoxib, lumiracoxib, 15 rofecoxib, valdecoxib, diclofenac, loxoprofen, naproxen, and paracetamol, and equivalents and pharmaceutically active isomer(s) and/or metabolite(s) thereof;

(xii) **insomnia therapies** including, for example, allobarbitol, alonimid, amobarbital, benzoctamine, butabarbital, capuride, chloral, cloperidone, clorethate, dexclamol, 20 ethchlorvynol, eszopiclone, etomidate, glutethimide, halazepam, hydroxyzine, lorediplon, mecloqualone, melatonin, mephobarbital, methaqualone, midaflur, nisobamate, pentobarbital, phenobarbital, propofol, ralmeteon, roletamide, suvorexant, triclofos, secobarbital, zaleplon, and zolpidem, zopiclone and equivalents and pharmaceutically active isomer(s) and/or metabolite(s) thereof;

25

(xiii) **mood stabilizers** including, for example, carbamazepine, divalproex, gabapentin, lamotrigine, lithium, olanzapine, quetiapine, valproate, valproic acid, and verapamil, and equivalents and pharmaceutically active isomer(s) and/or metabolite(s) thereof;

30 (xiv) **5HT1B ligands** such as, for example, compounds disclosed in WO 99/05134 and WO 02/08212;

(xv) mGluR2 agonists;

(xvi) alpha 7 nicotinic agonists such as, for example, compounds disclosed in WO 96/006098, WO 97/030998, WO 99/003859, WO 00/042044, WO 01/029034,
5 WO 01/60821, WO 01/36417, WO 02/096912, WO 03/087102, WO 03/087103,
WO 03/087104, WO 2004/016617, WO 2004/016616, and WO 2004/019947;

(xvii) chemokine receptor CCRI inhibitors; and

10 (xviii) delta opioid agonists such as, for example, compounds disclosed in WO 97/23466
and WO 02/094794.

Such combination products employ the compounds of this invention within the dosage
range described herein and the other pharmaceutically active agent within approved dosage
15 ranges and/or the dosage such as described in the publication reference.

In a further aspect the present invention provides a combination (for example for the
treatment of schizophrenia, cognitive disorders or pain) of a compound of formula (I) or a
pharmaceutically acceptable salt thereof as hereinbefore defined and one or more agents
20 selected from carbamazepine, olanzapine, quetiapine, verapamil, lamotrigine,
oxcarbazepine, risperidone, aripiprazole, ziprasidone and lithium.

The invention also provides a pharmaceutical product comprising, in combination, a
preparation of a first active ingredient which is a compound of formula (I) or a
25 pharmaceutically acceptable salt thereof as hereinbefore defined, and a preparation of a
second active ingredient which is carbamazepine, olanzapine, quetiapine, verapamil,
lamotrigine, oxcarbazepine, risperidone, aripiprazole, ziprasidone or lithium,
for simultaneous, sequential or separate use in therapy.

30 In another aspect, the invention provides a kit comprising a preparation of a first active
ingredient which is a compound of formula (I) or a pharmaceutically acceptable salt
thereof as hereinbefore defined, and a preparation of a second active ingredient which is

carbamazepine, olanzapine, quetiapine, verapamil, lamotrigine, oxcarbazepine, risperidone, aripiprazole, ziprasidone or lithium, and instructions for the simultaneous, sequential or separate administration of the preparations to a patient in need thereof.

- 5 The present invention will now be further explained by reference to the following illustrative examples.

The methods used for synthesis of the compounds of the invention are illustrated by the general schemes below and the preparative examples that follow. The starting materials
10 and reagents used in preparing these compounds are available from commercial suppliers. These general schemes are merely illustrative of methods by which the compounds of this invention can be synthesised, and various modifications to these schemes can be made and will be suggested to one skilled in the art having referred to this disclosure.

- 15 Nuclear magnetic resonance (NMR) spectra were recorded at 400MHz; the chemical shifts (δ) are reported in parts per million. Spectra were recorded using a Bruker 400 Avance instrument fitted with a 5 mm BBFO probe or DUL probe. Instrument control was by Bruker TopSpin 2.1 software, unless stated otherwise.

- 20 Purity was assessed using UPLC with UV (photodiode array) detection over a wide range of wavelengths, normally 220-450nm, using a Waters Acquity UPLC system equipped with Acquity UPLC BEH or HSS C18 columns (2.1mm id x 50mm long) operated at 50 or 60°C. Mobile phases typically consisted of acetonitrile or methanol mixed with water containing either 0.05% formic acid or 0.025% ammonia.

- 25 Mass spectra were recorded with a Waters SQD single quadrupole mass spectrometer using atmospheric pressure ionisation, unless stated otherwise.

- Compounds were purified using normal phase chromatography on silica or alumina, or by
30 reverse phase chromatographic methods, using Biotage or Isolute KPNH Cartridge, SCX cartridge and SCX-2 solid phase extraction cartridges.

Preparative High Performance Liquid Chromatography (HPLC) was performed using an Agilent Technologies 1100 Series system or Waters autopurification system typically using Waters 19mm id x 100mm or 19mm id x 250 mm C18 columns such as XBridge or SunFire 5µm materials at 20 mL/min. Mobile phases typically consisted of acetonitrile or methanol mixed with water containing either 0.1% formic acid or 0.1% ammonia, unless stated otherwise.

In the following descriptions “room temperature” denotes a temperature in the range from 20°C to 25°C.

The abbreviations used in the specific examples have the following meanings:

Aza-HOBt (HOAt) = 7-Aza-1-hydroxybenzotriazole

BINAP = 2,2'-bis(Diphenylphosphino)-1,1'-binaphthyl

Boc = *tert*-Butyloxycarbonyl

DCM = Dichloromethane

DIAD = Diisopropyl azodicarboxylate

DIPEA = *N,N*-Diisopropylethylamine

DMF = *N,N*-Dimethylformamide

DMSO = Dimethyl sulfoxide

EDC = 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide

HATU = 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate

IPA = propan-2-ol

LiHMDS = Lithium bis(trimethylsilyl)amine

MTBE = 2-methoxy-2-methylpropane


NMP = *N*-Methyl-2-pyrrolidone

TBTU = *O*-(Benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate

TOTU = [Bis(dimethylamino)methylene][(Z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxonium tetrafluoroborate

1. Intermediates

Intermediate 1: (1*S*,2*S*)-1-*N*-[5-(Trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride




A microwave vial was charged with *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 1.0 g, 4.99 mmol), 2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 0.997 g, 5.49 mmol), DIPEA (2.62 ml, 14.98 mmol) and DMSO (16.6 ml). The reaction was heated with microwave irradiation at 140 °C for 2 hours and then partitioned between ethyl acetate and water. The organics were washed with water and brine, dried over magnesium sulfate, filtered and concentrated *in vacuo*. This was then purified by column chromatography (silica, 0-50 % ethyl acetate / petrol) to afford a cream solid to which was then added methanol (10 ml) and HCl in 1,4-dioxane (4M, 6.24 ml, 24.97 mmol) and the reaction was stirred at room temperature for 17 hours. The reaction mixture was concentrated *in vacuo* and azeotropically distilled with toluene to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 1.56-1.83 (m, 4 H), 2.02-2.22 (m, 2 H), 3.25-3.35 (m, 1 H), 4.06-4.18 (m, 1 H), 6.68-6.72 (m, 1 H), 7.65-7.82 (m, 2 H), 8.18 (br. s., 2 H), 8.37 (br. s., 1 H).

MS ES⁺: 246

Intermediate 2: *N*-[(1*S*,2*S*)-2-Aminocyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide hydrochloride




A mixture of 2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid (CAS number 475105-77-2; 0.84 g, 4.12 mmol), *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number

586961-34-4; 0.75 g, 3.74 mmol), HATU (2.14 g, 5.62 mmol) and triethylamine (1.57 ml, 11.23 mmol) was stirred in dry DMF (12.5 ml) at room temperature for 17 hours. The reaction mixture was partitioned between ethyl acetate and water, washed with water and brine, dried over magnesium sulfate, filtered and concentrated *in vacuo*. The crude material
5 was then purified by column chromatography (silica, 0-100 % ethyl acetate / petrol). The resulting cream solid was recrystallised from ethyl acetate, to which was then added methanol (10 ml) and HCl in 1,4-dioxane (4M, 4.68 ml, 18.72 mmol) and the reaction was stirred at room temperature for 17 hours. The reaction was concentrated *in vacuo* and azeotropically distilled with toluene to afford the title compound.

10 ^1H NMR (DMSO- d_6) δ ppm 1.56-1.82 (m, 4 H), 1.94-2.04 (m, 2 H), 2.42 (s, 3 H), 3.35-3.43 (m, 1 H), 4.10-4.26 (m, 1 H), 7.12-7.28 (m, 1 H), 7.63-7.80 (m, 2 H), 7.94-8.00 (m, 1 H), 8.08-8.25 (br. s., 2 H) and 8.75-8.80 (m, 1 H).

MS ES⁺: 287


15 **Intermediate 3: N-[(1*S*,2*R*)-2-Aminocyclopentyl]-2,6-dimethoxybenzamide hydrochloride**



To a solution of *tert*-butyl N-[(1*R*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 721395-15-9; 0.50 g, 2.50 mmol) in dry DCM (8.3 ml) was added DIPEA (1.3 ml, 7.49
20 mmol) and 2,6-dimethoxybenzoyl chloride (CAS number 1989-53-3; 0.75 g, 3.74 mmol). The reaction was stirred at room temperature under an atmosphere of nitrogen for 17 hours and then partitioned between DCM and water, filtered through a hydrophobic frit and concentrated *in vacuo*. This was purified by column chromatography (silica, 50-100 % ethyl acetate / petrol). To the resulting solid was then added 1,4-dioxane (2 ml) and HCl in
25 1,4-dioxane (4M, 2 ml) and the reaction was stirred at room temperature for 2 hours and then concentrated *in vacuo*, and azeotropically distilled with toluene to afford the title compound.

MS ES⁺: 265

Intermediate 4: *N*-[(1*S*,2*S*)-2-Aminocyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide hydrochloride




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide hydrochloride (**Intermediate 2**) from *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 1.58 g, 7.94 mmol) and 2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 1.64 g, 8.68 mmol) to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 1.48-1.79 (m, 4 H), 1.93-2.10 (m, 2 H), 3.36-3.42 (m, 1 H), 4.06-4.14 (m, 1 H), 7.49-7.61 (m, 1 H), 7.62-7.69 (m, 2 H), 7.81-7.86 (m, 1 H), 8.08 (br. s., 2 H), 8.18 (br. s., 2 H) and 8.62-8.68 (m, 1 H).

MS ES⁺: 272


Intermediate 5: *N*-[(1*S*,2*S*)-2-Aminocyclopentyl]-2,6-dimethoxybenzamide hydrochloride



Prepared according to the procedure for *N*-[(1*S*,2*R*)-2-aminocyclopentyl]-2,6-dimethoxybenzamide hydrochloride (**Intermediate 3**) from *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 1.0 g, 4.99 mmol) and 2,6-dimethoxybenzoyl chloride (CAS number 1989-53-3; 1.50 g, 7.99 mmol) except that after the reaction was complete it was partitioned between DCM and a saturated solution of sodium bicarbonate, filtered through a hydrophobic frit and concentrated *in vacuo*. The Boc protected intermediate was purified by column chromatography (silica, 0-100 % ethyl acetate / petrol) to give a white solid. After deprotection with HCl in 1,4-dioxane, azeotropic distillation from toluene afforded the title compound.

MS ES⁺: 265

Intermediate 6: 5-Methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid




To a solution of 2H-1,2,3-triazole (CAS number 288-36-8; 1.99 g, 28.93 mmol) in DMF (7.0 ml) at 0-10 °C was added cesium carbonate (4.7 g, 14.45 mmol), *trans*-1-*N*,2-*N*-dimethylcyclohexane-1,2-diamine (0.127 g, 1.45 mmol), copper(I) iodide (0.068 g, 0.36 mmol) and 2-iodo-5-methylbenzoic acid (CAS number 52548-14-8; 3.79 g, 14.46 mmol). The reaction was subjected to microwave irradiation at 125 °C for 15 minutes, and then poured into water (20 ml) and extracted with ethyl acetate. The combined organics were washed with brine, dried over sodium sulfate and concentrated *in vacuo*. The crude product was purified by column chromatography (0-3 % methanol / DCM) to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 2.42 (s, 3 H), 7.49-7.52 (m, 1 H), 7.58-7.64 (m, 2 H), 8.05 (s, 2 H), 13.01 (s, 1 H).

MS ES⁺: 204

Intermediate 7: *N*-[(1*S*,2*S*)-2-Aminocyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride




To a solution of 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 6**; 254 mg, 1.25 mmol) in dry DCM (4.16 ml) was added EDC (359 mg, 1.87 mmol), 3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (255 mg, 1.87 mmol), triethylamine (6.9 ml, 4.99 mmol) and *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 250

mg, 1.25 mmol). The solution was stirred at room temperature under an atmosphere of nitrogen for 72 hours and then partitioned between DCM and water, filtered through a hydrophobic frit and concentrated *in vacuo*. This was then purified by column chromatography (silica, 0-100 % ethyl acetate / petrol) to afford a pale white solid. This

5 Boc protected intermediate was dissolved in HCl in 1,4-dioxane (4M, 3 ml) and stirred at room temperature for 17 hours. The reaction was concentrated *in vacuo* and azeotropically distilled with toluene to afford the title compound.

MS ES⁺: 285

10 **Intermediates 8 and 9: 5-Fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 8) and 5-Fluoro-2-(1H-1,2,3-triazol-1-yl)benzoic acid (Intermediate 9)**



To a solution of 2H-1,2,3-triazole (CAS number 288-36-8; 4.0 g, 57.97 mmol) in DMF (14.0 ml) was added cesium carbonate (18.84 g, 57.97 mmol), *trans*-1-*N*,2-*N*-dimethylcyclohexane-1,2-diamine (0.510 g, 5.797 mmol), copper(I) iodide (0.276 g, 1.449 mmol) and 5-fluoro-2-iodobenzoic acid (CAS number 52548-63-7; 7.71 g, 28.98 mmol) at 0-10 °C. The resulting reaction mixture was then heated with microwave irradiation at 125 °C for 15 hours with stirring. The reaction mass was poured into water and the product was extracted into ethyl acetate. The combined organic layers were washed with brine, dried

20 over sodium sulfate and concentrated *in vacuo*. This was then purified by column chromatography (silica, 0-3 % methanol / DCM) to obtain 5-fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 8**) (also commercially available CAS number 1186050-64-5) and crude 5-fluoro-2-(1H-1,2,3-triazol-1-yl)benzoic acid (**Intermediate 9**).

The crude compound (**Intermediate 9**) obtained was further purified by column chromatography (silica, 0-3 % methanol / DCM) and then by reverse phase preparative HPLC (eluted with acetonitrile / water with 0.1 % ammonia) to afford the title compound.


25

Intermediate 9:

^1H NMR (DMSO- d_6) δ ppm 7.41-7.45 (m, 1 H), 7.50-7.52 (m, 1 H), 7.57-7.60 (m, 1 H), 7.83-7.84 (m, 1 H), 8.42 (s, 1 H).

MS ES^+ : 208

Intermediates 10: *N*-[(*1S*,*2R*)-2-Hydroxycyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide




Triethylamine (1.52 ml, 10.90 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (0.59 g, 4.36 mmol) and EDC (0.84 g, 4.36 mmol) were added to a solution of (*1R*,*2S*)-2-

aminocyclopentan-1-ol hydrochloride (CAS number 137254-03-6; 0.50 g, 3.63 mmol) and 2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 0.76 g, 4.00 mmol) in DCM (10 ml). The reaction was stirred at room temperature for 18 hours and then diluted with DCM (50 ml) and washed with a saturated solution of sodium bicarbonate (2 x 20 ml). The crude product was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.36 - 1.59 (m, 3 H), 1.62 - 1.88 (m, 3 H), 3.79 - 3.93 (m, 1 H), 3.94 - 4.10 (m, 1 H), 4.29 - 4.39 (m, 1 H), 7.49 - 7.58 (m, 1 H), 7.58 - 7.67 (m, 2 H), 7.71 - 7.82 (m, 2 H), 8.05 (s, 2 H)

MS ES^+ : 273

Intermediates 11: *N*-[(*1S*,*2S*)-2-Hydroxycyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-[(*1S*,*2R*)-2-hydroxycyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide (**Intermediate 10**) from 2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 531 mg, 2.81 mmol), (*1S*,*2S*)-2-aminocyclopentan-1-ol


hydrochloride (CAS number 68327-04-8; 368 mg, 2.67 mmol) and DIPEA (1401 μ l, 8.02 mmol) to afford the title compound.

^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.33 - 1.48 (m, 2 H), 1.49 - 1.79 (m, 3 H), 1.83 - 1.97 (m, 1 H), 3.80 - 3.88 (m, 1 H), 3.89 - 3.98 (m, 1 H), 4.57 - 4.67 (m, 1 H), 7.43 - 7.55 (m, 2 H), 7.56 - 7.67 (m, 1 H), 7.73 - 7.83 (m, 1 H), 8.03 (s, 2 H), 8.09 - 8.23 (m, 1 H)

MS ES^+ : 273



Intermediate 12: 2-[[4-(Trifluoromethyl)pyridin-2-yl]methyl]cyclopentan-1-amine



Step (i): 2-[[4-(Trifluoromethyl)pyridin-2-yl]methylidene]cyclopentan-1-one

A solution of 4-(trifluoromethyl)pyridine-2-carbaldehyde (CAS number 132470-83-8; 1.00 g, 5.71 mmol) and 4-(cyclopent-1-en-1-yl)morpholine (CAS number 936-52-7; 0.90 ml, 5.60 mmol) in toluene (15 ml) was heated at 90 °C for 18 hours. The reaction was then cooled to room temperature and concentrated HCl (2 ml) and water (2 ml) was added drop wise. The reaction was stirred at room temperature for 20 minutes and then neutralised with a saturated solution of sodium bicarbonate and then basified with 2 M NaOH (aq). The organics were extracted with ethyl acetate (2 x 40 ml) and the combined organics were washed with brine (10 ml), dried over magnesium sulfate, filtered through a hydrophobic

frit and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-20% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 2.01 - 2.10 (m, 2 H), 2.34 - 2.48 (m, 2 H), 3.13 - 3.26 (m, 2 H), 7.23 - 7.34 (m, 1 H), 7.41 - 7.50 (m, 1 H), 7.63 - 7.71 (m, 1 H), 8.83 - 8.94 (m, 1 H)

MS ES⁺: 242

Step (ii): 2-{{4-(Trifluoromethyl)pyridin-2-yl}methyl}cyclopentan-1-one

A solution of 2-{{4-(trifluoromethyl)pyridin-2-yl}methylidene}cyclopentan-1-one

(0.513 g, 2.13 mmol) in ethyl acetate (20 mL) was added palladium on carbon (10% wt, 50% wet, 0.226 g, 0.11 mmol) and the resulting mixture was stirred under a balloon of hydrogen gas for 2 hours. The reaction was filtered through diatomaceous earth (commercially sold under the trade mark "Celite") and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-30% ethyl acetate / petrol) to afford the title compound.

¹H NMR (300 MHz, DCM-*d*₂) δ ppm 1.44 - 1.67 (m, 1 H), 1.68 - 1.89 (m, 1 H), 1.94 - 2.05 (m, 1 H), 2.05 - 2.25 (m, 2 H), 2.25 - 2.42 (m, 1 H), 2.54 - 2.73 (m, 1 H), 2.74 - 2.95 (m, 1 H), 3.21 - 3.41 (m, 1 H), 7.27 - 7.47 (m, 2 H), 8.59 - 8.80 (m, 1 H)

MS ES⁺: 244

Step (iii): 2-{{4-(Trifluoromethyl)pyridin-2-yl}methyl}cyclopentan-1-ol

Sodium borohydride (0.117 g, 3.08 mmol) was added to a solution of 2-{{4-(trifluoromethyl)pyridin-2-yl}methyl}cyclopentan-1-one (0.375 g, 1.54 mmol) in ethanol (10 ml). The reaction was stirred at room temperature for 3 hours and then quenched with water (5 mL) and 2M HCl (aq., 5 ml). The organics were extracted with ethyl acetate (2 x 30 ml) and the combined organics were washed with brine (10 ml), dried over magnesium sulfate, filtered through a hydrophobic frit and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-35% ethyl acetate / petrol) to afford the title compound as two diastereomers.

Diastereomer 1: 2-{{4-(trifluoromethyl)pyridin-2-yl}methyl}cyclopentan-1-ol

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.42 - 1.70 (m, 3 H), 1.72 - 1.94 (m, 3 H), 1.97 - 2.13 (m, 1 H), 2.87 - 3.00 (m, 1 H), 3.02 - 3.17 (m, 1 H), 3.82 - 4.00 (m, 1 H), 7.30 - 7.49 (m, 2 H), 8.59 - 8.77 (m, 1 H)

MS ES⁺: 246

5

Diastereomer 2: 2-([4-(trifluoromethyl)pyridin-2-yl]methyl)cyclopentan-1-ol

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.27 - 1.43 (m, 1 H), 1.51 - 1.80 (m, 3 H), 1.83 - 2.07 (m, 2 H), 2.09 - 2.25 (m, 1 H), 2.94 - 3.06 (m, 2 H), 3.84 - 3.98 (m, 1 H), 7.31 - 7.47 (m, 2 H), 8.63 - 8.73 (m, 1 H)

10 MS ES⁺: 246

Step (iv): 2-(2-([4-(Trifluoromethyl)pyridin-2-yl]methyl)cyclopentyl)-2,3-dihydro-1H-isoindole-1,3-dione

DIAD (0.26 ml, 1.36 mmol) was added to a solution of triphenylphosphine (0.350 g, 1.34 mmol), 2,3-dihydro-1H-isoindole-1,3-dione (CAS number 136918-14-4; 0.197 g, 1.34 mmol) and 2-([4-(trifluoromethyl)pyridin-2-yl]methyl)cyclopentan-1-ol (Diastereomer 2) (0.252 g, 1.03 mmol) in THF (5 ml). The reaction was stirred at room temperature for 24 hours and then further triphenylphosphine (0.175 g, 0.69 mmol) and DIAD (0.130 ml, 0.69 mmol) was added. The reaction was stirred for 72 hours at room temperature and then concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) and then by column chromatography (basic silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.46 - 1.65 (m, 2 H), 1.78 - 1.93 (m, 2 H), 2.01 - 2.12 (m, 2 H), 2.29 - 2.46 (m, 1 H), 2.76 - 2.93 (m, 2 H), 4.65 - 4.83 (m, 1 H), 7.11 - 7.26 (m, 2 H), 7.63 - 7.81 (m, 4 H), 8.50 - 8.58 (m, 1 H)

25 MS ES⁺: 375


Step (v): 2-([4-(Trifluoromethyl)pyridin-2-yl]methyl)cyclopentan-1-amine

Methanamine (40% aq, 1 ml, 11.55 mmol) was added to a solution of 2-(2-([4-(trifluoromethyl)pyridin-2-yl]methyl)cyclopentyl)-2,3-dihydro-1H-isoindole-1,3-dione (0.100 g, 0.27 mmol) in ethanol (6 ml) in a microwave vial. The vial was sealed and stirred at room temperature for 18 hours and then heated to 60 °C for 5 hours. The reaction was


cooled to room temperature and concentrated *in vacuo*. This was then purified by SCX chromatography (2M ammonia in methanol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.50 - 1.79 (m, 4 H), 1.79 - 2.02 (m, 2 H), 2.18 - 2.35 (m, 1 H), 2.86 - 3.02 (m, 1 H), 3.05 - 3.21 (m, 1 H), 3.26 - 3.38 (m, 1 H), 7.33 - 7.48 (m, 2 H), 8.62 - 8.74 (m, 1 H)

MS ES⁺: 245



Intermediate 13: 2-([5-(Trifluoromethyl)pyridin-2-yl]methyl)cyclopentan-1-amine



Step (i): 5-(Trifluoromethyl)pyridine-2-carbaldehyde

Dess-Martin periodinane (CAS number 87413-09-0; 13.17 g, 31.10 mmol) was added to a solution of [5-(trifluoromethyl)pyridin-2-yl]methanol (CAS number 31181-84-7; 5.00 g, 28.2 mmol) in DCM (60 ml). The reaction was stirred at room temperature for 18 hours and then a saturated solution of sodium thiosulfate (aq, 100 ml) was added. The reaction was stirred for 45 min at room temperature and then phases separated. The aqueous phase was further extracted with DCM (60 ml) and the combined organics were washed with a saturated solution of sodium bicarbonate (aq, 60 ml), filtered through a hydrophobic frit and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-20% ethyl acetate / petrol) to afford the title compound.

MS ES⁺: 176

Step (ii): 2-{{5-(Trifluoromethyl)pyridin-2-yl}methylidene}cyclopentan-1-one

A solution of 5-(trifluoromethyl)pyridine-2-carbaldehyde (3.32 g, 18.96 mmol) and 4-(cyclopent-1-en-1-yl)morpholine (CAS number 936-52-7; 2.97 ml, 18.58 mmol) in toluene (50 ml) was heated to 90 °C for 18 hours. The reaction was then cooled to room

temperature and concentrated HCl (2 ml) and water (2 ml) was added drop wise. The reaction was stirred at room temperature for 20 minutes and then neutralised with a saturated solution of sodium bicarbonate and then basified with 2M NaOH (aq). The organics were extracted with ethyl acetate (2 x 40 ml) and the combined organics were washed with brine (10 ml), dried over magnesium sulfate, filtered through a hydrophobic frit and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-20% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.94 - 2.13 (m, 2 H), 2.31 - 2.51 (m, 2 H), 3.11 - 3.36 (m, 2 H), 7.22 - 7.43 (m, 1 H), 7.51 - 7.72 (m, 1 H), 7.87 - 8.09 (m, 1 H), 8.95 (s, 1 H)

MS ES⁺: 242

Step (iii): 2-{{5-(Trifluoromethyl)pyridin-2-yl}methyl}cyclopentan-1-one

A solution of 2-{{5-(trifluoromethyl)pyridin-2-yl}methylidene}cyclopentan-1-one (0.513 g, 2.13 mmol) in ethyl acetate (20 ml) was added palladium on carbon (10% wt, 50% wet, 0.226 g, 0.11 mmol) and the resulting mixture was stirred under a balloon of hydrogen gas for 2 hours. The reaction was filtered through diatomaceous earth (commercially sold under the trade mark "Celite") and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-40% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.50 - 1.67 (m, 1 H), 1.71 - 1.88 (m, 1 H), 1.92 - 2.05 (m, 1 H), 2.07 - 2.24 (m, 2 H), 2.26 - 2.41 (m, 1 H), 2.62 - 2.79 (m, 1 H), 2.82 - 3.02 (m, 1 H), 3.16 - 3.41 (m, 1 H), 7.18 - 7.50 (m, 1 H), 7.80 - 8.00 (m, 1 H), 8.80 (br. s., 1 H)

MS ES⁺: 244

Step (iv): 2-{{5-(Trifluoromethyl)pyridin-2-yl}methyl}cyclopentan-1-ol

Sodium borohydride (0.036 g, 0.954 mmol) was added to a solution of 2-{{5-(trifluoromethyl)pyridin-2-yl}methyl}cyclopentan-1-one (0.116 g, 0.48 mmol) in ethanol (5 ml). The reaction was stirred at room temperature for 1 hour and then quenched with

water (5 ml) and 2M HCl (aq, 5 ml), basified with 2M NaOH (aq) and extracted with ethyl acetate (2 x 30 ml). The combined organics were dried over magnesium sulfate, filtered through a hydrophobic frit and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-30% ethyl acetate / petrol) to afford the title compound as two diastereomers.

Diastereomer 1: 2-([5-(trifluoromethyl)pyridin-2-yl]methyl)cyclopentan-1-ol

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 0.79 - 0.96 (m, 1 H), 1.22 - 1.40 (m, 1 H), 1.44 - 1.59 (m, 2 H), 1.60 - 1.71 (m, 1 H), 1.73 - 1.91 (m, 2 H), 1.98 - 2.13 (m, 1 H), 2.89 - 3.02 (m, 1 H), 3.03 - 3.14 (m, 1 H), 3.84 - 3.98 (m, 1 H), 7.26 - 7.41 (m, 1 H), 7.85 - 7.98 (m, 1 H), 8.77 (s, 1 H)

MS ES⁺: 246

Diastereomer 2: 2-([5-(trifluoromethyl)pyridin-2-yl]methyl)cyclopentan-1-ol

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 0.80 - 0.95 (m, 1 H), 1.26 - 1.40 (m, 1 H), 1.51 - 1.78 (m, 3 H), 1.84 - 2.05 (m, 2 H), 2.09 - 2.21 (m, 1 H), 2.92 - 3.11 (m, 2 H), 3.84 - 3.98 (m, 1 H), 7.29 - 7.45 (m, 1 H), 7.79 - 7.94 (m, 1 H), 8.78 (s, 1 H)

MS ES⁺: 246

Step (v): 2-(2-([5-(Trifluoromethyl)pyridin-2-yl]methyl)cyclopentyl)-2,3-dihydro-1H-isoindole-1,3-dione

DIAD (0.348 mL, 1.791 mmol) was added to a solution of 2,3-dihydro-1H-isoindole-1,3-dione (CAS number 136918-14-4; 0.263 g, 1.791 mmol), triphenylphosphine (0.470 g, 1.791 mmol) and 2-([5-(trifluoromethyl)pyridin-2-yl]methyl)cyclopentan-1-ol (Diastereomer 2) (0.366 g, 1.492 mmol) in THF (2 ml) under nitrogen. The reaction was stirred at room temperature for 72 hours and then concentrated. The crude product was purified by column chromatography (silica, 0-20% ethyl acetate / petrol) to afford the title compound.


¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.48 - 1.66 (m, 1 H), 1.74 - 1.92 (m, 2 H), 2.01 - 2.15 (m, 2 H), 2.32 - 2.53 (m, 1 H), 2.68 - 2.95 (m, 3 H), 4.76 (m, 1 H), 7.06 - 7.19 (m, 1 H), 7.64 - 7.81 (m, 5 H), 8.59 (s, 1 H)

MS ES⁺: 375

Step (vi): 2-[[5-(Trifluoromethyl)pyridin-2-yl]methyl]cyclopentan-1-amine

Methanamine (40% aq, 3 ml, 34.7 mmol) was added to a solution of 2-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)-2,3-dihydro-1H-isoin-
5 dole-1,3-dione (0.316 g, 0.84 mmol) in ethanol (5 ml). The reaction was stirred at room temperature for 24 hours and then further methanamine (40% aq, 3 ml, 34.7 mmol) was added. The reaction was stirred for 24 hours at room temperature and then re-suspended in ethanol (5 ml) and methanamine (40% aq, 3 ml, 34.7 mmol). The reaction stirred for 72 hours at room
10 temperature. The reaction mixture was concentrated *in vacuo* and was then purified by reverse phase preparative HPLC (eluted with acetonitrile / water with 0.1 % ammonia) and then purified by column chromatography (basic silica, 50-100% ethyl acetate / petrol) to afford the title compound.


MS ES⁺: 245

Intermediate 14: (1*S*,2*S*)-1-*N*-[5-(Trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride


A solution of 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 5.01 g,
20 27.5 mmol), *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 5 g, 24.97 mmol) and DIPEA (13.08 ml, 74.9 mmol) in DMSO (50 ml) was heated in a sealed vial at 120°C for 2 hours and then 140°C for 2 hours. The reaction mixture was partitioned between ethyl acetate (400 ml) and water (200 ml). The organics were washed with water (3 x 100 ml) and brine (100 ml), dried over sodium sulfate and concentrated *in*
25 *vacuo*. The resulting residue was purified by column chromatography (silica, 5-40% ethyl acetate / petrol). To the resulting solid was then added HCl in 1,4-dioxane (4M, 30 ml, 120 mmol) and the reaction was stirred at room temperature overnight. The reaction was concentrated *in vacuo*, triturated with diethyl ether and filtered to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.49 - 1.88 (m, 4 H), 2.02 - 2.22 (m, 2 H), 3.24 -
30 3.47 (m, 1 H), 4.12 - 4.28 (m, 1 H), 7.99 - 8.14 (m, 1 H), 8.18 - 8.48 (m, 5 H)

MS ES⁺: 247




5 **Intermediate 15: 2-Chloro-6-(2H-1,2,3-triazol-2-yl)benzoic acid**




To the solution of 2H-1,2,3-triazole (CAS number 288-36-8; 4.0 g, 57.97 mmol) in DMF (14 ml) was added cesium carbonate (18.84 g, 57.97 mmol), *trans*-1-*N*,2-*N*-
10 dimethylcyclohexane-1,2-diamine (0.510 g, 5.80 mmol), copper(I) iodide (0.276 g, 1.45 mmol) and 2-bromo-6-chlorobenzoic acid (CAS number 93224-85-2; 6.78 g, 28.98 mmol) at 0-10 °C. The reaction was subjected to microwave irradiation at 125°C for 15 minutes and was then partitioned between ethyl acetate (3 x 100 ml) and water (100 ml). The aqueous layer was acidified with 2M HCl (aq) to give pH 2 and then extracted with ethyl
15 acetate (3 x 100 ml). The combined organics were washed with brine, dried over sodium sulfate and concentrated *in vacuo*. This was then purified by column chromatography (0-3% methanol / DCM) to afford the title compound.

¹H NMR (400 MHz DMSO-*d*₆) δ ppm 7.62-7.67 (m, 2H), 7.92-7.94 (m, 1H), 8.17 (s, 2H), 13.73 (s, 1H)

20 MS ES⁺: 224, 226



Intermediate 16: 3-Cyclopropylpyridine-2-carboxylic acid



Step (i): Methyl 3-bromopyridine-2-carboxylate

To a solution of 3-bromopyridine-2-carboxylic acid (CAS number 30683-23-9; 2.0 g, 9.90 mmol) in methanol (15 ml) was added concentrated H_2SO_4 (3 ml) and the reaction mixture was refluxed for 2 hours. The reaction was diluted with a saturated solution of sodium bicarbonate and extracted with ethyl acetate (3 x 75 ml). The organics were washed with water (50 ml), brine (20 ml), dried over sodium sulfate and concentrated *in vacuo* to afford the title compound.

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 3.91 (s, 3H), 7.53-7.56 (m, 1H), 8.25-8.28 (m, 1H) 8.62-8.64 (m, 1H)

MS ES^+ : 218

Step (ii): Methyl 3-ethenylpyridine-2-carboxylate

Methyl 3-bromopyridine-2-carboxylate (1.0 g, 4.63 mmol) and potassium vinyltrifluoroborate (CAS number 13682-77-4; 0.744 g, 5.56 mmol) were dissolved in IPA (15 ml). To this was then added triethylamine (0.467 g, 4.63 mmol) and the mixture was degassed under nitrogen atmosphere for 15 minutes. [1,1'-Bis(diphenyl phosphino)ferrocene] dichloropalladium(II) (0.075 g, 0.092 mmol) was added and the reaction was stirred at 100°C for 4 hours. The reaction was diluted with water (75 ml) and filtered through diatomaceous earth (commercially sold under the trade mark "Celite"). The organics were extracted with ethyl acetate (3 x 50 ml), washed with water (25 ml),

brine (20 ml), dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0-18% ethyl acetate / n-hexane to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*) δ ppm 3.88 (s, 3H), 5.49-5.52 (m, 1H), 5.93-5.98 (m, 1H),
5 7.03-7.10 (m, 1H), 7.58-7.62 (m, 1H), 8.19-8.21 (m, 1H), 8.54-8.56 (m, 1H)

MS ES⁺: 164

Step (iii): Methyl 3-cyclopropylpyridine-2-carboxylate

To a stirred solution of diiodomethane (2.46 g, 9.20 mmol) in dry DCM (5 ml) at -10⁰C
10 was added diethyl zinc in hexane (1 M, 9.2 ml, 9.20 mmol). The reaction was stirred for 30 minutes under nitrogen. To this was then added methyl 3-ethenylpyridine-2-carboxylate (0.30 g, 1.84 mmol) as a solution in DCM (5 ml) over a 15 minute period. The reaction was then allowed to warm to room temperature and was stirred at room temperature for 15 hours. The reaction mixture was diluted with a saturated solution of ammonium chloride
15 (25 ml) and the organics were extracted with ethyl acetate (3 x 30 ml). The combined organics were washed with water (25 ml), brine (25 ml), dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0-15% ethyl acetate / n-hexane to afford the title compound.


MS ES⁺: 178

Step (iv): 3-cyclopropylpyridine-2-carboxylic acid

To a solution of methyl 3-cyclopropylpyridine-2-carboxylate (80 mg, 0.45 mmol) in THF (2 ml) and water (2 ml) was added lithium hydroxide (55 mg, 1.36 mmol) and the reaction mixture was refluxed for 2 hours. The reaction was then acidified to pH 2 using 1M HCl
25 (aq) and extracted with DCM (3 x 50 ml). The combined organics were washed with water (30 ml), brine (30 ml), dried over sodium sulfate and concentrated *in vacuo* to afford the title compound.

MS ES⁺: 164


Intermediate 17: 3,6-Difluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid




To the solution of 2H-1,2,3-triazole (CAS number 288-36-8; 0.23 g, 3.33 mmol) in 1,4-dioxane (4.0 ml) was added cesium carbonate (1.0 g, 3.33 mmol), *trans*-1-*N*,2-*N*-dimethylcyclohexane-1,2-diamine (0.047 g, 0.33 mmol), copper(I) iodide (0.015 g, 0.08 mmol) and 2-bromo-3,6-difluorobenzoic acid (CAS number 124244-65-1 ; 0.40 g, 1.68 mmol). The reaction was stirred at 120°C for 30 minutes and was then poured into water (10 ml) and extracted with ethyl acetate (2 x 30 ml). The organics were washed with brine, dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0-5% methanol / DCM) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*) 7.63-7.69 (m, 1H), 7.73-7.79 (m, 1H), 8.19 (s, 2H), 13.87 (br. s., 1H)

MS ES⁺: 225



Intermediate 18: *N*-[(1*S*,2*S*)-2-Aminocyclopentyl]-*N*-cyclobutyl-2,6-dimethoxybenzamide hydrochloride



Step (i): *tert*-Butyl *N*-[(1*S*,2*S*)-2-(cyclobutylamino)cyclopentyl]carbamate

To a solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 600 mg, 3.00 mmol) in dry DCM (10 ml) was added cyclobutanone (CAS number 1191-95-3; 248 µl, 3.30 mmol), acetic acid (257 µl, 4.49 mmol) and molecular sieves. The reaction was then stirred at room temperature for 1 hour. To this was then

added sodium triacetoxyborohydride (952 mg, 4.49 mmol) and the reaction was allowed to stir at room temperature for 17 hours. The reaction was basified by the addition of 2M NaOH (aq) and the organics were extracted DCM, filtered through a hydrophobic frit and concentrated *in vacuo*.

5

Step (ii): *tert*-Butyl *N*-[(1*S*,2*S*)-2-(*N*-cyclobutyl-2,6-dimethoxybenzamido)cyclopentyl]carbamate

To a solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-(cyclobutylamino)cyclopentyl]carbamate (400 mg, 1.573 mmol) in dry DCM (5.3 ml) was added DIPEA (1.3 ml, 7.86 mmol) and 2,6-dimethoxybenzoyl chloride (CAS number 1989-53-3; 473 mg, 2.359 mmol). The reaction was stirred at room temperature for 1 hour and was then partitioned between DCM and water, filtered through a hydrophobic frit and concentrated *in vacuo*. This was then purified by column chromatography (basic silica, 0-100% ethyl acetate / petrol) to afford the title compound.

15 MS ES⁺: 419


Step (iii): *N*-[(1*S*,2*S*)-2-Aminocyclopentyl]-*N*-cyclobutyl-2,6-dimethoxybenzamide hydrochloride

To a solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-(*N*-cyclobutyl-2,6-dimethoxybenzamido)cyclopentyl]carbamate (1.34 g, 3.20 mmol) in methanol (11 ml) was added HCl in 1,4-dioxane (4 M, 8.00 ml, 32.0 mmol). The reaction was stirred at room temperature for 17 hours (overnight) and then was concentrated *in vacuo*, azeotropically distilled with toluene to afford the title compound.

MS ES⁺: 319

25

Intermediate 19: *N*-[(1*S*,2*S*)-2-Aminocyclopentyl]-2-chlorobenzamide hydrochloride




To a stirred solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 500 mg, 2.497 mmol) in dry DCM (8.3 ml) was added triethylamine (1.74

ml, 12.48 mmol) and 2-chlorobenzoyl chloride (CAS number 609-65-4; 476 μ l, 3.74 mmol). The reaction was stirred at room temperature for 72 hours. The reaction was partitioned between DCM and a saturated solution of sodium bicarbonate, filtered through a hydrophobic frit and concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0-100% ethyl acetate / petrol). The Boc protect intermediate was dissolved in 1,4-dioxane (8 ml) and to this was added HCl in 1,4-dioxane (4 M, 6.0 ml, 23.91 mmol). The reaction was stirred at room temperature for 17 hours and then concentrated *in vacuo*, azeotropically distilled with toluene to afford the title compound.

^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.50 - 1.83 (m, 4 H), 1.98 - 2.16 (m, 2 H), 3.35 - 3.45 (m, 1 H), 4.06 - 4.31 (m, 1 H), 7.37 - 7.61 (m, 4 H), 8.03 - 8.25 (m, 2 H), 8.62 - 8.74 (m, 1 H)

MS ES⁺: 239

Intermediate 20: *N*-[(1*S*,2*S*)-2-Aminocyclopentyl]-2-fluoro-6-methoxybenzamide hydrochloride




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-chlorobenzamide hydrochloride (**Intermediate 19**) from *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 500 mg, 2.50 mmol), 2-fluoro-6-methoxybenzoic acid (CAS number 137654-21-8; 637 mg, 3.74 mmol) and 1,3,5,2,4,6-trioxatriphosphorinane,2,4,6-tripropyl-, 2,4,6-trioxide (CAS number 68957-94-8; 50% in ethyl acetate, 2.2 ml, 3.74 mmol). Subsequent deprotection with HCl afforded the title compound.

^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.51 - 1.79 (m, 4 H), 1.95 - 2.14 (m, 2 H), 3.34 - 3.42 (m, 1 H), 4.04 - 4.19 (m, 1 H), 6.77 - 6.99 (m, 2 H), 7.33 - 7.50 (m, 1 H), 7.94 - 8.11 (m, 2 H), 8.64 - 8.78 (m, 1 H)

MS ES⁺: 253


Intermediate 21: *N*-[(1*S*,2*S*)-2-Aminocyclopentyl]-2,6-difluorobenzamide hydrochloride




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-chlorobenzamide hydrochloride (**Intermediate 19**) from *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 500 mg, 2.50 mmol), 2,6-difluorobenzoic acid (CAS number 385-00-2; 592 mg, 3.74 mmol) and 1,3,5,2,4,6-trioxatriphosphorinane,2,4,6-tripropyl-, 2,4,6-trioxide (CAS number 68957-94-8; 50% in ethyl acetate, 2.2 ml, 3.74 mmol). Subsequent deprotection with HCl afforded the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.49 - 1.79 (m, 4 H), 1.94 - 2.13 (m, 2 H), 3.34 - 3.41 (m, 1 H), 4.02 - 4.16 (m, 1 H), 6.77 - 6.98 (m, 2 H), 7.34 - 7.47 (m, 1 H), 7.93 - 8.11 (m, 2 H), 8.66 - 8.78 (m, 1 H)

MS ES⁺: 241



Intermediate 22: (1*S*,2*S*)-1-*N*-Methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine



Step (i): *tert*-Butyl *N*-[(1*S*,2*S*)-2-(dibenzylamino)cyclopentyl]carbamate

To a suspension of *tert*-butyl *N*-[(*1S,2S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 500 mg, 2.50 mmol) and potassium carbonate (518 mg, 3.74 mmol) in DMF (5 ml) was added (bromomethyl)benzene (CAS number 100-39-0; 356 μ l, 3.00 mmol). The reaction was stirred at room temperature for 24 hours. To this was then added further (bromomethyl)benzene (CAS number 100-39-0; 356 μ l, 3.00 mmol) and stirring was continued for 24 hours. The reaction mixture was diluted with ethyl acetate (40 ml) and washed with water (3 x 30ml) and brine (30 ml). The organics were filtered through a hydrophobic frit and concentrated *in vacuo*. This was then purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.16 - 1.29 (m, 1 H), 1.37 - 1.67 (m, 12 H), 1.68 - 1.82 (m, 1 H), 1.92 - 2.06 (m, 1 H), 2.70 - 2.87 (m, 1 H), 3.46 (d, *J*=13.64 Hz, 2 H), 3.77 (d, *J*=13.64 Hz, 2 H), 4.28 - 4.49 (m, 1 H), 7.15 - 7.47 (m, 11 H)

MS ES⁺: 381

Step (ii): (*1S,2S*)-1-*N,1-N*-Dibenzyl-2-*N*-methylcyclopentane-1,2-diamine

To a solution of *tert*-butyl *N*-[(*1S,2S*)-2-(dibenzylamino)cyclopentyl]carbamate (320 mg, 0.841 mmol) in THF (2.8 ml) at room temperature was added drop wise lithium aluminium hydride in THF (1 M, 1.3 ml, 1.261 mmol). The reaction was stirred for 1 hour and then was heated to 60°C for 3 hours. The reaction was then cooled to room temperature and quenched by the addition of sodium sulfate decahydrate, filtered and washed with THF and ethyl acetate. The filtrate was concentrated *in vacuo* to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.16 - 1.33 (m, 1 H), 1.52 - 1.90 (m, 5 H), 2.24 - 2.33 (m, 3 H), 2.72 - 2.94 (m, 2 H), 3.37 - 3.50 (m, 2 H), 3.56 - 3.66 (m, 1 H), 3.69 - 3.85 (m, 2 H), 7.13 - 7.51 (m, 10 H)

Step (iii): (*1S,2S*)-1-*N,1-N*-Dibenzyl-2-*N*-methyl-2-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine

A solution of 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 198 mg, 1.087 mmol), (*1S,2S*)-1-*N,1-N*-dibenzyl-2-*N*-methylcyclopentane-1,2-diamine (291 mg, 0.988 mmol) and DIPEA (518 μ l, 2.97 mmol) in DMSO (3.3 ml) was subjected to microwave irradiation at 140 °C for 4 hours. The reaction was diluted with ethyl acetate (20 ml), washed with a saturated solution of sodium bicarbonate (3 x 20 ml), brine (20 ml),

filtered through a hydrophobic frit and concentrated *in vacuo*. This was then purified by column chromatography (silica, 0-15% ethyl acetate / petrol) to afford the title compound.

^1H NMR (400 MHz, $\text{DCM}-d_2$) δ ppm 1.43 - 1.58 (m, 2 H), 1.61 - 1.93 (m, 4 H), 2.58 (s, 3 H), 3.17 - 3.33 (m, 1 H), 3.41 (d, $J=13.64$ Hz, 2 H), 3.76 (d, $J=13.64$ Hz, 2 H), 5.12 - 5.29 (m, 1 H), 7.03 - 7.29 (m, 10 H), 7.96 (s, 1 H), 8.23 (s, 1 H)


MS ES^+ : 441

Step (iv): (1*S*,2*S*)-1-*N*-Methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine


To a solution of (1*S*,2*S*)-1-*N*,1-*N*-dibenzyl-2-*N*-methyl-2-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (285 mg, 0.647 mmol) in ethyl acetate (2 ml) and ethanol (1 ml) was added palladium on carbon (10% wt, 50% wet, 100 mg, 0.094 mmol). The resulting mixture was stirred under a balloon of hydrogen gas for 18 hours. The reaction was filtered through diatomaceous earth (commercially sold under the trade mark "Celite") and concentrated *in vacuo* to afford the title compound.

^1H NMR (400 MHz, $\text{DCM}-d_2$) δ ppm 1.37 - 1.56 (m, 1 H), 1.61 - 1.87 (m, 3 H), 1.88 - 2.08 (m, 2 H), 3.01 (s, 3 H), 3.24 - 3.42 (m, 1 H), 4.52 - 4.71 (m, 1 H), 8.11 (s, 1 H), 8.32 (s, 1 H)

MS ES^+ : 261



Intermediate 23: (1*S*,2*S*)-1-*N*-Methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride



Step (i): *tert*-Butyl *N*-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]carbamate

A solution of 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 2.0 g, 10.98 mmol), *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 2 g, 9.99 mmol) and DIPEA (5.23 ml, 30.0 mmol) in DMSO (20 ml) was sealed and heated at 140°C for 3 hours. The reaction mixture was partitioned between ethyl acetate (200 ml) and water (100 ml). The organics were washed with water (2 x 100ml), brine (100 ml), dried over sodium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography (silica, 10-40% ethyl acetate / petrol) to afford the title compound.

¹H NMR (300 MHz, CHLOROFORM-*d*) δ ppm 1.32 - 1.66 (m, 11 H), 1.71 - 1.96 (m, 2 H), 2.07 - 2.24 (m, 1 H), 2.30 - 2.51 (m, 1 H), 3.76 - 4.04 (m, 2 H), 4.69 - 4.92 (m, 1 H), 6.07 - 6.24 (m, 1 H), 7.91 (s, 1 H), 8.30 (s, 1 H)

MS ES⁺: 347

Step (ii): *tert*-Butyl *N*-[(1*S*,2*S*)-2-[[3-bromo-5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]carbamate

To a solution of *tert*-butyl ((1*S*,2*S*)-2-((5-(trifluoromethyl)pyrazin-2-yl)amino)cyclopentyl)carbamate (3.49 g, 10.08 mmol) in dry DCM (67 ml) at 0°C was added 1-bromopyrrolidine-2,5-dione (CAS number 128-08-5; 2.15 g, 12.09 mmol). The reaction was allowed to warm to room temperature overnight. A further portion of portion of 1-bromopyrrolidine-2,5-dione (CAS number 128-08-5; 1.70 g, 9.56 mmol) was added and the reaction stirred for an additional 24 hours. The reaction was concentrated *in vacuo* and then purified by column chromatography (silica, 0-30% ethyl acetate / petrol) to afford the title compound.

¹H NMR (300 MHz, CHLOROFORM-*d*) δ ppm 1.31 - 1.62 (m, 11 H), 1.72 - 1.92 (m, 2 H), 2.08 - 2.24 (m, 1 H), 2.36 - 2.56 (m, 1 H), 3.75 - 4.14 (m, 2 H), 4.63 - 4.87 (m, 1 H), 6.78 - 6.96 (m, 1 H), 8.25 (s, 1 H)

MS ES⁺: 425, 427

Step (iii): *tert*-Butyl *N*-[(1*S*,2*S*)-2-{{3-methyl-5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]carbamate

A mixture of *tert*-butyl *N*-[(1*S*,2*S*)-2-{{3-bromo-5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]carbamate (800 mg, 1.88 mmol), methylboronic acid (CAS number 13061-96-6; 338 mg, 5.64 mmol), tetrakis(triphenylphosphine)palladium (217 mg, 0.19 mmol) and, 2 M potassium carbonate (aq, 3.8 ml, 7.53 mmol) in 1,4-dioxane (6.3 ml) was sealed, evacuated and purged with nitrogen and then subjected to microwave irradiation at 120°C for 2 hours. The reaction mixture was then diluted with ethyl acetate (40 ml) and water (10 ml). The organics were washed with water and brine, dried over sodium sulfate and concentrated *in vacuo*. The residue was then purified by column chromatography (silica, 0-50% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 1.34 - 1.53 (m, 11 H), 1.73 - 1.93 (m, 2 H), 2.08 - 2.20 (m, 1 H), 2.43 (s, 3 H), 2.48 - 2.64 (m, 1 H), 3.73 - 3.89 (m, 1 H), 3.95 - 4.09 (m, 1 H), 4.75 - 4.85 (m, 1 H), 6.45 - 6.57 (m, 1 H), 8.20 (s, 1 H)


MS ES⁺: 361

Step (iv): (1*S*,2*S*)-1-*N*-Methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride


To a solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-{{3-methyl-5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]carbamate (480 mg, 1.332 mmol) in methanol (5 ml) was added HCl in 1,4-dioxane (4 M, 3.33 ml, 13.32 mmol). The reaction was stirred at room temperature overnight and then concentrated *in vacuo*, azeotropically distilled with toluene to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.58 - 1.85 (m, 4 H), 1.99 - 2.23 (m, 2 H), 2.43 (s, 3 H), 3.46 - 3.65 (m, 1 H), 4.28 - 4.46 (m, 1 H), 7.24 - 7.41 (m, 1 H), 8.13 - 8.37 (m, 4 H)

MS ES⁺: 261



Intermediate 24: *tert*-Butyl *N*-(2-amino-1-methylcyclopentyl)carbamate

**Step (i): 1-Methyl-6-(4-methylbenzenesulfonyl)-6-azabicyclo[3.1.0]hexane**

To a solution of 1-methylcyclopent-1-ene (CAS number 693-89-0; 50.0 g, 609.75 mmol) and sodium chloro(4-methylbenzenesulfonyl)azanide (CAS number 127-65-1; 192 g, 680.85 mmol) in THF (2500 ml) was added trimethylphenylammonium tribromide (13.3 g, 61.57 mmol). The reaction was stirred vigorously at 25 °C for 12 hours. The reaction mixture was poured into water (1500 ml) and the organics were extracted with ethyl acetate (3 x 1000 ml). The combined organics were washed with water (500 ml), brine (500 ml), dried over sodium sulfate and concentrated *in vacuo*. This was then purified by column chromatography (silica, 0-2.5% ethyl acetate / n-hexane) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.15 - 1.25 (m, 1H), 1.46 - 1.70 (m, 4H), 1.75 (s, 3H), 1.88 - 1.93 (m, 1H), 2.50 (s, 3H), 3.34-3.35 (m, 1H), 7.40-7.42 (m, 2H), 7.74-7.76 (m, 2H)

MS ES⁺: 251

Step (ii): N-(2-Azido-2-methylcyclopentyl)-4-methylbenzene-1-sulfonamide

To a solution of 1-methyl-6-(4-methylbenzenesulfonyl)-6-azabicyclo[3.1.0]hexane (55 g, 219.12 mmol) in IPA (1000 ml) and water (1000 ml) was added sodium azide (57.0 g, 876.92 mmol). The reaction mixture was stirred at room temperature for 17 hours. The reaction was cooled to room temperature and water (1000 ml) was added. The aqueous layer was extracted with diethyl ether (3 x 500 ml). The combined organics were washed with brine (250 ml), dried over sodium sulfate, concentrated *in vacuo* to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.20-1.30 (m, 4H), 1.45-1.63 (m, 5H), 2.38 (s, 3H) 3.33-3.39 (m, 1H), 7.38-7.40 (m, 2H), 7.69-7.77 (m, 3H)

MS ES⁺: 294

Step (iii): N-(2-Amino-2-methylcyclopentyl)-4-methylbenzene-1-sulfonamide

To a solution of *N*-(2-azido-2-methylcyclopentyl)-4-methylbenzene-1-sulfonamide (52.0 g, 176.87 mmol) in methanol (1100 ml) was added palladium on carbon (10% wt, 10.0 g). The reaction mixture was stirred at room temperature under a balloon of hydrogen gas for 12 hours. The reaction was filtered through diatomaceous earth (commercially sold under the trade mark "Celite") and concentrated *in vacuo* to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.93 (s, 3H), 1.20-1.22 (m, 1H), 1.36-1.52 (m, 5H) 2.38 (s, 3H) 2.94-2.98 (m, 1H) 4.11 (br. s, 1H), 7.37-7.39 (m, 2H), 7.69-7.71 (m, 2H)
MS ES⁺: 268

Step (iv): *tert*-Butyl *N*-[1-methyl-2-(4-methylbenzenesulfonamido)-cyclopentyl]carbamate

To a solution of *N*-(2-amino-2-methylcyclopentyl)-4-methylbenzene-1-sulfonamide (48.0 g, 179.10 mmol) in DCM (1400 ml) was added triethylamine (27.13 g, 268.65 mmol) and di-*tert*-butyl dicarbonate (CAS number 24424-99-5; 46.85 g, 214.92 mmol). The reaction mixture was stirred at room temperature for 15 hours. The reaction mixture was concentrated *in vacuo* and the resulting residue was partitioned between ethyl acetate (1000 ml) and water (800 ml). The organics were dried over sodium sulfate and concentrated *in vacuo*. The solid was then triturated with hexane (300 ml) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.16 (s, 3H), 1.18-1.57 (m, 14H), 1.92 (m, 1H) 2.67 (s, 3H) 3.53 (m, 1H) 6.24 (br. s, 1H), 7.27-7.39 (m, 2H), 7.60-7.69 (m, 3H)
MS ES⁺: 368


Step (v): *tert*-Butyl *N*-(2-amino-1-methylcyclopentyl)carbamate

A mixture of lithium granules (7.17 g, 1195 mmol) and naphthalene (57.39 g, 448.36 mmol) in dry dimethoxyethane (1900 ml) was stirred at room temperature for 2 hours. The deep blue solution was then cooled to 0°C and a solution of *tert*-butyl *N*-[1-methyl-2-(4-methylbenzenesulfonamido)cyclopentyl]carbamate (55.0 g, 149.45 mmol) in dry dimethoxyethane (300 ml) was added drop wise over 30 minutes. The mixture was stirred at 0°C for 3 hours. The un-dissolved lithium was removed by filtration and 1M HCl solution (aq, 720 ml) was added to the filtrate. The organic layer was washed with further 1M HCl (aq, 2 x 600 ml). The combined aqueous layers were washed with diethyl ether (2


x 600), and then basified with 2M NaOH (aq) to give pH 12-14. The aqueous layer was then extracted with ethyl acetate (5 x 600 ml). The combined organics were dried over sodium sulfate and then concentrated *in vacuo*. This was then purified by column chromatography (silica, 0-4% methanol / DCM) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.10 (s, 3H), 1.14-1.27 (m, 2H), 1.40 (s, 9H) 1.44-1.55 (m, 2H) 1.76-1.86 (m, 2H) 2.72 (br. s, 2H), 3.09 (m, 1H) 6.61 (br. s, 1H)
MS ES⁺: 214

Intermediate 25: (1*S*,2*S*)-1-Methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine



Method 1:



Step (i): (1*R*,2*S*,5*R*)-5-Methyl-2-(propan-2-yl)cyclohexyl *N*-(2-(((*tert*-butoxy)carbonyl]amino}-2-methylcyclopentyl)carbamate

To a solution of *tert*-butyl *N*-(2-amino-1-methylcyclopentyl)carbamate (**Intermediate 24**; 5.49 ml, 26.1 mmol) in DCM (87 ml) at 0 °C was added DIPEA (4.56 ml, 26.1 mmol) followed by (1*R*,2*S*,5*R*)-5-methyl-2-(propan-2-yl)cyclohexyl chloroformate (CAS number 14602-86-9; 17.15 g, 78 mmol) drop wise. The reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction was diluted with DCM (150 ml) and a saturated solution of sodium bicarbonate solution (200 ml). The aqueous layer was re-extracted with DCM (100 ml) and the combined organics were washed further with a

saturated solution of sodium bicarbonate (100 ml), dried over magnesium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography (silica, 0-50% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 0.72 - 1.79 (m, 30 H), 1.81 - 2.34 (m, 6 H), 3.80 - 4.01 (m, 1 H), 4.44 - 4.90 (m, 2 H), 5.98-6.11 (m, 1 H)

MS ES⁺: 397

Step (ii): (1*R*,2*S*,5*R*)-5-Methyl-2-(propan-2-yl)cyclohexyl *N*-(2-amino-2-methylcyclopentyl)carbamate hydrochloride

To a solution of (1*R*,2*S*,5*R*)-5-methyl-2-(propan-2-yl)cyclohexyl *N*-(2-{{(*tert*-butoxy)carbonyl}amino)-2-methylcyclopentyl)carbamate (6.12 g, 15.43 mmol) in 1,4-dioxane (35 ml) was added HCl in 1,4-dioxane (4 M, 38.6 ml, 154 mmol). The reaction mixture was stirred at room temperature overnight, concentrated *in vacuo* and azeotropically distilled with toluene to afford the title compound.

¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 0.62 - 2.09 (m, 27 H), 3.75 - 4.00 (m, 1 H), 4.30 - 4.55 (m, 1 H), 7.31 - 7.46 (m, 1 H), 7.96 (br. s., 3 H)

MS ES⁺: 297

Step (iii): (1*R*,2*S*,5*R*)-5-Methyl-2-(propan-2-yl)cyclohexyl *N*-[(1*S*,2*S*)-2-methyl-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]carbamate

A solution of (1*R*,2*S*,5*R*)-5-methyl-2-(propan-2-yl)cyclohexyl *N*-(2-amino-2-methylcyclopentyl)carbamate hydrochloride (5.14 g, 15.44 mmol), 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 2.097 ml, 16.98 mmol) and DIPEA (8.10 ml, 46.32 mmol) in DMSO (51.5 ml) was heated to 140 °C for 17 hours. The reaction mixture was diluted with water (200 ml) and extracted with ethyl acetate (2 x 200 ml). The combined organics were washed with brine (3 x 200 ml), dried over magnesium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography (silica, 0-15 % ethyl acetate / petrol) to afford the title compound as a single diastereomer.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 0.68 - 2.04 (m, 27 H), 2.06 - 2.20 (m, 1 H), 2.41 - 2.64 (m, 1 H), 4.56 - 4.70 (m, 1 H), 4.85 - 5.03 (m, 1 H), 7.64 - 8.08 (m, 1 H), 8.21 (br. s., 1 H)

MS ES⁺: 443


Step (iv): (1*S*,2*S*)-1-Methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine

To a solution of (1*R*,2*S*,5*R*)-5-methyl-2-(propan-2-yl)cyclohexyl *N*-[(1*S*,2*S*)-2-methyl-2-
 5 {5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate (1.03 g, 2.328 mmol) in
 acetic acid (8 ml) was added HBr (6 M, 1.940 ml, 11.64 mmol). The reaction was heated to
 90 °C for 20 hours in a sealed vial and then cooled. To this was then added further HBr (6
 M, 1.00 ml, 6 mmol) and the reaction was heated at 90 °C for 36 hours. The reaction was
 10 cooled to room temperature and concentrated *in vacuo*. The crude product was purified by
 reverse phase chromatography (C18 silica, 5-100% water (with 0.05% ammonia) /
 acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.32 (s, 3 H), 1.37 - 1.51 (m, 1 H), 1.63 - 1.76 (m, 2
 H), 1.85 - 2.22 (m, 3 H), 3.17 - 3.35 (m, 1 H), 5.44 (br. s., 1 H), 7.89 (s, 1 H), 8.29 (s, 1 H)

15 MS ES⁺: 261

Method 2:



Step (i): (1*R*,2*S*,5*R*)-5-Methyl-2-(propan-2-yl)cyclohexyl *N*-[(1*S*,2*S*)-2-methyl-2-{5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

A solution of 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 0.816 ml,
 25 6.61 mmol), (1*R*,2*S*,5*R*)-5-methyl-2-(propan-2-yl)cyclohexyl *N*-(2-amino-2-
 methylcyclopentyl)carbamate hydrochloride (**Intermediate 27**; 2.00 g, 6.01 mmol) and
 DIPEA (3.15 ml, 18.02 mmol) in DMSO (10 mL) was subjected to microwave irradiation
 at 140 °C for 5 hours. The reaction was diluted with ethyl acetate (100 ml) and a saturated
 solution of sodium bicarbonate (50 m). The organics were washed with water (40 ml),
 30 brine (40 ml), dried over magnesium sulfate, filtered through a hydrophobic frit and

concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0 - 20% ethyl acetate / petrol) to afford the title compound

MS ES⁺: 443


Step (ii): (1*S*,2*S*)-1-Methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine

To a solution of (1*R*,2*S*,5*R*)-5-methyl-2-(propan-2-yl)cyclohexyl *N*-[(1*S*,2*S*)-2-methyl-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]carbamate (1.03 g, 2.33 mmol) in acetic acid (8 ml) was added HBr (6M, 1.94 ml, 11.64 mmol). The reaction was sealed and heated to 90 °C for 20 hours. To this was added further HBr (6M, 1.00 ml, 6.00 mmol) and the reaction was heated at 90 °C for 36 hours and was then concentrated *in vacuo*. The crude product was purified by reverse phase chromatography (C18 silica, 0-100% water (with 0.05% ammonia) / acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.32 (s, 3 H), 1.33 - 2.19 (m, 6 H), 3.21 - 3.35 (m, 1 H), 5.44 (br. s., 1 H), 7.89 (s, 1 H), 8.29 (s, 1 H)

MS ES⁺: 261

Intermediate 26: *N*-(2-Amino-2-methylcyclopentyl)-2-(2*H*-1,2,3-triazol-2-yl)benzamide hydrochloride




To a solution of 2-(2*H*-1,2,3-triazol-2-yl)benzoyl chloride (213 mg, 1.03 mmol) (which was prepared from 2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 0.194 g, 1.03 mmol) and thionyl chloride (0.112 ml, 1.541 mmol)) in dry DCM (3.1 ml) was added *tert*-butyl *N*-(2-amino-1-methylcyclopentyl)carbamate (**Intermediate 24**; 200 mg, 0.93 mmol) and DIPEA (489 μl, 2.80 mmol). The reaction was stirred at room temperature for 17 hours and was then partitioned between a saturated solution of sodium bicarbonate and DCM, filtered through a hydrophobic frit and concentrated *in vacuo*. This was then purified by column chromatography (silica, 0-100% ethyl acetate / petrol). The


resulting product was then dissolved in 1,4-dioxane (5 ml) and to this was then added HCl in 1,4-dioxane (4 M, 2.3 ml, 9.33 mmol). The reaction was stirred at room temperature for 1 hour and then concentrated *in vacuo*, azeotropically distilled with toluene to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.23 (s, 3 H), 1.55 - 1.80 (m, 4 H), 1.84 - 2.01 (m, 2 H), 4.10 - 4.28 (m, 1 H), 7.54 - 7.60 (m, 1 H), 7.62 - 7.70 (m, 2 H), 7.81 - 7.86 (m, 1 H), 7.98 (br. s., 3 H), 8.07 (s, 2 H), 8.60 - 8.76 (m, 1 H)

MS ES⁺: 286



Intermediate 27: (1R,2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexyl N-(2-amino-2-methylcyclopentyl)carbamate hydrochloride



Step (i): 5-Methyl-6-azabicyclo[3.2.0]heptan-7-one

To a solution of 1-methylcyclopent-1-ene (CAS number 693-89-0; 38.5 mL, 365 mmol) in diethyl ether (220 ml) at 0 °C was added drop wise [(chlorosulfonyl)imino]methanone (CAS number 1189-71-5; 33.3 ml, 383 mmol). The reaction was then allowed to warm to room temperature and then heated to 36 °C for 72 hours. The reaction was then cooled to room temperature and a solution of sodium sulfite (73.5 g) in water (400 ml) was added drop wise, followed by the addition of 15% w/v potassium hydroxide (500 ml) to obtain pH 7-8. The phases were separated and aqueous phase was extracted with diethyl ether (2 x

200 ml). The combined organics were dried over magnesium sulfate and concentrated *in vacuo* to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.23 - 1.36 (m, 1 H), 1.37 - 1.81 (m, 8 H), 2.82 - 2.95 (m, 1 H), 7.60 (br. s., 1 H)

5

Step (ii): *tert*-Butyl 5-methyl-7-oxo-6-azabicyclo[3.2.0]heptane-6-carboxylate

To a solution of 5-methyl-6-azabicyclo[3.2.0]heptan-7-one (41.39 g, 331 mmol) in THF (500 ml) was added *N,N*-dimethylpyridin-4-amine (0.404 g, 3.31 mmol), triethylamine (115 ml, 827 mmol) and di-*tert*-butyl dicarbonate (81 ml, 347 mmol). The reaction was stirred at room temperature for 20 hours and then concentrated *in vacuo*. The residue was purified by column chromatography (silica, petrol then 10% ethyl acetate / petrol then 20% ethyl acetate / petrol (step gradient)) to afford the title compound.

10

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.30 - 1.69 (m, 15 H), 1.75 - 1.88 (m, 2 H), 2.07 - 2.20 (m, 1 H), 3.08 - 3.17 (m, 1 H)

15

Step (iii): Methyl 2-{{{*tert*-butoxy}carbonyl}amino}-2-methylcyclopentane-1-carboxylate

Sodium methoxide (30%, 85 ml, 457 mmol) was added drop wise to a solution of *tert*-butyl 5-methyl-7-oxo-6-azabicyclo[3.2.0]heptane-6-carboxylate (51.52 g, 229 mmol) in methanol (400 ml) at 0 °C. The reaction was stirred at room temperature for 68 hours. The reaction was then concentrated *in vacuo*, partitioned between ethyl acetate (200 ml) and water (100 ml) and the aqueous phase re-extracted with ethyl acetate (200 ml). The combined organics were dried over magnesium sulfate and concentrated *in vacuo* to afford the title compound which was used without further purification.

20

25

Step (iv): 2-{{{*tert*-Butoxy}carbonyl}amino}-2-methylcyclopentane-1-carboxylic acid

Lithium hydroxide (23.50 g, 981 mmol) was added to a solution of methyl 2-{{{*tert*-butoxy}carbonyl}amino}-2-methylcyclopentane-1-carboxylate (50.51 g, 196 mmol) in THF (300 ml) and water (150 ml). The reaction was heated at 50 °C for 18 hours and then to 60 °C for 18 hours. The reaction was concentrated *in vacuo* and then acidified to pH 7 with concentrated HCl and then to pH 3 with 2 M HCl (aq). The organics were extracted with ethyl acetate (3 x 300 ml) and the combined organics were washed with brine (50 ml),

30

dried over magnesium sulfate and concentrated *in vacuo* to afford the title compound which was used without further purification.


Step (v): (1*R*,2*S*,5*R*)-5-Methyl-2-(propan-2-yl)cyclohexyl *N*-(2-(((*tert*-butoxy)carbonyl]amino)-2-methylcyclopentyl)carbamate

To a solution of 2-(((*tert*-butoxy)carbonyl]amino)-2-methylcyclopentane-1-carboxylic acid (42.68 g, 175 mmol) and triethylamine (25.7 ml, 184 mmol) in toluene (250 ml) at room temperature was added [[azido(phenoxy)phosphoryl]oxy]benzene (CAS number 26386-88-9; 37.8 ml, 175 mmol) as a solution in toluene (100 ml). The reaction was heated to 60 °C for 2 hours, then (1*R*,2*S*,5*R*)-5-methyl-2-(propan-2-yl)cyclohexan-1-ol (CAS number 2216-51-5; 14.25 g, 91 mmol) was added. The reaction was heated at 90 °C for 20 hours and then cooled to room temperature, quenched by the addition of water (50 ml) and diluted with ethyl acetate (200 ml). The organics were washed with a saturated solution of sodium bicarbonate (2 x 100 ml), brine (100 ml), dried over magnesium sulfate, filtered through a hydrophobic frit and concentrated *in vacuo*. The residue was purified by column chromatography (silica, petrol - 10% ethyl acetate / petrol - 20% ethyl acetate / petrol (step gradient)) to afford the title compound (a mixture of trans-amino compounds) which was taken on to next stage without further purification.


Step (vi): (1*R*,2*S*,5*R*)-5-Methyl-2-(propan-2-yl)cyclohexyl *N*-(2-amino-2-methylcyclopentyl)carbamate hydrochloride

To a solution of (1*R*,2*S*,5*R*)-5-methyl-2-(propan-2-yl)cyclohexyl *N*-(2-(((*tert*-butoxy)carbonyl]amino)-2-methylcyclopentyl)carbamate (25.2 g, 63.5 mmol) in DCM (100 ml) was added HCl in 1,4-dioxane (4 M, 60 ml, 240 mmol). The reaction mixture was stirred at room temperature for 18 hours and then further HCl in 1,4-dioxane (4 M, 20 ml, 80 mmol) was added and the stirred for an additional 24 hours at room temperature. The reaction was concentrated *in vacuo* and purified by SCX chromatography (2M ammonia in methanol). The resulting residue was suspended in DCM / methanol and to this was added HCl in 1,4-dioxane (4 M, 10 ml, 40 mmol) and stirred for 2 hours. The reaction was concentrated *in vacuo* and further evaporated from diethyl ether and then methanol to afford the title compound as a mixture of trans-amino compounds.

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 0.68 - 1.76 (m, 22 H), 1.77 - 2.09 (m, 5 H), 3.81 - 4.00 (m, 1 H), 4.35 - 4.54 (m, 1 H), 7.29 - 7.46 (m, 1 H), 7.88 - 8.10 (m, 3 H)



Intermediate 28: 1-N-[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]-1-methylcyclopentane-1,2-diamine



Step (i): (1*R*,2*S*,5*R*)-5-Methyl-2-(propan-2-yl)cyclohexyl *N*-(2-[[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino]-2-methylcyclopentyl)carbamate

A solution of (1*R*,2*S*,5*R*)-5-methyl-2-(propan-2-yl)cyclohexyl *N*-(2-amino-2-methylcyclopentyl)carbamate hydrochloride (**Intermediate 27**; 1.00 g, 3.00 mmol), 2,3-difluoro-5-(trifluoromethyl)pyridine (CAS number 89402-42-6; 0.412 ml, 3.30 mmol) and DIPEA (1.57 ml, 9.01 mmol) in DMSO (10 ml) was subjected to microwave irradiation at 140 °C for 3 hours. The reaction was then partitioned between ethyl acetate (10 ml) and water (10 ml), filtered through a hydrophobic frit and concentrated *in vacuo*. The residue was purified by column chromatography (silica, 0-12% diethyl ether / petrol) to afford the title compound as a single trans-enantiomer.

^1H NMR (400 MHz, $\text{DCM}-d_2$) δ ppm 0.68 - 2.17 (m, 26 H), 2.51 - 2.72 (m, 1 H), 4.02 - 4.23 (m, 1 H), 4.53 - 4.69 (m, 1 H), 4.92 (br. s., 1 H), 7.15 - 7.32 (m, 2 H), 8.03 - 8.19 (m, 1 H)

MS ES^+ : 460


Step (ii): 1-N-[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]-1-methylcyclopentane-1,2-diamine

To a solution (1*R*,2*S*,5*R*)-5-methyl-2-(propan-2-yl)cyclohexyl *N*-(2-[[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino]-2-methylcyclopentyl)carbamate (0.533 g, 1.16 mmol) in acetic acid (4 ml) was added HBr (6 M, 0.98 ml, 5.80 mmol). The reaction was


sealed and heated at 90 °C for 24 hours. To this was then added further HBr (6 M, 0.50 ml, 3.00 mmol) and the reaction was heated at 90 °C for a further 6 hours. The reaction was cooled to room temperature and concentrated *in vacuo*. The residue was purified by SCX chromatography (2M ammonia in methanol) and then concentrated *in vacuo*. The crude product was further purified by reverse phase chromatography (C18 silica, 0-100% water (with 0.05% ammonia) / acetonitrile) to afford the title compound as a single trans-enantiomer.

¹H NMR (300 MHz, DCM-*d*₂) δ ppm 1.28 - 1.50 (m, 4 H), 1.59 - 1.79 (m, 4 H), 1.88 - 2.25 (m, 3 H), 3.25 - 3.45 (m, 1 H), 5.25 (br. s., 1 H), 7.21 - 7.36 (m, 1 H), 8.08 - 8.19 (m, 1 H)

MS ES⁺: 278



Intermediate 29: *N*-[(1*S*,2*S*)-2-[(3-Chloro-5-(trifluoromethyl)pyrazin-2-yl)amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide



Step (i): *tert*-Butyl *N*-[(1*S*,2*S*)-2-[(5-(trifluoromethyl)pyrazin-2-yl)amino]cyclopentyl]carbamate

A solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 1 g, 4.99 mmol), 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 1.09 g, 5.99 mmol) and DIPEA (2.62 ml, 14.98 mmol) in DMSO (17 ml) was subjected to microwave irradiation at 140 °C for 1 hour. The reaction was partitioned between ethyl acetate and water, washed with water, brine, dried over magnesium sulfate and concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, METHANOL-*d*₄) δ ppm 1.35 (s, 9 H), 1.48 - 1.64 (m, 2 H), 1.71 - 1.85 (m, 2 H), 2.03 - 2.23 (m, 2 H), 3.72 - 3.86 (m, 1 H), 4.14 - 4.25 (m, 1 H), 7.84 - 7.98 (m, 1 H), 8.18 - 8.29 (m, 1 H)

MS ES⁺: 347

5

Step (ii): (*1S,2S*)-1-*N*-[3-Chloro-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride

To a solution of *tert*-butyl *N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate (1.04 g, 3.00 mmol) in dry DCM (10 ml) at 0 °C under an atmosphere of nitrogen was added 1-bromopyrrolidine-2,5-dione (CAS number 128-08-5; 0.80 g, 4.50 mmol). The reaction was allowed to warm to room temperature and stirred for 17 hours and then was concentrated *in vacuo*. The resulting residue was purified by column chromatography (basic silica, 0-50% ethyl acetate / petrol). To this was then added HCl in 1,4-dioxane (4 M, 7.51 ml, 30.0 mmol) and stirred at room temperature for 72 hours. The reaction mixture was concentrated *in vacuo* and azeotropically distilled with toluene to afford the title compound.

15

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.58 - 1.83 (m, 4 H), 2.00 - 2.16 (m, 2 H), 3.54 - 3.66 (m, 1 H), 4.39 - 4.57 (m, 1 H), 7.80 - 8.04 (m, 4 H), 8.42 - 8.53 (m, 1 H)

MS ES⁺: 281

20

Step (iii): *N*-[(*1S,2S*)-2-{[3-Chloro-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide


To a solution of (*1S,2S*)-1-*N*-[3-chloro-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (530 mg, 1.67 mmol) in dry DMF (5.6 ml) was added 2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 348 mg, 1.84 mmol), HATU (953 mg, 2.51 mmol) and triethylamine (699 μl, 5.01 mmol) and then stirred at room temperature for 17 hours. The reaction was partitioned between ethyl acetate and a saturated solution of sodium bicarbonate. The organics were washed with water, brine, dried over magnesium sulfate and concentrated *in vacuo*. The resulting residue was purified by column chromatography (basic silica, 0-100% ethyl acetate / petrol) to afford the title compound.

30


^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.49 - 1.77 (m, 4 H), 1.93 - 2.05 (m, 1 H), 2.06 - 2.17 (m, 1 H), 4.18 - 4.29 (m, 1 H), 4.33 - 4.44 (m, 1 H), 7.40 - 7.46 (m, 1 H), 7.46 - 7.53 (m, 1 H), 7.56 - 7.64 (m, 1 H), 7.72 - 7.78 (m, 1 H), 7.79 - 7.87 (m, 3 H), 8.41 - 8.57 (m, 2 H)

5 MS ES⁺: 452


Intermediate 30a and 30b: *N*-[(1*S*,2*S*)-2-[(5-Bromopyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide (Intermediate 30a) and *N*-[(1*S*,2*S*)-2-[(5-Chloropyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide (Intermediate 30b)



A solution of *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 4**; 1.00 g, 3.25 mmol), 2-bromo-5-chloropyrazine (CAS number 912773-21-8; 0.691 g, 3.57 mmol) and DIPEA (1.7 ml, 9.75 mmol) in DMSO (11 ml) was subjected to microwave irradiation at 140 °C for 3 hours. The reaction was partitioned between ethyl acetate and water, washed with water, brine, dried over magnesium sulfate and concentrated *in vacuo*. This was then purified by column chromatography (silica, 0-100% ethyl acetate / petrol then 0-20% methanol / ethyl acetate) to afford title compound as a mixture of both products.



Intermediate 31: *N*-[(1*S*,2*S*)-2-Aminocyclopentyl]-5-chloro-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride



Step (i): *tert*-Butyl *N*-[(1*S*,2*S*)-2-[5-chloro-2-(2*H*-1,2,3-triazol-2-yl)benzamido]cyclopentyl]carbamate

A solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 120 mg, 0.60 mmol), 5-chloro-2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 38a**; CAS number 1293284-54-4; 134 mg, 0.60 mmol), TBTU (231 mg, 0.72 mmol) and DIPEA (0.116 g, 0.9 mmol) in DMF (3 ml) was stirred at room temperature for 2 hours. The reaction was diluted with water (30 ml) and extracted with ethyl acetate (3 x 30 ml). The combined organics were washed with water (20 ml), brine (20 ml), dried over sodium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography (silica, 0-30% ethyl acetate / *n*-hexane) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*) δ ppm 1.20-1.42 (m, 11H), 1.55-1.60 (m, 2H), 1.83-1.86 (m, 2H), 3.73-3.77 (m, 1H), 3.92-3.96 (m, 1H), 6.85-6.87 (m, 1H), 7.58 (s, 1H), 7.67-7.70 (m, 1H), 7.81-7.83 (m, 1H), 8.05 (s, 2H), 8.45-8.47 (m, 1H)


MS ES⁺: 406

Step (ii): *N*-[(1*S*,2*S*)-2-Aminocyclopentyl]-5-chloro-2-(2*H*-1,2,3-triazol-2-yl)benzamide hydrochloride

To a solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-[5-chloro-2-(2*H*-1,2,3-triazol-2-yl)benzamido]cyclopentyl]carbamate (170 mg, 0.418 mmol) in DCM (5 ml) was added HCl in 1,4-dioxane (4 M, 3 ml). The reaction was stirred at room temperature overnight and then concentrated *in vacuo*. The solid was triturated with diethyl ether (3 x 1 ml) to afford the title compound.


¹H NMR (400 MHz, DMSO-*d*) δ ppm 1.55-1.73 (m, 4H), 1.92-2.10 (m, 2H), 3.40-3.42 (m, 1H), 4.06-4.13 (m, 1H), 7.72-7.75 (m, 1H), 7.79-7.80 (m, 1H), 7.87-7.90 (m, 1H), 8.10-8.14 (m, 4H), 8.76-8.78 (m, 2H)

MS ES⁺: 306



Intermediate 33: (1S,2S)-1-N-[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride

5



Step (i): *tert*-Butyl *N*-[(1*S*,2*S*)-2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]carbamate

10 A solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 2 g, 9.99 mmol), 3-chloro-2-fluoro-5-(trifluoromethyl)pyridine (CAS number 72537-17-8; 1.44 ml, 10.98 mmol), DIPEA (1.744 ml, 9.99 mmol) in DMSO (35 ml) was heated at 140 °C for 5 hours. The reaction was partitioned between ethyl acetate and water. The phases were separated and the aqueous layer was re-extracted with ethyl acetate (2 x 50

15 ml). The combined organics were washed with brine (50 ml), filtered through a hydrophobic frit and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-15% ethyl acetate / petrol) and then by column chromatography (silica, 0-10% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*) δ ppm 1.31 (s, 9 H), 1.39 - 1.77 (m, 4 H), 1.81 - 1.95 (m, 1 H), 2.03 - 2.21 (m, 1 H), 3.86 - 3.98 (m, 1 H), 4.09 - 4.20 (m, 1 H), 6.78 - 7.10 (m, 2 H), 7.95 (s, 1 H), 8.31 (s, 1 H)

20

MS ES⁺: 380

Step (ii): (1*S*,2*S*)-1-*N*-[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride


25

To a solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]carbamate (2.23 g, 5.87 mmol) in 1,4-dioxane (20 ml) was added


HCl in 1,4-dioxane (4 M, 15 ml, 60.0 mmol). The reaction was stirred at room temperature for 18 hours. The reaction mixture was concentrated *in vacuo* to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.57 - 1.83 (m, 4 H), 1.98 - 2.19 (m, 2 H), 4.35 - 4.53 (m, 1 H), 7.17 - 7.36 (m, 1 H), 7.95 - 8.05 (m, 1 H), 8.15 (br. s., 3 H), 8.31 - 8.44 (m, 1 H)

MS ES⁺: 280



Intermediate 34: (1*S*,2*S*)-1-*N*-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride



Step (i): *tert*-Butyl *N*-[(1*S*,2*S*)-2-[[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino]cyclopentyl]carbamate

A solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 2 g, 9.99 mmol), 2,3-difluoro-5-(trifluoromethyl)pyridine (CAS number 89402-42-6; 2.011 g, 10.98 mmol) and DIPEA (1.744 ml, 9.99 mmol) in DMSO (35 ml) was heated at 140 °C for 5 hours. The reaction was partitioned between ethyl acetate and water. The phases were separated and the aqueous layer was re-extracted with ethyl acetate (2 x 50 ml). The combined organics were washed with brine (50 ml), filtered through a hydrophobic frit and concentrated *in vacuo*. The crude product was purified by column chromatography (0-15% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.41 (s, 9 H), 1.47 - 1.65 (m, 2 H), 1.73 - 1.92 (m, 2 H), 2.08 - 2.24 (m, 1 H), 2.29 - 2.48 (m, 1 H), 3.78 - 4.17 (m, 2 H), 4.93 - 5.15 (m, 1 H), 5.86 - 6.03 (m, 1 H), 7.26 - 7.39 (m, 1 H), 8.08 - 8.21 (m, 1 H)


MS ES⁺: 364

Step (ii): (1*S*,2*S*)-1-*N*-[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride


To a solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-[[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino]cyclopentyl]carbamate (2.57 g, 7.08 mmol) in 1,4-dioxane (25 ml) was added
 5 HCl in 1,4-dioxane (4 M, 20 ml, 80 mmol). The reaction was stirred at room temperature for 20 hours. The reaction mixture was concentrated *in vacuo* and azeotropically distilled with toluene to afford the title compound.

¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.51 - 1.83 (m, 4 H), 1.99 - 2.20 (m, 2 H), 3.39 -
 10 3.53 (m, 1 H), 4.29 - 4.47 (m, 1 H), 7.54 - 7.69 (m, 1 H), 7.73 - 7.89 (m, 1 H), 8.11 - 8.33 (m, 4 H)

MS ES⁺: 264



Intermediate 35: (1*S*,2*S*)-1-*N*-[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride



Step (i): *tert*-Butyl *N*-[(1*S*,2*S*)-2-[[3-bromo-5-(trifluoromethyl)pyridin-2-yl]amino]cyclopentyl]carbamate

A solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 2 g, 9.99 mmol), 3-bromo-2-chloro-5-(trifluoromethyl)pyridine (CAS number
 25 71701-92-3; 2.86 g, 10.98 mmol), DIPEA (1.74 ml, 9.99 mmol) in DMSO (35 ml) was heated at 140 °C for 5 hours. The reaction was partitioned between ethyl acetate and water. The phases were separated and the aqueous layer was re-extracted with ethyl acetate (2 x 50 ml). The combined organics were washed with brine (50 ml), filtered through a

hydrophobic frit and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-50% ethyl acetate / petrol), then by column chromatography (silica, 0-15% ethyl acetate / petrol) and then by column chromatography (silica, 0-10% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.42 (s, 9 H), 1.45 - 1.56 (m, 2 H), 1.75 - 1.92 (m, 2 H), 2.09 - 2.53 (m, 2 H), 3.77 - 4.19 (m, 2 H), 4.80 - 5.09 (m, 1 H), 6.20 - 6.37 (m, 1 H), 7.72 - 7.89 (m, 1 H), 8.21 - 8.38 (m, 1 H)

MS ES⁺: 425

Step (ii): *tert*-Butyl *N*-[(1*S*,2*S*)-2-{[3-methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]carbamate

A mixture of *tert*-butyl *N*-[(1*S*,2*S*)-2-{[3-bromo-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]carbamate (1.26 g, 2.96 mmol), methylboronic acid (CAS number 13061-96-6; 0.532 g, 8.88 mmol), tetrakis(triphenylphosphine)palladium (0.342 g, 0.296 mmol) and potassium carbonate (1.303 g, 9.43 mmol) in 1,4-dioxane (10ml) and water (1.5 ml) was sealed, evacuated and purged with nitrogen and subjected to microwave irradiation at 140°C for 1 hour. The mixture was partitioned between ethyl acetate (10 ml) and water (10 ml). The organics were extracted with ethyl acetate (2 x 20 ml). The combined organics were washed with brine (20 ml), filtered through a hydrophobic frit and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-60% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.31 (s, 9 H), 1.37 - 1.57 (m, 2 H), 1.58 - 1.71 (m, 2 H), 1.82 - 1.95 (m, 1 H), 2.08 - 2.19 (m, 4 H), 3.81 - 3.97 (m, 1 H), 4.07 - 4.19 (m, 1 H), 6.31 - 6.47 (m, 1 H), 6.86 - 7.00 (m, 1 H), 7.43 - 7.54 (m, 1 H), 8.11 - 8.21 (m, 1 H)

MS ES⁺: 360


Step (iii): (1*S*,2*S*)-1-*N*-[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride

To a solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-{[3-methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]carbamate (580 mg, 1.614 mmol) in 1,4-dioxane (5 ml) was added HCl in 1,4-dioxane (4M, 4 ml, 16.00 mmol). The reaction was stirred at room temperature


for 18 hours. The reaction mixture was concentrated *in vacuo* and azeotropically distilled with toluene to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.74 - 1.96 (m, 4 H), 2.17 - 2.32 (m, 1 H), 2.37 - 2.57 (m, 1 H), 3.63 (s, 3 H), 4.30 - 4.50 (m, 1 H), 4.77 - 4.94 (m, 1 H), 7.63 (s, 1 H), 8.10 (s, 1 H), 8.53 - 8.86 (m, 4 H)

MS ES⁺: 260



Intermediate 36: 2-[[5-(Trifluoromethyl)pyridin-2-yl]methyl]cyclopentan-1-amine hydrochloride



Step (i): [5-(Trifluoromethyl)pyridin-2-yl]methanol

To the solution of 2-iodo-5-(trifluoromethyl)pyridine (CAS number 100366-75-4; 10 g, 69.4 mmol) in toluene (250 ml) at -78⁰C was added *n*-BuLi in hexane (2.5 M, 15.0 mL, 37.5 mmol). The reaction was stirred at -78⁰C for 15 minutes. To this was then added drop wise DMF (3.5 ml) and then stirred at -78⁰C for 1 hour. Sodium borohydride (2.74 g, 72.0 mmol) and methanol (50 ml) were added and the resulting reaction mixture was stirred for 30 minutes and then allowed to warm to room temperature. The reaction was cooled to -10⁰C and to this was then added a saturated solution of ammonium chloride. The organics were extracted with ethyl acetate (2 x 200 ml) and the combined organics were washed with brine, dried over sodium sulfate and concentrated *in vacuo* to afford the title compound which was used without further purification.

¹H NMR (400 MHz, DMSO) δ ppm 4.66-4.65 (m, 2H), 5.69-5.66 (m, 1H), 7.71-7.69 (m, 1H), 8.23-8.21 (m, 1H), 8.87 (s, 1H)

MS ES⁺: 178

Step (ii): 2-(Bromomethyl)-5-(trifluoromethyl)pyridine

To a solution of [5-(trifluoromethyl)pyridin-2-yl]methanol (5.0 g, 28.24 mmol) in DCM (50 ml) was added tribromophosphane (0.58 g, 3.50 mmol) at 0°C. The reaction was allowed to warm to room temperature and stirred for 3 hours. The reaction was then poured into water (50 ml) and the organics were extracted with DCM (2 x 50 ml), washed with brine, dried over sodium sulfate and concentrated *in vacuo* to afford the title compound which was used without further purification.

MS ES⁺: 240, 242

Step (iii): Diethyl {[5-(trifluoromethyl)pyridin-2-yl]methyl}phosphonate

To a solution of 2-(bromomethyl)-5-(trifluoromethyl)pyridine (3.0 g, 12.5 mmol) in toluene (100 ml) was added triethyl phosphite (6.2 g, 37.0 mmol). The reaction was refluxed for 17 hours and was then concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0-50% ethyl acetate / n-hexane) to afford the title compound.

¹H NMR (400 MHz, DMSO) δ ppm 1.06-1.27(m, 6H), 3.57-3.65 (m, 2H), 3.95-4.08 (m, 4H), 7.61-7.59 (m, 1H), 8.20-8.18 (m, 1H), 8.90-8.89 (m, 1H)

MS ES⁺: 298

Step (iv): *tert*-Butyl *N*-[(2*E*)-2-{[5-(trifluoromethyl)pyridin-2-yl]methylidene}cyclopentyl]carbamate

To the suspension of diethyl ((5-(trifluoromethyl)pyridin-2-yl)methyl)phosphonate (2.0 g, 6.71 mmol) in THF (50 ml) at 0°C was added potassium *tert*-butoxide (1.5 g, 13.42 mmol) and then stirred at room temperature for 30 minutes. To this was then added a solution of *tert*-butyl *N*-(2-oxocyclopentyl)carbamate (CAS number 477585-30-1; 1.62 g, 8.05 mmol) in THF (20 ml) and the resulting reaction was stirred at room temperature for 1 hour and

then heated at reflux overnight. The reaction was quenched with water (50 ml) and extracted with ethyl acetate (3 x 100 ml). The combined organics were washed with brine, dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0-15% ethyl acetate / n-hexane) to afford the title compound.

MS ES⁺: 343

Step (v): *tert*-Butyl N-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)carbamate

To a solution of *tert*-butyl N-[(2*E*)-2-{[5-(trifluoromethyl)pyridin-2-yl]methylidene}cyclopentyl]carbamate (1.5 g, 4.38 mmol) in methanol (5 ml) was added palladium on carbon (10% wt, 50% wet, 300 mg) and 2M NaOH (5 ml). The resulting reaction was stirred under a balloon of hydrogen gas for 2 hours. The reaction was filtered through diatomaceous earth (commercially sold under the trade mark "Celite") and concentrated *in vacuo* to afford the title compound. The resulting residue was purified by column chromatography (silica, 0-70% ethyl acetate / n-hexane) to afford the title compound.

MS ES⁺: 345

Step (vi): 2-{[5-(Trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-amine hydrochloride


To a solution of *tert*-butyl N-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)carbamate (1.0 g, 2.9 mmol) in 1,4-dioxane (5 ml) at 0°C was added drop wise HCl in 1,4-dioxane (12%, 15.0 ml). The reaction was stirred at room temperature for 1 hour, then concentrated *in vacuo*. To this was then added DCM (50 ml) and a solution of sodium bicarbonate (aq, 7.5%, 15 ml). The organics were dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by column chromatography (0-2% methanol / DCM) and then treated with HCl in 1,4-dioxane (12%, 5 ml), stirred for 2 hours, concentrated *in vacuo*, triturated with diethyl ether to afford the title compound as a single diastereomer.

^1H NMR (400 MHz, DMSO) δ ppm 1.40-1.76 (m, 5H), 1.95-1.99 (m, 1H), 2.79-2.85 (m, 1H), 3.05-3.15 (m, 1H), 3.55-3.59 (m, 1H), 7.54-7.56 (m, 1H), 7.75 (bs, 3H), 8.15-8.17 (m, 1H), 8.90 (s, 1H)

MS ES⁺: 245

5

Intermediate 37a and 37b: 2-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)benzoic acid (Intermediate 37a) and 2-(1H-1,2,3-Triazol-1-yl)-5-(trifluoromethyl)benzoic acid (Intermediate 37b)



10

To a solution of 2H-1,2,3-triazole (CAS number 288-36-8; 1.0 g, 10.86 mmol) in DMF (4 ml) at 0-10 °C was added cesium carbonate (4.71 g, 14.49 mmol), copper (I) iodide (68 mg, 0.36 mmol), *trans*-1-*N*,2-*N*-dimethylcyclohexane-1,2-diamine (200 mg, 1.44 mmol) and 2-iodo-5-(trifluoromethyl)benzoic acid (CAS number 702641-04-1; 2.28 g, 7.24

15 mmol). The reaction was subjected to microwave irradiation at 120 °C for 15 minutes and was then partitioned between ethyl acetate (2 x 100 ml) and water (50 ml). The aqueous layer was acidified with HCl (aq, 2M) to give pH 2 and the organics were extracted with ethyl acetate (3 x 100 ml). The combined organics were washed with brine, dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0-3% methanol / DCM) to afford 2-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)benzoic acid (**Intermediate 37a**; also commercially available CAS number 1384066-81-2). The mixed fractions were further purified by column chromatography (silica, 0-3% methanol / DCM) followed by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1 % formic acid) to afford 2-(1H-1,2,3-triazol-1-yl)-5-(trifluoromethyl)benzoic acid (**Intermediate 37b**).

20
25

Intermediate 37a:

^1H NMR (400 MHz, DMSO) δ ppm 8.07-8.08 (m, 3 H), 8.20 (s, 2 H), 13.57 (bs, 1 H)

MS ES⁺: 258


Intermediate 37b:

¹H NMR (400 MHz, DMSO) δ ppm 7.90-7.97 (m, 2 H), 8.16-8.21 (m, 2 H), 8.65 (s, 1 H),
 13.65 (bs, 1 H)

MS ES⁺: 258

Intermediate 38a and 38b: 5-Chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid

(Intermediate 38a) and 5-Chloro-2-(1H-1,2,3-triazol-1-yl)benzoic acid (Intermediate 38b)



Prepared according to the procedure for 2-(2H-1,2,3-triazol-2-yl)-5-

(trifluoromethyl)benzoic acid (**Intermediate 37a**) and 2-(1H-1,2,3-triazol-1-yl)-5-

(trifluoromethyl)benzoic acid (**Intermediate 37b**) from 2H-1,2,3-triazole (CAS number
 288-36-8; 1.0 g, 10.86 mmol) and 5-chloro-2-iodobenzoic acid (CAS number 13421-00-6;
 2.00 g, 7.24 mmol). The crude solid was purified by column chromatography (silica, 0-3%
 methanol / DCM) to afford 5-chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 38a**;
 also commercially available CAS number 1293284-54-4). The mixed fractions were
 further purified by column chromatography (silica, 0-3% methanol / DCM) to afford 5-
 chloro-2-(1H-1,2,3-triazol-1-yl)benzoic acid (**Intermediate 38b**).

Intermediate 38a:

¹H NMR (400 MHz, DMSO) δ ppm 7.76-7.83 (m, 3 H), 8.12 (s, 2 H), 13.42 (bs, 1 H)

MS ES⁺: 224


Intermediate 38b:

^1H NMR (400 MHz, DMSO) δ ppm 7.66-7.68 (m, 1 H), 7.84-7.93 (m, 3 H), 8.54 (s, 1 H), 13.50 (bs, 1 H)

MS ES^+ : 224

5

Intermediate 39a and 39b: 2,3-Difluoro-6-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 39a) and 2,3-Difluoro-6-(1H-1,2,3-triazol-1-yl)benzoic acid (Intermediate 39b)



10

Prepared according to the procedure for 2-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)benzoic acid (**Intermediate 37a**) and 2-(1H-1,2,3-triazol-1-yl)-5-(trifluoromethyl)benzoic acid (**Intermediate 37b**) from 2H-1,2,3-triazole (CAS number 288-36-8; 0.75 g, 10.86 mmol) and 2,3-difluoro-6-iodobenzoic acid (CAS number 333780-75-9; 1.54 g, 5.43 mmol) in 1,4-dioxane (10 ml) and water (0.2 ml). The crude solid was purified by column chromatography (silica, 0-3% methanol / DCM) to afford 2,3-difluoro-6-(2H-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 39a**). The mixed fractions were further purified by column chromatography (silica, 0-3% methanol / DCM) followed by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1 % formic acid) to afford 2,3-difluoro-6-(1H-1,2,3-triazol-1-yl)benzoic acid (**Intermediate 39b**).

15

20


Intermediate 39a:

^1H NMR (400 MHz, DMSO) δ ppm 7.73-7.79 (m, 2 H), 8.16 (s, 2 H), 14.05 (bs, 1 H)
MS ES^+ : 226

25

Intermediate 39b:

^1H NMR (400 MHz, DMSO) δ ppm 7.60-7.63 (m, 1 H), 7.79-7.86 (m, 1 H), 7.96 (s, 1 H), 8.61 (s, 1 H), 14.17 (bs, 1 H)

MS ES⁺: 226**Intermediate 40a and 40b: 3,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid****(Intermediate 40a) and 3,5-Difluoro-2-(1H-1,2,3-triazol-1-yl)benzoic acid****(Intermediate 40b)**

Prepared according to the procedure for 2-(2H-1,2,3-triazol-2-yl)-5-

(trifluoromethyl)benzoic acid (**Intermediate 37a**) and 2-(1H-1,2,3-triazol-1-yl)-5-(trifluoromethyl)benzoic acid (**Intermediate 37b**) from 2H-1,2,3-triazole (CAS number

288-36-8; 1.0 g, 10.86 mmol) and 2-bromo-3,5-difluorobenzoic acid (CAS number

651027-01-9; 1.27 g, 5.43 mmol) in 1,4-dioxane (5 ml) and water (1 ml). The crude solid

was purified by using column chromatography (silica, 0-3% methanol / DCM) to afford


3,5-difluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 40a**). The mixed

fractions were further purified by column chromatography (silica, 0-3% methanol / DCM)


followed by reverse phase preparative HPLC (eluted with acetonitrile / water containing

0.1 % formic acid) to afford 3,5-difluoro-2-(1H-1,2,3-triazol-1-yl)benzoic acid

(Intermediate 40b).**Intermediate 40a:**¹H NMR (400 MHz, DMSO) δ ppm 7.63-7.66 (m, 1H), 7.86-7.92 (m, 1H), 8.12 (s, 2H), 13.63 (bs, 1H)MS ES⁺: 226**Intermediate 40b:**¹H NMR (400 MHz, DMSO) δ ppm 7.68-7.71 (m, 1H), 7.90-7.95 (m, 2H), 8.54 (s, 1H), 13.70 (bs, 1H)MS ES⁺: 226



5 **Intermediate 41: (1S,2S)-1-N-[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride**



Step (i): tert-Butyl N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

10 A solution of 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 2.0 g, 10.98 mmol), *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 2 g, 9.99 mmol) and DIPEA (5.23 ml, 30.0 mmol) in DMSO (20 ml) was sealed and heated at 140°C for 3 hours. The reaction mixture was partitioned between ethyl acetate (200 ml) and water (100 ml). The organics were washed with water (2 x 100ml), brine (100

15 ml), dried over sodium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography (silica, 10-40% ethyl acetate / petrol) to afford the title compound.

¹H NMR (300 MHz, CHLOROFORM-*d*) δ ppm 1.32 - 1.66 (m, 11 H), 1.71 - 1.96 (m, 2 H), 2.07 - 2.24 (m, 1 H), 2.30 - 2.51 (m, 1 H), 3.76 - 4.04 (m, 2 H), 4.69 - 4.92 (m, 1 H), 6.07 - 6.24 (m, 1 H), 7.91 (s, 1 H), 8.30 (s, 1 H)

20 MS ES⁺: 347

Step (ii): tert-Butyl N-[(1S,2S)-2-{[3-bromo-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

To a solution of *tert*-butyl ((1*S*,2*S*)-2-((5-(trifluoromethyl)pyrazin-2-yl)amino)cyclopentyl)carbamate (3.49 g, 10.08 mmol) in dry DCM (67 ml) at 0°C was added 1-bromopyrrolidine-2,5-dione (CAS number 128-08-5; 2.15 g, 12.09 mmol). The reaction was allowed to warm to room temperature overnight. A further portion of portion
5 of 1-bromopyrrolidine-2,5-dione (CAS number 128-08-5; 1.70 g, 9.56 mmol) was added and the reaction stirred for an additional 24 hours. The reaction was concentrated *in vacuo* and then purified by column chromatography (silica, 0-30% ethyl acetate / petrol) to afford the title compound.

¹H NMR (300 MHz, CHLOROFORM-*d*) δ ppm 1.31 - 1.62 (m, 11 H), 1.72 - 1.92 (m, 2
10 H), 2.08 - 2.24 (m, 1 H), 2.36 - 2.56 (m, 1 H), 3.75 - 4.14 (m, 2 H), 4.63 - 4.87 (m, 1 H), 6.78 - 6.96 (m, 1 H), 8.25 (s, 1 H)

MS ES⁺: 425, 427

Step (iii): *tert*-Butyl *N*-[(1*S*,2*S*)-2-{[3-ethenyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

A suspension of *tert*-butyl *N*-[(1*S*,2*S*)-2-{[3-bromo-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate (650 mg, 1.53 mmol), 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (CAS number 75927-49-0; 942 mg, 6.11 mmol), tetrakis(triphenylphosphine)palladium (177 mg, 0.15 mmol) and potassium carbonate (845
20 mg, 6.11 mmol) in 1,4-dioxane (5 ml) and water (0.8 ml) was subjected to microwave irradiation at 120°C for 1 hour. The reaction was partitioned between ethyl acetate (10 ml) and water (10 ml). The aqueous layer was further extracted with ethyl acetate (3 x 20 ml). The combined organics were washed with brine (20 ml), filtered through a hydrophobic frit and concentrated *in vacuo*. The resulting residue was purified by column chromatography
25 (silica, 0-50% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DICHLOROMETHANE-*d*₂) δ ppm 1.30 - 1.62 (m, 11 H), 1.74 - 1.87 (m, 2 H), 2.02 - 2.17 (m, 1 H), 2.41 - 2.61 (m, 1 H), 3.73 - 3.85 (m, 1 H), 3.91 - 4.04 (m, 1 H), 4.81 - 4.95 (m, 1 H), 5.62 - 5.74 (m, 1 H), 6.30 - 6.42 (m, 1 H), 6.71 - 6.90 (m, 2 H), 8.21 (s, 1 H)

MS ES⁺: 373

Step (iv): *tert*-Butyl *N*-[(1*S*,2*S*)-2-[[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]carbamate

To a solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-[[3-ethenyl-5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]carbamate (460 mg, 1.24 mmol) in methanol (12 ml) was added
5 palladium on carbon (10% wt, 50% wet) (131 mg, 0.124 mmol) and the resulting mixture was stirred under a balloon of hydrogen gas for 2 hours. The reaction was filtered through diatomaceous earth (commercially sold under the trade mark "Celite"). To this was then added further palladium on carbon (10% wt, 50% wet) (131 mg, 0.124 mmol) and the
10 resulting mixture was stirred under a balloon of hydrogen gas for 72 hours. The reaction was filtered through diatomaceous earth (commercially sold under the trade mark "Celite") and concentrated *in vacuo* to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.24 - 1.64 (m, 14 H), 1.71 - 1.89 (m, 2 H), 2.01 - 2.19 (m, 1 H), 2.37 - 2.57 (m, 1 H), 2.61 - 2.80 (m, 2 H), 3.77 - 3.90 (m, 1 H), 3.91 - 4.09 (m, 1 H), 4.82 - 4.97 (m, 1 H), 6.36 - 6.55 (m, 1 H), 8.16 (s, 1 H)


15 MS ES⁺: 375

Step (v): (1*S*,2*S*)-1-*N*-[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride


To a solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-[[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]carbamate (366 mg, 0.98 mmol) in 1,4-dioxane (3 ml) was added
20 HCl in 1,4-dioxane (4M, 3 ml, 12.0 mmol). The reaction was stirred at room temperature for 18 hours and was then concentrated *in vacuo* and azeotropically distilled with toluene to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.16 - 1.29 (m, 3 H), 1.53 - 1.84 (m, 4 H), 1.95 - 2.20 (m, 2 H), 2.66 - 2.82 (m, 2 H), 3.43 - 3.71 (m, 1 H), 4.28 - 4.47 (m, 1 H), 8.16 (br. s., 3 H), 8.30 (s, 1 H)

25 MS ES⁺: 275



Intermediate 42: N-(2-Amino-4,4-difluorocyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride



5

Step (i): 1-[(Cyclopent-3-en-1-yloxy)methyl]-4-methoxybenzene

To a solution of cyclopent-3-en-1-ol (CAS number 14320-38-8; 15 g, 178 mmol) in dry THF (357 ml) at 0 °C under nitrogen was added sodium hydride (60%, 9.27 g, 232 mmol). After fizzing had ceased, to this was then added drop wise 1-(chloromethyl)-4-methoxybenzene (CAS number 824-94-2; 31.4 ml, 232 mmol). The reaction was allowed to warm to room temperature and stirred for 17 hours then quenched by the addition of methanol and concentrated *in vacuo*. The residue was partitioned between ethyl acetate and water. The organics were dried over magnesium sulfate, filtered and concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 0-50% DCM / petrol) to afford the title compound.

15

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 2.33 - 2.47 (m, 2 H), 2.49 - 2.66 (m, 2 H), 3.79 (s, 3 H), 4.20 - 4.32 (m, 1 H), 4.40 (s, 2 H), 5.62 - 5.75 (m, 2 H), 6.86 (d, *J*=8.59 Hz, 2 H), 7.24 (d, *J*=8.59 Hz, 2 H)

20

Step (ii): 3-[(4-Methoxyphenyl)methoxy]-6-oxabicyclo[3.1.0]hexane

To a solution of 1-[(cyclopent-3-en-1-yloxy)methyl]-4-methoxybenzene (9.64 g, 47.2 mmol) in dry DCM (52 ml) at 0 °C under an atmosphere of nitrogen was added 3-chlorobenzene-1-carboxoperoxoic acid (CAS number 937-14-4; 16.29 g, 94 mmol). The reaction mixture was warmed to room temperature for 17 hours then filtered. The filtrate
5 was washed with a saturated solution of sodium thiosulfate and then with a saturated solution of sodium bicarbonate. The organics were dried over magnesium sulfate, filtered and concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 0-50% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.86 - 2.17 (m, 4 H), 3.39 - 3.50 (m, 2 H), 3.78 (s, 3
10 H), 3.99 - 4.14 (m, 1 H), 4.32 (s, 2 H), 6.85 (d, *J*=8.60 Hz, 2 H), 7.22 (d, *J*=8.59 Hz, 2 H)

Step (iii): 2-[Bis(prop-2-en-1-yl)amino]-4-[(4-methoxyphenyl)methoxy]cyclopentan-1-ol

To a solution of 3-[(4-methoxyphenyl)methoxy]-6-oxabicyclo[3.1.0]hexane (10.21 g, 46.4
15 mmol) in ethanol (66 ml) was added bis(prop-2-en-1-yl)amine (CAS number 124-02-7; 13.51 g, 139 mmol). The reaction was heated in a sealed vial at 105 °C for 72 hours. The reaction mixture was concentrated *in vacuo* then purified by column chromatography (silica, 0-50% ethyl acetate / petrol then 0-30% (0.1% ammonia / methanol) / ethyl acetate) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.33 - 1.54 (m, 1 H), 1.56 - 1.73 (m, 1 H), 1.73 - 1.88 (m, 1 H), 2.06 - 2.25 (m, 1 H), 2.78 - 2.95 (m, 1 H), 2.99 - 3.23 (m, 4 H), 3.74 (s, 3
20 H), 3.78 - 3.94 (m, 1 H), 3.95 - 4.09 (m, 1 H), 4.27 - 4.36 (m, 2 H), 4.57 - 4.67 (m, 1 H), 5.02 - 5.25 (m, 4 H), 5.71 - 5.90 (m, 2 H), 6.89 (d, *J*=8.59 Hz, 2 H), 7.22 (d, *J*=8.60 Hz, 2 H)

25 MS ES⁺: 318

Step (iv): 4-[(4-Methoxyphenyl)methoxy]-1-*N*,1-*N*-bis(prop-2-en-1-yl)cyclopentane-1,2-diamine

To a solution of 2-[bis(prop-2-en-1-yl)amino]-4-[(4-methoxyphenyl)methoxy]cyclopentan-
30 1-ol (8.75 g, 27.6 mmol) in dry MTBE (92 ml) at 0 °C under nitrogen was added triethylamine (7.68 ml, 55.1 mmol) and methanesulfonyl chloride (2.58 ml, 33.1 mmol). The reaction mixture was stirred at 0 °C for 30 minutes. To this was then added further

triethylamine (7.68 ml, 55.1 mmol) and the reaction was stirred at 0 °C for 30 minutes followed by the addition of ammonium hydroxide (25% aq, 82 ml, 590 mmol). The reaction was warmed to room temperature for 17 hours then partitioned between MTBE and water. The aqueous layer was re-extracted with MTBE. The combined organics were
5 dried over magnesium sulphate, filtered and concentrated *in vacuo* to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.28 - 2.21 (m, 4 H), 2.72 - 3.29 (m, 6 H), 3.66 - 3.78 (m, 3 H), 3.81 - 3.99 (m, 1 H), 4.25 - 4.43 (m, 2 H), 5.00 - 5.32 (m, 4 H), 5.65 - 5.93 (m, 2 H), 6.82 - 6.98 (m, 2 H), 7.14 - 7.29 (m, 2 H)

10 MS ES⁺: 317

Step (v): *tert*-Butyl *N*-{2-[bis(prop-2-en-1-yl)amino]-4-[(4-methoxyphenyl)methoxy]cyclopentyl}carbamate

To a solution of 4-[(4-methoxyphenyl)methoxy]-1-*N*,1-*N*-bis(prop-2-en-1-yl)cyclopentane-
15 1,2-diamine (9.79 g, 30.9 mmol) in THF (56 ml) at 0 °C under nitrogen was added a saturated solution of sodium carbonate (46.4 ml, 46.4 mmol) and di-*tert*-butyl dicarbonate (CAS number 24424-99-5; 10.77 ml, 46.4 mmol). The reaction was warmed to room temperature for 72 hours then partitioned between ethyl acetate and water. The organics were washed with water and brine, dried over magnesium sulfate, filtered and concentrated
20 *in vacuo*. The crude material was purified by reverse phase column chromatography (C18 silica, 5 - 95 % water (0.05 % ammonia) / acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.38 (s, 9 H), 1.47 - 1.59 (m, 1 H), 1.61 - 1.79 (m, 1 H), 1.79 - 1.93 (m, 1 H), 1.93 - 2.21 (m, 1 H), 2.91 - 3.07 (m, 3 H), 3.07 - 3.24 (m, 2 H), 3.74 (s, 3 H), 3.79 - 3.98 (m, 2 H), 4.24 - 4.41 (m, 2 H), 4.93 - 5.26 (m, 4 H), 5.66 - 5.89
25 (m, 2 H), 6.89 (d, *J*=8.34 Hz, 2 H), 7.22 (d, *J*=8.34 Hz, 2 H)

MS ES⁺: 417

Step (vi): *tert*-Butyl *N*-{2-amino-4-[(4-methoxyphenyl)methoxy]cyclopentyl}-carbamate

30 To a solution of *tert*-butyl *N*-{2-[bis(prop-2-en-1-yl)amino]-4-[(4-methoxyphenyl)methoxy]cyclopentyl}carbamate (1.77 g, 4.25 mmol) in dry DCM (21 ml) was added 1,3-dimethyl-1,3-diazinane-2,4,6-trione (CAS number 769-42-6; 1.161 g, 7.44

mmol) and tetrakis(triphenylphosphane) palladium (0.113 g, 0.098 mmol). The reaction was stirred at 45 °C under an atmosphere of nitrogen for 3 hours. The reaction mixture was concentrated *in vacuo* and purified by SCX chromatography (2M ammonia in methanol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.28 - 1.42 (m, 10 H), 1.44 - 1.61 (m, 1 H), 1.81 - 2.07 (m, 1 H), 2.12 - 2.37 (m, 1 H), 2.72 - 3.09 (m, 1 H), 3.18 - 3.52 (m, 1 H), 3.73 (s, 3 H), 3.81 - 3.95 (m, 1 H), 4.22 - 4.38 (m, 2 H), 6.89 (d, *J*=8.34 Hz, 2 H), 7.22 (d, *J*=8.30 Hz, 2 H)

MS ES⁺: 337

Step (vii): *tert*-Butyl *N*-{4-[(4-methoxyphenyl)methoxy]-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate

To a solution of *tert*-butyl *N*-{2-amino-4-[(4-methoxyphenyl)methoxy]cyclopentyl}-carbamate (1.71 g, 5.08 mmol) in dry DMF (17 ml) was added 2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 1.06 g, 5.59 mmol), HATU (2.90 g, 7.62 mmol) and triethylamine (2.13 ml, 15.25 mmol). The reaction was stirred at room temperature for 72 hours then partitioned between ethyl acetate and water. The organics were washed with brine, dried over magnesium sulfate, filtered and concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.37 (s, 9 H), 1.46 - 1.59 (m, 1 H), 1.58 - 1.77 (m, 1 H), 1.86 - 1.97 (m, 1 H), 2.18 - 2.37 (m, 1 H), 3.67 - 3.79 (m, 4 H), 3.83 - 4.01 (m, 2 H), 4.32 (s, 2 H), 6.85 - 6.95 (m, 2 H), 7.17 - 7.31 (m, 2 H), 7.44 - 7.54 (m, 2 H), 7.55 - 7.66 (m, 1 H), 7.76 (s, 1 H), 7.96 - 8.05 (m, 2 H)

MS ES⁺: 508

Step (viii): *tert*-Butyl *N*-{4-hydroxy-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate

To a solution of *tert*-butyl *N*-{4-[(4-methoxyphenyl)methoxy]-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate (1.85 g, 3.64 mmol) in DCM (36 ml) and water (0.364 ml) at 0 °C under an atmosphere of nitrogen was added 4,5-dichloro-3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile (CAS number 84-58-2; 1.655 g, 7.29 mmol).

The reaction was stirred at 0 °C for 1 hour, then was partitioned between a saturated solution of sodium bicarbonate and DCM. The organics were filtered through a hydrophobic frit and concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 0-100% ethyl acetate / petrol then 0-30% methanol / ethyl acetate) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.25 - 1.48 (m, 10 H), 1.55 - 1.86 (m, 2 H), 2.11 - 2.27 (m, 1 H), 3.90-3.94 (m, 1 H), 3.99 - 4.11 (m, 1 H), 4.57 - 4.71 (m, 1 H), 6.64 - 6.86 (m, 1 H), 7.41 - 7.56 (m, 2 H), 7.57 - 7.66 (m, 1 H), 7.71 - 7.83 (m, 1 H), 7.95 - 8.06 (m, 2 H), 8.19 - 8.36 (m, 1 H)

MS ES⁺: 388

Step (ix): *tert*-Butyl N-{4-oxo-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate

To a solution of *tert*-butyl N-{4-hydroxy-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate (910 mg, 2.35 mmol) in dry DCM (12 ml) at 0 °C under an atmosphere of nitrogen was added Dess–Martin periodinane (3.4 g, 7.99 mmol). The reaction was warmed to room temperature for 2 hours then concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.28 - 1.47 (m, 10 H), 1.56 - 1.87 (m, 2 H), 2.07 - 2.27 (m, 1 H), 3.82 - 4.00 (m, 1 H), 4.00 - 4.12 (m, 1 H), 6.58 - 6.79 (m, 1 H), 7.41 - 7.54 (m, 2 H), 7.55 - 7.71 (m, 1 H), 7.73 - 7.85 (m, 1 H), 7.93 - 8.06 (m, 2 H), 8.17 - 8.40 (m, 1 H)

MS ES⁺: 386

Step (x): *tert*-Butyl N-{4,4-difluoro-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate

To a solution of *tert*-butyl N-{4-oxo-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate (950 mg, 2.47 mmol) in dry DCM (12.3 ml) at 0 °C under an atmosphere of nitrogen was added drop wise diethylaminosulfur trifluoride (CAS number 38078-09-0; 1.63 ml, 12.32 mmol) as a solution in dry DCM (12.3 ml). The reaction mixture was warmed to room temperature for 2 hours then cooled to 0 °C. To this

was added further diethylaminosulfur trifluoride (CAS number 38078-09-0; 1.63 ml, 12.32 mmol). The reaction was then allowed to warm to room temperature for 17 hours. The reaction was then cooled to 0 °C and basified by the cautious addition of sodium carbonate (2M, aq). The reaction mixture was extracted with DCM, filtered through a hydrophobic frit and concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 0-100% ethyl acetate in petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.37 (s, 9 H), 1.88 - 2.17 (m, 2 H), 2.36 - 2.48 (m, 2 H), 3.93 - 4.09 (m, 1 H), 4.14 - 4.30 (m, 1 H), 6.97 - 7.15 (m, 1 H), 7.45 - 7.56 (m, 2 H), 7.57 - 7.70 (m, 1 H), 7.75 - 7.86 (m, 1 H), 8.03 (s, 2 H), 8.46 - 8.60 (m, 1 H)

MS ES⁺: 408


Step (xi): *N*-(2-Amino-4,4-difluorocyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride

To a solution of *tert*-butyl *N*-{4,4-difluoro-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl} carbamate (640 mg, 1.57 mmol) in dry 1,4-dioxane (5 ml) was added HCl in 1,4-dioxane (4M, 3.9 ml, 15.71 mmol). The reaction was stirred at room temperature for 6 hours then concentrated *in vacuo* and azeotropically distilled with toluene to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.01 - 2.42 (m, 2 H), 2.55 - 2.78 (m, 2 H), 3.30 - 3.54 (m, 1 H), 3.60 - 3.75 (m, 1 H), 7.50 - 7.61 (m, 1 H), 7.62 - 7.77 (m, 2 H), 7.80 - 7.91 (m, 1 H), 8.08 (s, 2 H), 8.51 (br. s, 3 H), 8.72 - 8.88 (m, 1 H)

MS ES⁺: 308


Intermediate 43: *N*-Chloro-2-methyl-*N*-sodiopropane-2-sulfonamide




To a rapidly stirred sodium hypochlorite solution (25 ml, 12.76 mmol), with the temperature maintained below 10°C and in the dark was added a solution of acetic acid (1.85 ml, 12.76 mmol) and 2-methylpropan-2-ol (1.22 ml, 12.76 mmol) in a single portion and the reaction mixture stirred for 3 minutes. The reaction mixture was partitioned and the organics washed with 10% aqueous sodium carbonate and water, dried over calcium chloride and filtered to afford *tert*-butyl hypochlorite (845 mg, 7.78 mmol). This was

slowly added to a stirred solution of 2-methylpropane-2-sulfonamide (2 g, 14.58 mmol) in sodium hydroxide solution (1M, 20.60 ml, 20.6 mmol) at room temperature. The resulting mixture was stirred at room temperature for 1 hour then concentrated *in vacuo*. The resultant solid was triturated with diethyl ether, filtered and dried *in vacuo* to afford the

Prepared as detailed in Organic Letters 1999, 1, 783-786



Intermediate 44: Benzyl *N*-[2-(2-methylpropane-2-sulfonamido)-4-oxocyclopentyl]-*N*-[(*1R*)-1-phenylethyl]carbamate



Step (i): 1,4-Dioxaspiro[4.4]non-7-ene

To a solution of trimethylsilyl trifluoromethanesulfonate (CAS number 27607-77-8; 0.22 ml, 1.22 mmol) in DCM (12 ml) at -78°C was successively added 2,2,7,7-tetramethyl-3,6-dioxo-2,7-disilaoctane (CAS number 7381-30-8; 2.51 g, 12.18 mmol) and cyclopent-3-en-1-one (CAS number 14320-37-7; 1 g, 12.18 mmol). The reaction mixture was stirred at -

solution of sodium bicarbonate and extracted with diethyl ether. The organics were dried over sodium sulfate, filtered and concentrated *in vacuo* to afford the title compound.

¹H NMR (300 MHz, CHLOROFORM-*d*) δ ppm 2.59 (s, 4 H), 3.96 (s, 4 H), 5.71 (s, 2 H)

5 **Step (ii): 6-(2-Methylpropane-2-sulfonyl)-6-azaspiro[bicyclo[3.1.0]hexane-3,2'-[1,3]dioxolane]**

To a solution of 1,4-dioxaspiro[4.4]non-7-ene (370 mg, 2.93 mmol) and *N*-chloro-2-methyl-*N*-sodiopropane-2-sulfonamide (**Intermediate 43**; 965 mg, 4.99 mmol) in acetonitrile (16 ml) was added trimethylphenylammonium tribromide (CAS number 4207-56-1; 110 mg, 0.29 mmol) under an atmosphere of nitrogen. The reaction mixture was stirred at room temperature for 2 hours then heated to 40°C for 18 hours. The reaction mixture was filtered through a plug of silica, washed with diethyl ether and the filtrate concentrated *in vacuo*. The crude material was purified column chromatography (silica, 0-50% diethyl ether / petroleum) to afford the title compound.

15 ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 1.45 - 1.53 (m, 9 H), 2.16 - 2.23 (m, 4 H), 3.34 (s, 2 H), 3.77 - 3.86 (m, 2 H), 3.88 - 3.93 (m, 2 H)

Step (iii): 2-Methyl-*N*-(8-{[(*IR*)-1-phenylethyl]amino}-1,4-dioxaspiro[4.4]nonan-7-yl)propane-2-sulfonamide

20 To a solution of 6-(2-methylpropane-2-sulfonyl)-6-azaspiro[bicyclo[3.1.0]hexane-3,2'-[1,3]dioxolane] (477 mg, 1.83 mmol) in acetonitrile (10 ml) was added lithium perchlorate (20 mg, 0.19 mmol) and (*R*)-1-phenylethylamine (CAS number 3886-69-9; 0.29 ml, 2.28 mmol). The reaction was heated to reflux for 24 hours. Further portions of lithium perchlorate (12 mg, 0.11 mmol) and (*R*)-1-phenylethylamine (0.20 ml, 1.57 mmol) were added and the reaction mixture heated to 100°C overnight. The reaction mixture was transferred to a microwave vial and was then subjected to microwave irradiation at 120°C for 3 hours. To this was then added water (1 ml) and the volume reduced to a third by concentrating *in vacuo*. The resultant mixture was partitioned between ethyl acetate and water. The organics were washed with water and brine, dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 0-70% ethyl acetate / petrol) to afford the title compound.

30 MS ES⁺: 383

Step (iv): Benzyl *N*-[8-(2-methylpropane-2-sulfonamido)-1,4-dioxaspiro[4.4]nonan-7-yl]-*N*-[(1*R*)-1-phenylethyl]carbamate


To a solution of 2-methyl-*N*-(8-[(1*R*)-1-phenylethyl]amino)-1,4-dioxaspiro[4.4]nonan-7-yl)propane-2-sulfonamide (274 mg, 0.72 mmol) and sodium carbonate (114 mg, 1.074 mmol) in 1,4-dioxane (2 ml) and water (0.4 ml) at 0°C was added drop wise benzyl chloroformate (CAS number 501-53-1; 0.13 ml, 0.90 mmol). The reaction mixture was allowed to warm to room temperature for 2 hours then concentrated *in vacuo*. The residue was diluted with ethyl acetate and washed with water and brine, dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 0-70% ethyl acetate / petrol) to afford the title compound.

MS ES⁺: 515


Step (v): Benzyl *N*-[2-(2-methylpropane-2-sulfonamido)-4-oxocyclopentyl]-*N*-[(1*R*)-1-phenylethyl]carbamate

To a solution of benzyl *N*-[8-(2-methylpropane-2-sulfonamido)-1,4-dioxaspiro[4.4]nonan-7-yl]-*N*-[(1*R*)-1-phenylethyl]carbamate (331 mg, 0.64 mmol) in THF (1.1 ml) was added HCl (aq, 2M, 1.65 ml, 3.30 mmol) was stirred at room temperature for 18 hours. The reaction mixture was concentrated *in vacuo* and azeotropically distilled with toluene to afford the title compound.

MS ES⁺: 473



Intermediate 45: 4,4-Difluoro-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine



5

Step (i): Benzyl *N*-[4,4-difluoro-2-(2-methylpropane-2-sulfonamido)cyclopentyl]-*N*-[(*IR*)-1-phenylethyl]carbamate

To a solution of benzyl *N*-[2-(2-methylpropane-2-sulfonamido)-4-oxocyclopentyl]-*N*-[(*IR*)-1-phenylethyl]carbamate (**Intermediate 44**; 330 mg, 0.70 mmol) in DCM (3.5 ml) at 10 0°C was added diethylaminosulfur trifluoride (CAS number 38078-09-0; 0.92 ml, 6.98 mmol). The mixture was stirred at 0°C for 20 minutes and then at room temperature for 5 hours. The reaction mixture was quenched at 0°C with a saturated solution of sodium bicarbonate and extracted with DCM. The organics were dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude material was purified by column chromatography 15 (silica, 0-50% ethyl acetate / petrol) to afford the title compound.

MS ES⁺: 493

Step (ii): *N*-(2-Amino-4,4-difluorocyclopentyl)-2-methylpropane-2-sulfonamide

A solution of benzyl *N*-[4,4-difluoro-2-(2-methylpropane-2-sulfonamido)cyclopentyl]-*N*- 20 [(*IR*)-1-phenylethyl]carbamate (130 mg, 0.26 mmol) and palladium hydroxide on carbon (20%, 100 mg, 0.14 mmol) in methanol (3.5 ml) was stirred under a balloon of hydrogen gas for 2 hours. The reaction was filtered through diatomaceous earth (commercially sold under the trade mark "Celite") and concentrated *in vacuo* to afford the title compound.

MS ES⁺: 257

25

Step (iii): *N*-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-methylpropane-2-sulfonamide

To a solution of *N*-(2-amino-4,4-difluorocyclopentyl)-2-methylpropane-2-sulfonamide (66 mg, 0.26 mmol) in DMSO (650 µl) was added DIPEA (135 µl, 0.77 mmol) and 2-chloro- 30 5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 47 mg, 0.26 mmol). The reaction

mixture was sealed and heated at 120°C for 18 hours then partitioned between ethyl acetate and water. The organics were washed with water and brine, dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 10-60 % ethyl acetate / petrol) to afford the title compound.


¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 1.42 (s, 9 H), 1.92 - 2.04 (m, 1 H), 2.12 - 2.30 (m, 1 H), 2.68 - 2.85 (m, 1 H), 2.96 - 3.12 (m, 1 H), 3.86 - 4.03 (m, 1 H), 4.18 - 4.27 (m, 1 H), 4.43 - 4.54 (m, 1 H), 5.90 - 6.04 (m, 1 H), 8.02 (s, 1 H), 8.34 (s, 1 H)

MS ES⁺: 403


Step (iv): 4,4-Difluoro-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine.

To a solution of *N*-(4,4-difluoro-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl)-2-methylpropane-2-sulfonamide (45 mg, 0.11 mmol) in DCM (3 ml) at 0°C was added anisole (CAS number 100-66-3; 0.22 ml, 2.01 mmol) followed by the drop wise addition of trifluoromethanesulfonic acid in DCM (0.2M, 2.5 ml, 0.500 mmol). The reaction mixture was stirred at 0°C for 1 hour then at room temperature for 2 hours. A further portion of trifluoromethanesulfonic acid in DCM (0.2M, 0.5 ml, 0.100 mmol) was added, the reaction mixture stirred for another hour at room temperature then quenched with sodium hydroxide (0.1M) until pH 11 was obtained. The reaction mixture was then extracted with DCM. The organics were filtered through a hydrophobic frit and concentrated *in vacuo*. The crude material was purified by SCX chromatography (2M ammonia in methanol) to afford the title compound.

MS ES⁺: 283



Intermediate 46: *N*-[(1*S*,2*S*)-2-Amino-4,4-difluorocyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide



5

Step (i): Benzyl *N*-[(1*S*,2*S*)-4,4-difluoro-2-(2-methylpropane-2-sulfonamido)cyclopentyl]-*N*-[(1*R*)-1-phenylethyl]carbamate

To a solution of benzyl *N*-[2-(2-methylpropane-2-sulfonamido)-4-oxocyclopentyl]-*N*-[(1*R*)-1-phenylethyl]carbamate (**Intermediate 44**; 6.39 g, 13.52 mmol) in DCM (67.6 ml) at 0°C was added diethylaminosulfur trifluoride (CAS number 38078-09-0; 8.93 ml, 67.6 mmol). The mixture was stirred at 0°C for 15 minutes then at room temperature for 3.5 hours. A further portion of diethylaminosulfur trifluoride (3 ml, 22.71 mmol) was added and the mixture stirred at room temperature for a further 2 hours. The reaction mixture was then quenched at 0°C by the addition of a saturated solution of sodium bicarbonate until pH7 was achieved. The reaction mixture was then extracted with DCM. The combined organics were washed with brine, dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 35 - 60% diethyl ether / petrol) to afford the title compound.

MS ES⁺: 493

Step (ii): *N*-[(1*S*,2*S*)-2-Amino-4,4-difluorocyclopentyl]-2-methylpropane-2-sulfonamide

A solution of benzyl *N*-[(1*S*,2*S*)-4,4-difluoro-2-(2-methylpropane-2-sulfonamido)cyclopentyl]-*N*-[(1*R*)-1-phenylethyl]carbamate (2.24 g, 4.53 mmol) and
5 palladium hydroxide on carbon (20%, 1.59 g, 2.26 mmol) in methanol (65 ml) was stirred under a balloon of hydrogen gas for 17 hours. The reaction was filtered through diatomaceous earth (commercially sold under the trade mark "Celite") and concentrated *in vacuo* to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 1.44 (s, 9 H), 1.84 - 2.17 (m, 2 H), 2.52 -
10 2.67 (m, 1 H), 2.68 - 2.85 (m, 1 H), 3.26 - 3.38 (m, 1 H), 3.57 - 3.68 (m, 1 H)

MS ES⁺: 257

Step (iii): *N*-[(1*S*,2*S*)-4,4-Difluoro-2-(2-methylpropane-2-sulfonamido)cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

15 To a solution of *N*-[(1*S*,2*S*)-2-amino-4,4-difluorocyclopentyl]-2-methylpropane-2-sulfonamide (1.03 g, 4.02 mmol) in dry DCM (13.4 ml) was added 2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 0.91 g, 4.82 mmol), EDC (2.31 g, 12.06 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (1.64 g, 12.06 mmol) and DIPEA (2.11 ml, 12.06 mmol). The reaction was stirred at room temperature overnight then partitioned
20 between ethyl acetate and water. The organics were washed with water and brine, dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 30-80% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.36 - 1.44 (m, 9 H), 1.93 - 2.08 (m, 1 H), 2.10 - 2.28 (m, 1 H), 2.65 - 2.84 (m, 2 H), 3.75 - 3.96 (m, 1 H), 4.24 - 4.41 (m, 1 H), 4.89 - 5.06 (m, 1
25 H), 6.35 - 6.52 (m, 1 H), 7.51 - 7.57 (m, 1 H), 7.61 - 7.70 (m, 2 H), 7.83 - 7.88 (m, 1 H), 7.90 (s, 2 H)


MS ES⁺: 428

Step (iv): *N*-[(1*S*,2*S*)-2-Amino-4,4-difluorocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide


30 To a solution of *N*-[(1*S*,2*S*)-4,4-difluoro-2-(2-methylpropane-2-sulfonamido)cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide (1.7 g, 3.98 mmol) in DCM (100 ml) at 0°C was added

anisole (CAS number 100-66-3; 7.82 ml, 71.6 mmol) followed by the drop wise addition of trifluoromethanesulfonic acid in DCM (0.2M, 1.55 ml, 17.5 mmol). The reaction mixture was stirred at 0°C for 1 hour and then at room temperature for 18 hours. The reaction mixture was quenched with sodium hydroxide (0.2M) until pH 11 obtained then
 5 extracted with DCM. The organics were filtered through a hydrophobic frit and concentrated *in vacuo*. The crude material was purified by SCX chromatography (2M ammonia in methanol) to afford the title compound.

MS ES⁺: 308



Intermediate 47: 2-(5-Ethoxypyrimidin-2-yl)benzoic acid



Step (i): 2-(5-Fluoropyrimidin-2-yl)benzonitrile

A suspension of 2-bromo-5-fluoropyrimidine (CAS number 947533-45-1; 301 mg, 1.70 mmol), potassium carbonate (705 mg, 5.10 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (62 mg, 0.085 mmol) in DMF (5 ml) was purged and evacuated with nitrogen. To this was then added (2-cyanophenyl)boronic acid (CAS number 138642-62-3; 300 mg, 2.04 mmol) and the
 20 reaction was subjected to microwave irradiation at 140°C for 10 minutes and then at 130°C for 35 minutes. The reaction was partitioned between ethyl acetate (50 ml) and water (50 ml) and filtered through diatomaceous earth (commercially sold under the trade mark "Celite"). The organics were washed with brine, dried over magnesium sulfate and
 25 concentrated *in vacuo*. The resulting residue was purified column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

^1H NMR (300 MHz, $\text{DCM}-d_2$) δ ppm 7.54 - 7.65 (m, 1 H), 7.67 - 7.79 (m, 1 H), 7.81 - 7.92 (m, 1 H), 8.27 - 8.40 (m, 1 H), 8.78 (s, 2 H)


MS ES^+ : 200

5 **Step (ii): 2-(5-Ethoxypyrimidin-2-yl)benzoic acid**


To a solution of 2-(5-fluoropyrimidin-2-yl)benzonitrile (40 mg, 0.20 mmol) in ethanol (1 ml) was added sodium hydroxide (3M, 3 ml, 9.0 mmol). The reaction was heated to reflux for 20 hours and then was concentrated *in vacuo*. The reaction was diluted with water and concentrated HCl was added drop wise until pH2 was reached. The aqueous layer was
10 concentrated *in vacuo* and the resulting residue was dissolved in methanol, filtered through a hydrophobic frit and concentrated *in vacuo* to afford the title compound.

MS ES^- : 243

15



Intermediate 48: (1S,2S)-1-N-[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride



20

Step (i): tert-Butyl N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

A solution of 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 6.78 ml, 54.9 mmol), *tert*-butyl *N*-[(1*S*,2*S*)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 10 g, 49.9 mmol) and DIPEA (26.2 ml, 150 mmol) in DMSO (160 ml) was heated at 140°C for 18 hours. The reaction mixture was partitioned between ethyl acetate (200 ml) and water (200 ml). The aqueous layer was extracted with ethyl acetate (2 x 100 ml). The combined organics were washed with brine (3 x 100ml), filtered through a hydrophobic frit, further dried over magnesium sulphate and then concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0 - 40% ethyl acetate / petrol). Impure fractions were further purified by column chromatography (silica, 10 - 40% ethyl acetate / petrol) and combined to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.29 (s, 9 H), 1.40 - 1.54 (m, 2 H), 1.58 - 1.73 (m, 2 H), 1.86 - 2.10 (m, 2 H), 3.68 - 3.83 (m, 1 H), 4.07 - 4.17 (m, 1 H), 6.83 - 6.96 (m, 1 H), 7.84 - 7.95 (m, 1 H), 7.99 (br. s., 1 H), 8.28 - 8.37 (m, 1 H)
MS ES⁺: 347

Step (ii): *tert*-Butyl *N*-[(1*S*,2*S*)-2-{[3-bromo-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

To a solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate (11.61 g, 33.5 mmol) in DCM (70 ml) and acetonitrile (35 ml) at 0°C under was added 1-bromopyrrolidine-2,5-dione (12.53 g, 70.4 mmol). The reaction was allowed to warm to room temperature and stirred for 20 hours. The mixture was concentrated *in vacuo* and then purified by column chromatography (silica, 0 - 50% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.29 (s, 9 H), 1.42 - 1.73 (m, 4 H), 1.82 - 1.96 (m, 1 H), 1.98 - 2.13 (m, 1 H), 3.92 - 4.17 (m, 2 H), 6.90 - 7.01 (m, 1 H), 7.39 - 7.48 (m, 1 H), 8.43 (s, 1 H)
MS ES⁺: 425, 427

Step (iii): *tert*-Butyl *N*-[(1*S*,2*S*)-2-{[3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

A suspension of *tert*-butyl *N*-[(1*S*,2*S*)-2-{[3-bromo-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate (2.44 g, 5.73 mmol), cyclopropylboronic acid (2.46 g,

28.6 mmol), potassium carbonate (3.17 g, 22.9 mmol) and tetrakis(triphenylphosphine)palladium (0.662 g, 0.57 mmol) in 1,4-dioxane (15 ml) and water (4 ml) was subjected to microwave irradiation at 140°C for 2 hours. The reaction was partitioned between ethyl acetate (20 ml) and water (20 ml). The aqueous layer was
 5 extracted with ethyl acetate (2 x 50 ml) and combined organics were washed with brine (50 ml), filtered through a hydrophobic frit and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0 - 50% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.83 - 0.91 (m, 2 H), 0.96 - 1.03 (m, 2 H), 1.29 (s, 9 H), 1.44 - 1.58 (m, 2 H), 1.59 - 1.73 (m, 2 H), 1.85 - 1.96 (m, 1 H), 2.03 - 2.13 (m, 1 H), 2.15 - 2.24 (m, 1 H), 3.89 - 4.00 (m, 1 H), 4.11 - 4.27 (m, 1 H), 6.88 - 7.00 (m, 1 H), 7.23 - 7.38 (m, 1 H), 8.14 (s, 1 H)


MS ES⁺: 387

Step (iv): (1*S*,2*S*)-1-*N*-[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride


To a solution of *tert*-butyl *N*-[(1*S*,2*S*)-2-{[3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate (1.54 g, 3.99 mmol) in 1,4-dioxane (14 ml) was added HCl in 1,4-dioxane (4M, 10 ml, 40 mmol). The reaction was stirred at room temperature
 20 for 20 hours and was then concentrated *in vacuo* and azeotropically distilled with toluene to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.80 - 0.92 (m, 1 H), 0.94 - 1.12 (m, 3 H), 1.57 - 1.89 (m, 4 H), 2.03 - 2.26 (m, 2 H), 2.36 - 2.48 (m, 1 H), 3.52 - 3.69 (m, 1 H), 4.30 - 4.48 (m, 1 H), 7.67 - 7.80 (m, 1 H), 8.15 - 8.40 (m, 4 H)

MS ES⁺: 287



Intermediate 50: 1-Methyl-1-*N*-[5-(trifluoromethyl)pyrimidin-2-yl]cyclopentane-1,2-diamine



Step (i): (1R,2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexyl N-(2-methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)carbamate

A solution of (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl N-(2-amino-2-methylcyclopentyl)carbamate hydrochloride (**Intermediate 27**; 2.0 g, 6.01 mmol), 2-chloro-5-(trifluoromethyl)pyrimidine (CAS number 69034-12-4; 1.21 g, 6.61 mmol) and DIPEA (3.15 ml, 18.02 mmol) in dry DMSO (15 ml) was subjected to microwave irradiation at 140 °C for 4 hours. The reaction was partitioned between ethyl acetate and brine. The aqueous layer was extracted further with ethyl acetate (2 x 100 ml). The combined organics were washed with brine (3 x 125 ml), dried over magnesium sulfate and concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0 - 30 % diethyl ether / petrol) to afford the title compound as a single trans-enantiomer.


MS ES⁺: 443

Step (ii): 1-Methyl-1-N-[5-(trifluoromethyl)pyrimidin-2-yl]cyclopentane-1,2-diamine


To a solution of (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl N-(2-methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)carbamate (1.04 g, 2.35 mmol) in acetic acid (8 ml) was added HBr (1.28 ml, 23.48 mmol). The reaction was heated sealed and heated at 90 °C overnight. To this was then added further HBr (1.28 ml, 23.48 mmol) and the reaction mixture heated at 90 °C for 24 hours. Further acetic acid (5 ml) and HBr (5 ml) was added and the reaction mixture heated to 90 °C for 5 hours. The reaction mixture was concentrated *in vacuo* and azeotropically distilled with toluene. The resulting residue was purified by SCX chromatography (2M ammonia in methanol) to afford the title compound as a single trans-enantiomer.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.25 - 1.43 (m, 4 H), 1.60 - 1.73 (m, 2 H), 1.86 - 2.00 (m, 1 H), 2.00 - 2.16 (m, 2 H), 3.30 - 3.37 (m, 1 H), 5.84 (br. s., 1 H), 8.32 - 8.56 (m, 2 H)

MS ES⁺: 261



Intermediate 51: 1-Methyl-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine



5

Step (i): (1R,2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexyl N-(2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)carbamate

A solution of (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl N-(2-amino-2-methylcyclopentyl)carbamate hydrochloride (**Intermediate 27**; 1.50 g, 4.51 mmol), 2-fluoro-5-(trifluoromethyl)pyridine (CAS number 69045-82-5; 0.652 mL, 5.41 mmol) and DIPEA (2.36 mL, 13.5 mmol) in DMSO (10 mL) was subjected to microwave irradiation at 140 °C for 4 hours. The reaction was diluted with ethyl acetate (200 mL) and a saturated solution of sodium bicarbonate (100 mL). The aqueous layer was further extracted with ethyl acetate (100 mL). The combined organics were washed with water (50 mL), brine (50 mL), dried over magnesium sulfate, filtered through a hydrophobic frit and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 10 - 20% diethyl ether / petrol) to afford the title compound as a single trans-enantiomer.

MS ES⁺: 442

20

Step (ii): 1-Methyl-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine

To a solution of (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl N-(2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)carbamate in acetic acid (3 mL) was added HBr (6 M, 1.68 mL, 10.10 mmol). The reaction was sealed and heated at 90 °C for 24 hours. To this was then added further HBr (6 M, 1.68 mL, 10.10 mmol) and the reaction was heated at 90 °C for 24 hours. The reaction was concentrated *in vacuo* and the resulting residue was purified by SCX chromatography (2M ammonia in methanol). The product was purified by reverse phase chromatography (C18 silica, 5-100% water (with 0.05% ammonia) / acetonitrile) to afford the title compound as a single trans-enantiomer.

^1H NMR (400 MHz, $\text{DCM}-d_2$) δ ppm 1.33 (s, 3 H), 1.43 - 1.58 (m, 1 H), 1.66 - 1.78 (m, 2 H), 1.84 - 1.97 (m, 1 H), 2.04 - 2.16 (m, 2 H), 3.21 - 3.36 (m, 1 H), 5.14 - 5.21 (m, 1 H), 6.43 - 6.55 (m, 1 H), 7.47 - 7.60 (m, 1 H), 8.25 - 8.33 (m, 1 H)


MS ES^+ : 260

5

2. Examples

Example 1: 2,6-Dimethoxy-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

10



A mixture of 2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 266 mg, 1.46 mmol), *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2,6-dimethoxybenzamide hydrochloride (**Intermediate 5**; 400 mg, 1.33 mmol), DIPEA (0.70 ml, 3.99 mmol) and DMSO (4.8 ml) was subjected to microwave irradiation at 140 °C for 2 hours. Upon cooling, the resulting mixture was partitioned between ethyl acetate (10 ml) and water (10 ml) and the combined organics were washed with brine (10 ml), dried over magnesium sulfate, filtered and concentrated *in vacuo*. The crude product was further purified by trituration with di-isopropylether to afford the title compound.


20

^1H NMR ($\text{DMSO}-d_6$) δ ppm 1.39-1.60 (m, 2 H), 1.70 (m, 2 H), 1.95-2.11 (m, 2 H), 3.32 (s, 6 H), 4.03-4.20 (m, 2 H), 6.59-6.78 (m, 3 H), 7.21-7.34 (m, 2 H), 7.63-7.70 (m, 1 H), 7.65 7.69 (m, 1 H) and 8.08 (m, 1 H)

MS ES^+ : 410

25

Example 2: 2,6-Dimethoxy-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide




A microwave vial was charged with *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2,6-dimethoxybenzamide hydrochloride (**Intermediate 5**; 80 mg, 0.27 mmol), DIPEA (0.139 ml, 0.80 mmol), 2-chloro-5-(trifluoromethyl)pyrimidine (CAS number 69034-12-4; 0.058 mg, 0.32 mmol) and dry NMP (0.9 ml). The resulting mixture was subjected to microwave irradiation at 250 °C for 20 minutes. The crude material was purified by reverse phase preparative HPLC (eluted with acetonitrile / water with 0.1 % ammonia) to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 1.45-1.75 (m, 4 H), 1.96-2.14 (m, 2 H), 3.61 (s, 6 H), 4.18-4.33 (m, 2 H), 6.51-6.69 (m, 2 H), 7.16-7.38 (m, 1 H), 8.03 (m, 2 H) and 8.60 (s, 2 H).

MS ES⁺: 411

Example 3: 5-Methyl-2-(2H-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]cyclopentyl]benzamide




To a mixture of *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 7**; 100 mg, 0.31 mmol) and NMP (1 ml) was added DIPEA (0.200 mg, 1.56 mmol) and 2-bromo-5-(trifluoromethyl)pyrimidine (70 mg, 0.31 mmol). The mixture was subjected to microwave irradiation at 150 °C for 1 hour.

Upon cooling, the reaction mass was poured into water (5 ml) and extracted with ethyl acetate (2 x 10 ml). The combined organics were dried over sodium sulfate and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1 % ammonia) to afford the title compound.

¹H NMR (CD₃CN) δ ppm 1.52-1.59 (m, 2 H), 1.74-1.80 (m, 2 H), 2.09-2.19 (m, 2 H), 2.42 (s, 3 H), 4.06-4.18 (m, 2 H), 6.65-6.67 (m, 1 H), 6.90-6.92 (m, 1 H), 7.30-7.30 (m, 1 H), 7.40-7.42 (m, 1 H), 7.63-7.65 (m, 1 H), 7.73 (s, 2 H), 8.52 (s, 2 H).

MS ES⁺: 432

Example 4: *N*-[(1*S*,2*S*)-2-[(5-Ethylpyrimidin-2-yl)amino]cyclopentyl]-5-methyl-2-(2*H*-1,2,3-triazol-2-yl)benzamide




A mixture of *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-5-methyl-2-(2*H*-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 7**; 100 mg, 0.31 mmol), toluene (1 ml), BINAP (19 mg, 0.03 mmol), cesium carbonate (404 mg, 0.12 mmol) and 2-chloro-5-ethylpyrimidine (CAS number 111196-81-7; 48 mg, 0.34 mmol) was purged with nitrogen gas for 5 minutes before tris(dibenzylideneacetone)dipalladium(0) (14 mg, 0.02 mmol) was added. The reaction mixture was stirred at 100 °C for 15 hours and upon cooling poured into water (3 ml) and extracted with ethyl acetate (3 x 10 ml). The combined organics were dried over sodium sulfate and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1 % ammonia) to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 1.02-1.15 (m, 3 H), 1.45-1.49 (m, 2 H), 1.50-1.58 (m, 2 H), 1.60-1.65 (m, 2 H), 2.32 (s, 3 H), 2.33-2.39 (m, 2 H), 4.03-4.10 (m, 2 H), 6.84-6.86 (m, 1 H), 7.22-7.22 (m, 1 H), 7.38-7.40 (m, 1 H), 7.61-7.63 (m, 1 H), 7.90 (s, 2 H), 8.15 (m, 1 H), 8.30 (m, 1 H), 8.33-8.35 (m, 1 H)

MS ES⁺: 392

Example 5: *N*-[(1*S*,2*S*)-2-[(5-Chloropyridin-2-yl)amino]cyclopentyl]-5-methyl-2-(2*H*-1,2,3-triazol-2-yl)benzamide




To a solution of *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-5-methyl-2-(2*H*-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 7**; 100 mg, 0.31 mmol) in toluene (1.0 ml) was added BINAP (19 mg, 0.03 mmol), cesium carbonate (405 mg, 1.25 mmol) and 2-bromo-

5-chloropyridine (CAS number 40473-01-6; 72 mg, 0.38 mmol). The mixture was purged with nitrogen for 5 minutes and then tris(dibenzylideneacetone)dipalladium(0) (14 mg, 0.02 mmol) was added and the resulting mixture was stirred at 100 °C for 15 hours. The resulting mass was poured into water (3 ml) and extracted into ethyl acetate (3 x 10 ml).

The combined organics were dried over sodium sulfate and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 1.40-1.52 (m, 2 H), 1.63-1.64 (m, 2 H), 1.93-2.01 (m, 2 H), 2.37 (s, 3 H), 3.97-4.06 (m, 2 H), 6.56-6.58 (m, 1 H), 6.73-6.75 (m, 1 H), 7.19 (m, 1 H), 7.38-7.44 (m, 2 H), 7.62-7.64 (m, 2 H), 7.93 (m, 1 H), 7.94 (m, 1 H), 8.34-8.36 (m, 1 H). MS ES⁺: 396

Example 6: 5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide




A microwave vial was charged *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 7**; 650 mg, 2.02 mmol), 2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 403 mg, 2.22 mmol) and DIPEA (1058 µl, 6.06 mmol) in dry DMSO (6.7 ml). The reaction was subjected to microwave irradiation at 120 °C for 2 hours and then at 140 °C for 5 hours. Upon cooling the mixture was partitioned between ethyl acetate and water, washing with water and brine, dried over magnesium sulfate, filtered through a hydrophobic frit and concentrated *in vacuo*. This was then purified by column chromatography (silica, 0-100 % ethyl acetate / petrol) and then further purified by column chromatography (basic silica 0-100 % DCM / petrol) to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 1.43-1.59 (m, 2 H), 1.62-1.73 (m, 2 H), 1.92-2.08 (m, 2 H), 2.39 (s, 3 H), 4.00-4.45 (m, 2 H), 6.62-6.69 (m, 1 H), 7.19-7.21 (m, 1 H), 7.28-7.32 (m, 1 H), 7.38-7.44 (m, 1 H), 7.61-7.67 (m, 2 H), 7.93 (s, 2 H), 7.28-7.32 (m, 1 H), 8.33-8.39 (m, 1 H).

MS ES⁺: 431

Example 7: 5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1*S*,2*S*)-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]benzamide

5




A microwave vial was charged with *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 7**; 450 mg, 1.40 mmol), 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 306 mg, 1.68 mmol) and DIPEA (733 μ l, 4.20 mmol) in dry DMSO (4.7 ml). The reaction was subjected to microwave irradiation at 140 $^{\circ}$ C for 2 hours and then partitioned between ethyl acetate and water, washed with water, brine and concentrated *in vacuo*. The crude product was then purified by column chromatography (basic silica, 0-100 % ethyl acetate / petrol) to give a cream solid which was then recrystallised from a mixture of ethyl acetate and pentane to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 1.45-1.60 (m, 2 H), 1.62-1.72 (m, 2 H), 1.93-2.10 (m, 2 H), 2.38 (s, 3 H), 4.08-4.25 (m, 2 H), 7.19 (m, 1 H), 7.39-7.42 (m, 1 H), 7.63-7.68 (m, 1 H), 7.89 (s, 2 H), 7.94-7.89 (m, 1 H), 8.03-8.08 (br. s., 1 H), 8.36 (s, 2 H).

MS ES⁺: 432

20

Example 8: 2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1*S*,2*S*)-2-{{5-(trifluoromethyl)pyridin-2-yl}amino}cyclopentyl]benzamide




A solution of 2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid (CAS number 475105-77-2; 57.4 mg, 0.28 mmol), (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-

diamine hydrochloride (**Intermediate 1**; 72 mg, 0.26 mmol), HATU (146 mg, 0.38 mmol) and triethylamine (107 μ l, 0.77 mmol) in dry DMF (852 μ l) was stirred at room temperature for 72 hours. The reaction was diluted with DMSO and filtered through cotton wool before being purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

^1H NMR (DMSO- d_6) δ ppm 1.42-1.78 (m, 4 H), 1.98-2.15 (m, 2 H), 2.39 (s, 3 H), 4.10-4.29 (m, 2 H), 6.64-6.69 (m, 1 H), 7.36-7.42 (m, 1 H), 7.46-7.52 (m, 1 H), 7.62-7.72 (m, 3 H), 7.91-7.97 (m, 1 H), 8.26 (br. s., 1 H), 7.56-7.63 (m, 1 H).

MS ES^+ : 432

Example 9: *N*-[(1*S*,2*S*)-2-[(5-Chloropyrazin-2-yl)amino]cyclopentyl]-5-methyl-2-(2*H*-1,2,3-triazol-2-yl)benzamide




To a solution of *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-5-methyl-2-(2*H*-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 7**; 100 mg, 0.31 mmol) in NMP (1.0 ml) was added DIPEA (160 mg, 1.24 mmol) and 2,5-dichloropyrazine (CAS number 19745-07-4; 92 mg, 0.62 mmol). The resulting reaction mixture was stirred and heated under microwave irradiation at 180 $^{\circ}\text{C}$ for 15 minutes. Upon completion, the reaction mixture was poured into water (3 ml) and extracted with ethyl acetate (3 x 10 ml). The combined organics were dried over sodium sulfate and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

^1H NMR (DMSO- d_6) δ ppm 1.44-1.56 (m, 2 H), 1.62-1.68 (m, 2 H), 1.92-2.04 (m, 2 H), 2.38 (s, 3 H), 4.01-4.10 (m, 2 H), 7.19 (s, 1 H), 7.28-7.30 (m, 1 H), 7.39-7.41 (m, 1 H), 7.62-7.64 (m, 1 H), 7.80-7.81 (s, 1 H), 7.93 (s, 2 H), 8.03 (s, 1 H), 8.35-8.37 (m, 1 H)

MS ES^+ : 398

Example 10: 5-Fluoro-2-(2*H*-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-[(5-(trifluoromethyl)pyridin-2-yl)amino]cyclopentyl]benzamide




Prepared according to the procedure for 2-(3-methyl-1,2,4-oxadiazol-5-yl)-*N*-[(1*S*,2*S*)-2-
 5 {5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 8**) from 5-
 fluoro-2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 8**; 72 mg, 0.26 mmol) and
 (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride
 (**Intermediate 1**; 61 mg, 0.28 mmol) to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 1.42-1.59 (m, 2 H), 1.60-1.75 (m, 2 H), 1.92-2.10 (m, 2 H),
 4.02-4.23 (m, 2 H), 6.64-6.70 (m, 1 H), 7.21-7.26 (m, 1 H), 7.27-7.30 (m, 1 H), 7.42-7.51
 10 (m, 1 H), 7.62-7.66 (m, 1 H), 7.78-7.84 (m, 1 H), 7.96 (s, 2 H), 8.26-8.29 (br. s., 1 H),
 8.46-8.51 (m, 1 H)

MS ES⁺: 435

**Example 11: 2-(1*H*-Pyrazol-1-yl)-*N*-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyridin-2-
 15 yl]amino}cyclopentyl]benzamide**




Prepared according to the procedure for 2-(3-methyl-1,2,4-oxadiazol-5-yl)-*N*-[(1*S*,2*S*)-2-
 {5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 8**) from 2-(1*H*-
 pyrazol-1-yl)benzoic acid (CAS number 55317-53-8; 53 mg, 0.28 mmol) and (1*S*,2*S*)-1-*N*-
 20 [5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 1**;
 72 mg, 0.26 mmol) to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 1.38-1.53 (m, 2 H), 1.60-1.74 (m, 2 H), 1.91-2.09 (m, 2 H),
 3.95-4.18 (m, 2 H), 6.28-6.32 (m, 1H), 6.62-6.67 (m, 1 H), 7.28-7.36 (m, 1 H), 7.46-7.48
 (m, 1 H), 7.52-7.59 (m, 1 H), 7.60-7.68 (m, 3 H), 8.09 (s, 1 H), 8.29 (br. s., 1 H), 8.44-8.50
 25 (m, 1 H), 8.74 (s, 1 H).

MS ES⁺: 416

Example 12: 2-(2H-1,2,3-Triazol-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 8**) from 2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 57 mg, 0.28 mmol) and (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 1**; 72 mg, 0.26 mmol) to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 1.37-1.60 (m, 2 H), 1.61-1.86 (m, 2 H), 1.92-2.10 (m, 2 H), 4.02-4.20 (m, 2 H), 6.70-6.80 (m, 1 H), 7.26-7.35 (m, 1 H), 7.37-7.53 (m, 2 H), 7.45-7.54 (m, 2 H), 7.73-7.79 (m, 1 H), 7.98 (s, 2 H), 8.27 (br. s., 1 H), 8.37-8.45 (m, 1 H).

MS ES⁺: 417

Example 13: 2-(Pyrimidin-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 8**) from 2-(pyrimidin-2-yl)benzoic acid (CAS number 400892-62-8; 56 mg, 0.28 mmol) and (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 1**; 72 mg, 0.26 mmol) to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 1.37-1.73 (m, 4 H), 1.94-2.10 (m, 2 H), 4.04-4.21 (m, 2 H), 6.64-6.69 (m, 1 H), 7.33-7.41 (m, 3 H), 7.43-7.57 (m, 2 H), 7.59-7.64 (m, 1 H), 7.95-7.99 (m, 1 H), 8.27 (br. s., 2 H), 8.83-8.85 (m, 2 H).

MS ES⁺: 428

Example 14: 5-Fluoro-2-(pyrimidin-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 8**) from 5-fluoro-2-(pyrimidin-2-yl)benzoic acid (CAS number 1293284-57-7; 61 mg, 0.28 mmol) and (1*S*,2*S*)-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 1**; 72 mg, 0.26 mmol) to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 1.42-1.75 (m, 4 H), 1.95-2.13 (m, 2 H), 4.04-4.23 (m, 2 H), 6.63-6.69 (m, 1 H), 7.12-7.18 (m, 1 H), 7.31-7.45 (m, 3 H), 7.60-7.67 (m, 1 H), 8.03-8.09 (m, 1 H), 8.26 (br. s., 1 H), 8.32-8.38 (m, 1 H), 8.76-8.92 (m, 2 H).

MS ES⁺: 446

Example 15: 2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2,6-dimethoxy-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 1**) from N-[(1*S*,2*S*)-2-aminocyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide hydrochloride (**Intermediate 2**; 100 mg, 0.31 mmol) and 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 68 mg, 0.37 mmol). The crude reaction was filtered through cotton wool before being purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

^1H NMR (DMSO- d_6) δ ppm 1.45-1.76 (m, 4 H), 2.00-2.18 (m, 2 H), 2.34 (s, 3 H), 4.16-4.32 (m, 2 H), 7.47-7.52 (m, 1 H), 7.59-7.74 (m, 2 H), 7.92-7.96 (m, 1 H), 7.99-8.09 (m, 2 H), 8.35 (br. s., 1 H), 8.56-8.63 (m, 1 H).

MS ES⁺: 433

5

Example 16: 2-(3-Methyl-1,2,4-oxadiazol-5-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide



Prepared according to the procedure for 2,6-dimethoxy-*N*-[(1*S*,2*S*)-2-{[5-

(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 1**) from *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide hydrochloride (**Intermediate 2**; 100 mg, 0.31 mmol) and 2-chloro-5-(trifluoromethyl)pyrimidine (CAS number 69034-12-4; 68 mg, 0.37 mmol). The crude reaction was filtered through cotton wool before being purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.


15

^1H NMR (DMSO- d_6) δ ppm 1.45-1.73 (m, 4 H), 1.95-2.13 (m, 2 H), 2.37 (s, 3 H), 4.21-4.37 (m, 2 H), 7.45-7.49 (m, 1 H), 7.59-7.71 (m, 2 H), 7.91-7.95 (m, 1 H), 8.09-8.16 (m, 1 H), 8.51-8.64 (m, 3 H).

MS ES⁺: 433

20

Example 17: 2-(2*H*-1,2,3-Triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide



Prepared according to the procedure for 2,6-dimethoxy-*N*-[(1*S*,2*S*)-2-{[5-

(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 1**) from *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 4**; 100 mg, 0.33 mmol) and 2-chloro-5-(trifluoromethyl)pyrazine (CAS


25

number 799557-87-2; 59 mg, 0.33 mmol). The crude reaction was filtered through cotton wool before being purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 1.43-1.59 (m, 2 H), 1.62-1.74 (m, 2 H), 1.95-2.10 (m, 2 H),
 4.08-4.25 (m, 2 H), 7.41-7.44 (m, 1 H), 7.46-7.51 (m, 1 H), 7.57-7.62 (m, 1 H), 7.76-7.79
 (m, 1 H), 7.92-7.99 (m, 3 H), 8.06 (br. s., 1 H), 8.36 (s, 1 H), 8.39-8.44 (m, 1 H).

MS ES⁺: 418

Example 18: 2-(2H-1,2,3-Triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2,6-dimethoxy-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 1**) from *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride
 (**Intermediate 4**; 100 mg, 0.325 mmol) and 2-chloro-5-(trifluoromethyl)pyrimidine (CAS
 number 69034-12-4; 59.3 mg, 0.325 mmol). The crude reaction was filtered through cotton
 wool before being purified by reverse phase preparative HPLC (eluted with acetonitrile /
 water containing 0.1% ammonia) to afford the title compound.

¹H NMR (DMSO-*d*₆) δ ppm 1.45-1.59 (m, 2 H), 1.60-1.73 (m, 2 H), 1.94-2.08 (m, 2 H),
 4.13-4.21 (m, 2 H), 7.41-7.44 (m, 1 H), 7.46-7.51 (m, 1 H), 7.55-7.63 (m, 1 H), 7.74-7.79
 (m, 1 H), 7.92 (s, 2 H), 8.03-8.08 (m, 1 H), 8.35-8.39 (m, 1 H), 8.62 (m, 2 H).

MS ES⁺: 418

Example 19: 2-(2H-1,2,3-Triazol-2-yl)-*N*-[(1*S*,2*R*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]oxy}cyclopentyl]benzamide




LiHMDS in THF (1.0 M, 0.477 ml, 0.477 mmol) was added to a solution of *N*-[(1*S*,2*R*)-2-hydroxycyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Intermediate 10**; 0.100 g, 0.37 mmol) in THF (3 ml) at 0 °C under nitrogen. The reaction was stirred at this temperature for 1 hour and then 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2;
 5 0.059 ml, 0.48 mmol) was added. The mixture was allowed to warm to room temperature and stirred for 5 hours. The reaction was then quenched with water (2 ml) and extracted with ethyl acetate (30 ml). The organics were washed with brine (10 ml), dried over magnesium sulfate and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-50% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.31 - 1.43 (m, 1 H), 1.57 - 1.80 (m, 2 H), 1.82 - 1.92 (m, 1 H), 2.04 - 2.14 (m, 2 H), 4.36 - 4.45 (m, 1 H), 5.39 - 5.44 (m, 1 H), 5.46 - 5.52 (m, 1 H), 7.50 - 7.56 (m, 1 H), 7.63 - 7.73 (m, 2 H), 7.77 - 7.86 (m, 4 H) and 8.30 (s, 1 H).

MS ES⁺: 419

Example 20: 2-(2*H*-1,2,3-Triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopentyl]benzamide




To a solution of *N*-[(1*S*,2*S*)-2-hydroxycyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Intermediate 11**; 200 mg, 0.73 mmol) in dry DMF (1.2 ml) was added sodium hydride (60% dispersion in mineral oil, 29.4 mg, 0.73 mmol). To this was then added 2-chloro-4-(trifluoromethyl)pyridine (CAS number 81565-18-6; 133 mg, 0.73 mmol) as a solution in dry DMF (1.2 ml). The reaction was stirred at room temperature for 17 hours and was then partitioned between ethyl acetate and water. The organics were washed with water and brine, dried over magnesium sulfate and concentrated *in vacuo*. The crude oil was purified
 20 by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.52 - 1.78 (m, 4 H), 2.00 - 2.13 (m, 2 H), 4.18 - 4.30 (m, 1 H), 5.30 - 5.38 (m, 1 H), 7.22 (s, 1 H), 7.30 - 7.34 (m, 1 H), 7.47 - 7.56 (m, 2 H), 7.59 - 7.65 (m, 1 H), 7.77 - 7.81 (m, 1 H), 7.98 (s, 2 H), 8.40 - 8.48 (m, 2 H)


MS ES⁺: 418

Example 21: 2,6-Dimethoxy-*N*-[(1*S*,2*S*)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopentyl]benzamide



- 5 Prepared according to the procedure for 2-(2*H*-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopentyl]benzamide (**Example 20**) from *N*-[(1*S*,2*S*)-2-hydroxycyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Intermediate 11**; 100 mg, 0.37 mmol) and 2-bromo-4-(trifluoromethyl)pyridine (CAS number 175205-81-9; 100 mg, 0.45 mmol) except that the reaction was stirred at room temperature for 2 hours. After
- 10 work-up, the resulting residue was purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.
- ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.64-1.79 (m, 4H), 2.04-2.14(m, 2H), 3.68 (s, 6H), 4.25-4.31 (m, 1H), 5.29-5.32 (m, 1H), 6.64-6.66 (m, 2H), 7.24-7.32 (m, 3H), 8.17-8.19 (m, 1H), 8.43-8.44 (m, 1H)
- 15 MS ES⁺: 411

Example 22: 2-(2*H*-1,2,3-Triazol-2-yl)-*N*-(2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide




- 20 Triethylamine (0.099 ml, 0.71 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (0.039 g, 0.29 mmol) and EDC (0.055 g, 0.29 mmol) were added to a solution 2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-amine (**Intermediate 12**; 0.058 g, 0.24 mmol) and 2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 0.054
- 25 g, 0.29 mmol) in DCM (3 ml). The reaction was stirred at room temperature for 24 hours and then diluted with DCM (40 ml) and washed with a saturated solution of sodium bicarbonate (10 ml). The organics were dried over magnesium sulfate, filtered through a

hydrophobic frit and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-80% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.19 - 1.31 (m, 1 H), 1.39 - 1.49 (m, 1 H), 1.50 - 1.64 (m, 2 H), 1.65 - 1.75 (m, 1 H), 1.91 - 2.02 (m, 1 H), 2.48 - 2.59 (m, 1 H), 2.68 - 2.76 (m, 1 H), 3.00 - 3.08 (m, 1 H), 4.36 - 4.45 (m, 1 H), 6.45 - 6.53 (m, 1 H), 7.30 - 7.34 (m, 1 H), 7.37 (s, 1 H), 7.48 - 7.54 (m, 1 H), 7.55 - 7.61 (m, 1 H), 7.62 - 7.66 (m, 1 H), 7.71 - 7.75 (m, 1 H), 7.82 (s, 2 H) and 8.59 - 8.62 (m, 1 H).

MS ES⁺: 416

Example 23: 2-(2H-1,2,3-Triazol-2-yl)-N-(2-([4-(trifluoromethyl)pyridin-2-yl]methyl)cyclopentyl)benzamide




Prepared according to the procedure for 2-(2H-1,2,3-triazol-2-yl)-N-(2-([4-(trifluoromethyl)pyridin-2-yl]methyl)cyclopentyl)benzamide (**Example 22**) except this was then was chirally separated using SFC (Waters prep30/MS system using 20% Ethanol, Daicel IA 10mm id x 250mm long columns at 30ml/min, 40°C and 100bar) to afford the title compound as a single enantiomer.

¹H NMR (300 MHz, DCM-*d*₂) δ ppm 1.15 - 1.35 (m, 1 H), 1.35 - 1.79 (m, 4 H), 1.85 - 2.06 (m, 1 H), 2.42 - 2.63 (m, 1 H), 2.64 - 2.79 (m, 1 H), 2.95 - 3.16 (m, 1 H), 4.28 - 4.53 (m, 1 H), 6.44 - 6.59 (m, 1 H), 7.26 - 7.43 (m, 2 H), 7.43 - 7.68 (m, 3 H), 7.69 - 7.77 (m, 1 H), 7.82 (s, 2 H), 8.54 - 8.68 (m, 1 H).

MS ES⁺: 416

Example 24: 2-(2H-1,2,3-Triazol-2-yl)-N-(2-([5-(trifluoromethyl)pyridin-2-yl]methyl)cyclopentyl)benzamide




Prepared according to the procedure for 2-(2H-1,2,3-triazol-2-yl)-N-(2-{{4-(trifluoromethyl)pyridin-2-yl}methyl}cyclopentyl)benzamide (**Example 22**) from 2-{{5-(trifluoromethyl)pyridin-2-yl}methyl}cyclopentan-1-amine (**Intermediate 13**; 33 mg, 0.14 mmol) and 2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 31 mg, 0.16 mmol) and then was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.22 - 1.32 (m, 1 H), 1.38 - 1.48 (m, 1 H), 1.50 - 1.65 (m, 2 H), 1.66 - 1.77 (m, 1 H), 1.90 - 2.01 (m, 1 H), 2.47 - 2.58 (m, 1 H), 2.69 - 2.77 (m, 1 H), 3.00 - 3.08 (m, 1 H), 4.36 - 4.45 (m, 1 H), 6.37 - 6.44 (m, 1 H), 7.29 - 7.34 (m, 1 H), 7.49 - 7.54 (m, 1 H), 7.56 - 7.65 (m, 2 H), 7.72 - 7.76 (m, 1 H), 7.83 (s, 2 H), 7.84 - 7.86 (m, 1 H) and 8.67 - 8.71 (m, 1 H)

MS ES⁺: 416

Example 25: 2-(2H-1,2,3-Triazol-2-yl)-N-(2-{{5-(trifluoromethyl)pyridin-2-yl}methyl}cyclopentyl)benzamide




Prepared according to the procedure for 2-(2H-1,2,3-triazol-2-yl)-N-(2-{{4-(trifluoromethyl)pyridin-2-yl}methyl}cyclopentyl)benzamide (**Example 24**) except this was then was chirally separated using SFC (Waters prep30/MS system using 20% Ethanol, Daicel IA 10mm id x 250mm long columns at 30ml/min, 40°C and 100bar) to afford the title compound as a single enantiomer.

¹H NMR (300 MHz, DCM-*d*₂) δ ppm 1.14 - 1.35 (m, 1 H), 1.35 - 1.81 (m, 4 H), 1.86 - 2.08 (m, 1 H), 2.41 - 2.60 (m, 1 H), 2.62 - 2.81 (m, 1 H), 2.95 - 3.13 (m, 1 H), 4.29 - 4.50 (m, 1 H), 6.35 - 6.49 (m, 1 H), 7.23 - 7.35 (m, 1 H), 7.44 - 7.67 (m, 3 H), 7.68 - 7.77 (m, 1 H), 7.77 - 7.88 (m, 3 H), 8.69 (s, 1 H)

MS ES⁺: 416


Example 26: 5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-(2-{{5-(trifluoromethyl)pyridin-2-yl}methyl}cyclopentyl)benzamide



To a solution of 2-([5-(trifluoromethyl)pyridin-2-yl]methyl)cyclopentan-1-amine hydrochloride (**Intermediate 36**; 0.60 g, 2.44 mmol) in DMF (5 ml) was added DIPEA (0.63 g, 4.80 mmol), TBTU (0.94 g, 2.93 mmol) and added 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 6**; 0.49 g, 2.44 mmol). The reaction was stirred at room temperature for 1 hour and then partitioned between ethyl acetate (50 ml) and water (10.0 ml). The aqueous layer was further extracted with ethyl acetate (50 ml) and the combined organics were concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0-2% methanol / DCM) to afford the title compound.

¹H NMR (400 MHz, DMSO) δ ppm 1.61-1.38 (m, 6 H), 2.33 (s, 3 H), 2.68-2.74 (m, 1 H), 3.04-3.09 (m, 1 H), 4.24-4.26 (m, 1 H), 7.30 (s, 1H), 7.41-7.43 (m, 1 H), 7.47-7.49 (m, 1 H), 7.64-7.66 (m, 1 H), 7.98 (m, 2 H), 8.09-8.11 (m, 1 H), 8.28-8.30 (m, 1 H), 8.87 (s, 1 H)
MS ES⁺: 430

Example 27: 2,6-Dimethoxy-N-[(1S,2S)-2-{[6-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide




To a microwave vial were charged N-[(1S,2S)-2-Aminocyclopentyl]-2,6-dimethoxybenzamide hydrochloride (**Intermediate 5**; 80 mg, 0.266 mmol) in dry NMP (1 ml). To this was then added DIPEA (138 μ l, 0.798 mmol) and 2-fluoro-6-(trifluoromethyl)pyridine (CAS number 94239-04-0; 53 mg, 0.319 mmol). The reaction was subjected to microwave irradiation at 200 °C for 30 minutes and then at 250 °C for 20 minutes. The reaction mixture was directly purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.44 - 1.58 (m, 2 H), 1.65 - 1.76 (m, 2 H), 1.97 - 2.10 (m, 2 H), 3.63 (s, 6 H), 3.95 - 4.04 (m, 1 H), 4.04 - 4.13 (m, 1 H), 6.55 - 6.67 (m, 2 H), 6.84 - 6.92 (m, 2 H), 7.05 - 7.11 (m, 1 H), 7.21 - 7.29 (m, 1 H), 7.55 - 7.62 (m, 1 H), 8.02 - 8.09 (m, 1 H)

5 MS ES^+ : 410

Example 28: 3-Bromo-*N*-[(1*S*,2*S*)-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]pyridine-2-carboxamide



10 EDC (509 mg, 2.65 mmol) was added to a solution of 3-bromopyridine-2-carboxylic acid (429 mg, 2.12 mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (361 mg, 2.65 mmol), (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 500mg, 1.77 mmol) and triethylamine (0.74 ml, 5.31 mmol) in DCM (5.9 ml). The reaction was stirred at room temperature overnight. The reaction was diluted


15 with DCM, washed with water, brine, filtered through a hydrophobic frit and concentrated *in vacuo*. The crude pproduct was purified by column chromatography (silica 0-100% ethyl acetate / petrol) to afford the title compound.

^1H NMR (400 MHz, $\text{DCM}-d_2$) δ ppm 1.57 - 1.82 (m, 2 H), 1.82 - 2.04 (m, 2 H), 2.19 - 2.35 (m, 1 H), 2.35 - 2.47 (m, 1 H), 4.06 - 4.23 (m, 1 H), 4.24 - 4.39 (m, 1 H), 6.99 (br. s., 1 H),

20 7.27 - 7.32 (m, 1 H), 8.02 - 8.06 (m, 1 H), 8.11 - 8.21 (m, 1 H), 8.22 (s, 1 H), 8.46 - 8.52 (m, 1 H)

MS ES^+ : 432

Example 29: 2-Ethoxy-5-methyl-*N*-[(1*S*,2*S*)-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]benzamide




Prepared according to the procedure for 3-bromo-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide (**Example 28**) from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 75 mg, 0.27 mmol) and 2-ethoxy-5-methylbenzoic acid

(CAS number 854645-34-4; 57 mg, 0.32 mmol) and was then purified by column chromatography (silica, 40-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.47 (t, J=6.95 Hz, 3 H), 1.57 - 1.71 (m, 2 H), 1.82 - 1.97 (m, 2 H), 2.14 - 2.28 (m, 1 H), 2.31 (s, 3 H), 2.41 - 2.54 (m, 1 H), 3.84 - 3.94 (m, 1 H), 4.15 (q, J=6.95 Hz, 2 H), 4.35 - 4.49 (m, 1 H), 6.85 - 6.90 (m, 1 H), 7.22 - 7.28 (m, 1 H), 7.92 - 7.96 (m, 1 H), 8.08 (br. s., 1 H), 8.23 (s, 1 H), 8.38 - 8.47 (m, 1 H)

MS ES⁺: 409

Example 30: 3-Ethoxy-6-methyl-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide




Prepared according to the procedure for 3-bromo-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide (**Example 28**) from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 75 mg, 0.27 mmol) and 3-ethoxy-6-methylpyridine-2-carboxylic acid (CAS number 1228188-14-4; 58 mg, 0.32 mmol) and was then purified by column chromatography (silica, 40-100% ethyl acetate / petrol) followed by partitioning between ethyl acetate and a saturated solution of sodium bicarbonate. The organics were filtered through a hydrophobic frit and concentrated *in vacuo* to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.39 - 1.47 (m, 3 H), 1.51 - 1.63 (m, 1 H), 1.63 - 1.76 (m, 1 H), 1.82 - 1.95 (m, 2 H), 2.17 - 2.30 (m, 1 H), 2.39 - 2.49 (m, 1 H), 2.50 (s, 3 H), 3.95 - 4.06 (m, 1 H), 4.07 - 4.14 (m, 2 H), 4.32 - 4.47 (m, 1 H), 6.64 - 7.05 (m, 1 H), 7.20 - 7.36 (m, 2 H), 7.97 - 8.10 (m, 2 H), 8.23 - 8.25 (m, 1 H)

MS ES⁺: 410

Example 31: 2-(1H-Pyrazol-1-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




A solution of (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 213 mg, 0.75 mmol), HATU (430 mg, 1.13 mmol), triethylamine (0.315 ml, 2.26 mmol) and 2-(1*H*-pyrazol-1-yl)benzoic acid (CAS number 55317-53-8; 156 mg, 0.83 mmol) was stirred at room temperature overnight. This was then partitioned between DCM and a saturated solution of sodium bicarbonate, filtered through a hydrophobic frit and concentrated *in vacuo*. The resulting residue was purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.39 - 1.53 (m, 2 H), 1.60 - 1.72 (m, 2 H), 1.92 - 2.07 (m, 2 H), 4.09 - 4.20 (m, 2 H), 6.27 - 6.31 (m, 1 H), 7.35 - 7.44 (m, 2 H), 7.51 - 7.60 (m, 3 H), 7.88 - 7.92 (m, 1 H), 7.94 - 8.00 (m, 1 H), 8.03 (s, 1 H), 8.34 (s, 1 H), 8.36 - 8.41 (m, 1 H)

MS ES⁺: 417

Example 32: 2-Fluoro-6-(2*H*-1,2,3-triazol-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-(1*H*-pyrazol-1-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 31**) from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 213 mg, 0.75 mmol) and 2-fluoro-6-(2*H*-1,2,3-triazol-2-yl)benzoic acid (CAS number 1186050-58-7; 172 mg, 0.83 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.43 - 1.59 (m, 2 H), 1.60 - 1.75 (m, 2 H), 1.96 -

2.08 (m, 2 H), 4.12 - 4.24 (m, 2 H), 7.32 - 7.38 (m, 1 H), 7.58 - 7.65 (m, 1 H), 7.70 - 7.74 (m, 1 H), 7.94 - 8.00 (m, 3 H), 8.06 (br. s., 1 H), 8.35 (s, 1 H) and 8.60 - 8.65 (m, 1 H)
MS ES⁺: 436


Example 33: 2,6-Difluoro-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide



Prepared according to the procedure for 2-(1*H*-pyrazol-1-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 31**) from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 213 mg, 0.75 mmol) and 2,6-difluorobenzoic acid (CAS number 385-00-2; 131 mg, 0.83 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.44 - 1.60 (m, 2 H), 1.68 - 1.77 (m, 2 H), 2.01 - 2.14 (m, 2 H), 4.18 - 4.29 (m, 2 H), 7.07 - 7.15 (m, 2 H), 7.43 - 7.52 (m, 1 H), 7.99 - 8.09 (m, 2 H), 8.33 (s, 1 H), 8.79 - 8.87 (m, 1 H)
MS ES⁺: 387

Example 34: 2,6-Dimethoxy-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-(1*H*-pyrazol-1-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 31**) from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 213 mg, 0.75 mmol) and 2,6-dimethoxybenzoic acid (CAS number 1466-76-8 ; 151 mg, 0.83 mmol) except this was then purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.43 - 1.60 (m, 2 H), 1.64 - 1.75 (m, 2 H), 1.95 - 2.09 (m, 2 H), 3.61 (s, 6 H), 4.13 - 4.24 (m, 2 H), 6.60 - 6.64 (m, 2 H), 7.21 - 7.28 (m, 1 H), 7.93 - 8.01 (m, 1 H), 8.03 - 8.12 (m, 2 H) and 8.34 (s, 1 H).

MS ES⁺: 411

5

Example 35: 2-(1H-1,2,3-Triazol-1-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide



Prepared according to the procedure for 2-(1H-pyrazol-1-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 31**) from (1*S*,2*S*)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 213 mg, 0.75 mmol) and 2-(1H-1,2,3-triazol-1-yl)benzoic acid (CAS number 1085458-53-2; 157 mg, 0.83 mmol) except this was then purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.


15

^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.35 - 1.49 (m, 2 H), 1.58 - 1.72 (m, 2 H), 1.87 - 2.09 (m, 2 H), 4.01 - 4.19 (m, 2 H), 7.47 - 7.54 (m, 1 H), 7.55 - 7.69 (m, 3 H), 7.76 (s, 1 H), 7.89 - 7.98 (m, 1 H), 7.98 - 8.07 (m, 1 H), 8.27 (s, 1 H), 8.35 (s, 1 H), 8.43 - 8.53 (m, 1 H)

MS ES⁺: 418

20

Example 36: 5-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-(1H-pyrazol-1-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 31**) from (1*S*,2*S*)-

25

1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 213 mg, 0.75 mmol) and 5-fluoro-2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 8**; 172 mg, 0.83 mmol) except this was then purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.41 - 1.60 (m, 2 H), 1.61 - 1.77 (m, 2 H), 1.93 - 2.10 (m, 2 H), 4.02 - 4.26 (m, 2 H), 7.22 - 7.33 (m, 1 H), 7.42 - 7.53 (m, 1 H), 7.75 - 7.85 (m, 1 H), 7.90 - 8.00 (m, 3 H), 8.00 - 8.08 (m, 1 H), 8.36 (s, 1 H), 8.45 - 8.54 (m, 1 H)
MS ES⁺: 436

Example 37: 2-Methoxy-5-methyl-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




A solution of (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 75 mg, 0.27 mmol), 2-methoxy-5-methylbenzoic acid (CAS number 25045-36-7; 53 mg, 0.32 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (61 mg, 0.40 mmol), EDC (76 mg, 0.40 mmol) and triethylamine (111 µl, 0.80 mmol) in dry DCM (1 ml) was stirred at room temperature for 24 hours. The reaction mixture was partitioned between DCM (3 ml) and water (2 ml), filtered through a hydrophobic frit and concentrated *in vacuo*. The resulting residue was purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.49 - 1.74 (m, 2 H), 1.83 - 1.94 (m, 2 H), 2.16 - 2.27 (m, 1 H), 2.31 (s, 3 H), 2.41 - 2.54 (m, 1 H), 3.86 - 4.01 (m, 4 H), 4.40 - 4.53 (m, 1 H), 6.82 - 7.04 (m, 2 H), 7.24 - 7.30 (m, 1 H), 7.86 - 8.00 (m, 2 H), 8.08 - 8.21 (m, 1 H), 8.24 (s, 1 H)

MS ES⁺: 395

Example 38: 2-(Pyrimidin-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-methoxy-5-methyl-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 75 mg, 0.27 mmol) and 2-(pyrimidin-2-yl)benzoic acid (CAS number 400892-62-8; 64 mg, 0.32 mmol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.44 - 1.59 (m, 2 H), 1.75 - 1.89 (m, 2 H), 2.11 - 2.24 (m, 1 H), 2.32 - 2.45 (m, 1 H), 3.86 - 3.98 (m, 1 H), 4.20 - 4.34 (m, 1 H), 6.40 - 6.44 (m, 1 H), 6.53 - 6.71 (m, 1 H), 7.03 - 7.10 (m, 1 H), 7.44 - 7.59 (m, 3 H), 7.85 (s, 1 H), 7.97 - 8.08 (m, 1 H), 8.21 (s, 1 H), 8.51 - 8.60 (m, 2 H)

MS ES⁺: 429

Example 39: 5-Fluoro-2-(pyrimidin-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-methoxy-5-methyl-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 75 mg, 0.27 mmol) and 5-fluoro-2-(pyrimidin-2-yl)benzoic acid (CAS number 1293284-57-7; 69 mg, 0.32 mmol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.48 - 1.70 (m, 2 H), 1.74 - 1.98 (m, 2 H), 2.17 - 2.43 (m, 2 H), 3.94 - 4.09 (m, 1 H), 4.17 - 4.28 (m, 1 H), 6.47 - 6.61 (m, 1 H), 6.83 - 7.05 (m, 1

H), 7.07 - 7.13 (m, 1 H), 7.17 - 7.28 (m, 2 H), 7.96 - 8.08 (m, 1 H), 8.09 - 8.19 (m, 2 H), 8.53 - 8.62 (m, 2 H)

MS ES⁺: 447

Example 40: 2-Chloro-6-(2H-1,2,3-triazol-2-yl)-N-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]benzamide




Prepared according to the procedure for 2-methoxy-5-methyl-N-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 75 mg, 0.265 mmol) and 2-chloro-6-(2H-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 15**, 71 mg, 0.318 mmol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.52 - 1.67 (m, 2 H), 1.81 - 1.95 (m, 2 H), 2.21 - 2.41 (m, 2 H), 4.04 - 4.15 (m, 1 H), 4.24 - 4.38 (m, 1 H), 6.14 - 6.29 (m, 1 H), 6.47 - 6.62 (m, 1 H), 7.46 - 7.55 (m, 2 H), 7.61 (s, 2 H), 7.88 - 7.96 (m, 2 H), 8.17 (s, 1 H)

MS ES⁺: 452

Example 41: 5-Fluoro-2-(1H-1,2,3-triazol-1-yl)-N-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]benzamide




Prepared according to the procedure for 2-methoxy-5-methyl-N-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 75 mg, 0.27 mmol) and 5-fluoro-2-(1H-1,2,3-triazol-1-yl)benzoic acid (**Intermediate 9**, 66 mg, 0.32 mmol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.39 - 1.64 (m, 2 H), 1.77 - 1.92 (m, 2 H), 2.08 - 2.22 (m, 1 H), 2.25 - 2.41 (m, 1 H), 3.92 - 4.04 (m, 1 H), 4.08 - 4.23 (m, 1 H), 6.28 - 6.47 (m, 1 H), 6.69 - 6.80 (m, 1 H), 7.28 - 7.44 (m, 2 H), 7.47 - 7.56 (m, 1 H), 7.72 (d, *J*=1.01 Hz, 1 H), 7.87 (d, *J*=1.01 Hz, 1 H), 8.09 (s, 1 H), 8.24 (s, 1 H)

5 MS ES⁺: 436

Example 42: 5-Methyl-2-(1H-1,2,3-triazol-1-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




10 Prepared according to the procedure for 2-methoxy-5-methyl-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 75 mg, 0.27 mmol) and 5-methyl-2-(1H-1,2,3-triazol-1-yl)benzoic acid (CAS number 1149352-55-5; 65 mg, 0.32 mmol) to afford the title compound.

15 ¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.42 - 1.65 (m, 2 H), 1.76 - 1.91 (m, 2 H), 2.07 - 2.19 (m, 1 H), 2.27 - 2.40 (m, 1 H), 3.89 - 4.05 (m, 1 H), 4.09 - 4.28 (m, 1 H), 6.55 - 6.78 (m, 2 H), 7.34 - 7.41 (m, 1 H), 7.43 - 7.49 (m, 2 H), 7.70 (d, *J*=1.01 Hz, 1 H), 7.86 (d, *J*=1.01 Hz, 1 H), 8.13 (s, 1 H), 8.23 (s, 1 H)

MS ES⁺: 432

20

Example 43: 3-(1H-Pyrazol-1-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide



A solution of 3-bromo-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide (**Example 28**; 100mg, 0.23 mmol), 1H-pyrazole (CAS number 288-13-1; 32 mg, 0.47 mmol), cesium carbonate (151 mg, 0.47


25

mmol), copper (I) iodide (2.2 mg, 0.012 mmol) and *trans*-1-*N*,2-*N*-dimethylcyclohexane-1,2-diamine (1.7 mg, 0.012 mmol) in dry DMF (0.8 ml) was subjected to microwave irradiation at 120°C for 1 hour. The reaction mixture was diluted with ethyl acetate and washed with water (x 3) and brine, filtered through a hydrophobic frit and concentrated *in vacuo*. The resulting residue was purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

¹H NMR (400 MHz, DCME-*d*₂) δ ppm 1.42 - 1.59 (m, 1 H), 1.59 - 1.77 (m, 1 H), 1.77 - 1.93 (m, 2 H), 2.10 - 2.31 (m, 1 H), 2.31 - 2.48 (m, 1 H), 3.94 - 4.18 (m, 1 H), 4.19 - 4.35 (m, 1 H), 6.21 - 6.36 (m, 1 H), 6.37 - 6.43 (m, 1 H), 7.51 - 7.58 (m, 1 H), 7.61 - 7.67 (m, 1 H), 7.71 - 7.75 (m, 1 H), 7.84 - 7.88 (m, 1 H), 7.90 - 7.96 (m, 1 H), 7.97 - 8.07 (m, 1 H), 8.25 (s, 1 H), 8.49 - 8.59 (m, 1 H)

MS ES⁺: 418

Example 44: 2-(5-Methyl-1,3,4-oxadiazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-methoxy-5-methyl-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride

(**Intermediate 14**; 75 mg, 0.27 mmol) and 2-(5-methyl-1,3,4-oxadiazol-2-yl)benzoic acid (CAS number 898289-64-0; 75 mg, 0.37 mmol) except this was purified by column chromatography (silica, 40-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.53 - 1.69 (m, 2 H), 1.80 - 1.94 (m, 2 H), 2.23 - 2.34 (m, 1 H), 2.37 - 2.47 (m, 1 H), 2.50 (s, 3 H), 3.98 - 4.14 (m, 1 H), 4.26 - 4.40 (m, 1 H), 6.53 - 6.74 (m, 1 H), 6.78 - 6.90 (m, 1 H), 7.48 - 7.55 (m, 1 H), 7.55 - 7.61 (m, 2 H), 7.80 - 7.90 (m, 1 H), 8.12 (s, 1 H), 8.15 (s, 1 H)

MS ES⁺: 433

Example 45: 2-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-methoxy-5-methyl-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 75 mg, 0.27 mmol) and 2-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)benzoic acid (**Intermediate 37a**; CAS number 1384066-81-2; 94 mg, 0.37 mmol) except this was purified by column chromatography (silica, 40-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.49 - 1.73 (m, 2 H), 1.75 - 2.00 (m, 2 H), 2.21 - 2.40 (m, 2 H), 4.03 - 4.16 (m, 1 H), 4.15 - 4.30 (m, 1 H), 6.58 - 6.67 (m, 1 H), 6.67 - 6.89 (m, 1 H), 7.64 - 7.71 (m, 2 H), 7.76 - 7.80 (m, 1 H), 7.81 - 7.86 (m, 1 H), 8.01 - 8.06 (m, 1 H), 8.09 (s, 1 H), 8.14 (s, 1 H)

MS ES⁺: 486

Example 46: 2-Fluoro-6-(1H-pyrazol-1-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide



Prepared according to the procedure for 2-methoxy-5-methyl-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 75 mg, 0.27 mmol) and 2-fluoro-6-(1H-pyrazol-1-yl)benzoic acid (CAS number 1521055-55-9; 75 mg, 0.37 mmol) except this was purified by column chromatography (silica, 40-100% ethyl acetate / petrol) to afford the title compound.


¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.41 - 1.59 (m, 2 H), 1.73 - 1.93 (m, 2 H), 2.12 - 2.38

(m, 2 H), 3.93 - 4.04 (m, 1 H), 4.16 - 4.27 (m, 1 H), 6.24 (s, 1 H), 6.52 - 6.60 (m, 1 H), 7.10 - 7.18 (m, 1 H), 7.29 - 7.35 (m, 1 H), 7.42 - 7.53 (m, 2 H), 7.72 - 7.76 (m, 1 H), 8.01 (s, 1 H), 8.16 (s, 1 H)

MS ES⁺: 435

5

Example 47: 5-Fluoro-2-(1H-pyrazol-1-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-methoxy-5-methyl-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 75 mg, 0.27 mmol) and 5-fluoro-2-(1H-pyrazol-1-yl)benzoic acid (CAS number 1152964-04-9; 75 mg, 0.37 mmol) except this was purified by column chromatography (silica, 40-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.30 - 1.58 (m, 2 H), 1.68 - 1.90 (m, 2 H), 1.97 - 2.11 (m, 1 H), 2.22 - 2.36 (m, 1 H), 3.70 - 3.81 (m, 1 H), 4.08 - 4.21 (m, 1 H), 6.31 - 6.39 (m, 2 H), 6.73 - 6.81 (m, 1 H), 7.21 - 7.30 (m, 1 H), 7.36 - 7.42 (m, 1 H), 7.42 - 7.49 (m, 1 H), 7.61 (s, 2 H), 7.99 (s, 1 H), 8.23 (s, 1 H)

MS ES⁺: 435

20

Example 48: 5-Methyl-2-(1H-pyrazol-1-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide



Prepared according to the procedure for 2-methoxy-5-methyl-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-


1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 75 mg, 0.27 mmol) and 5-methyl-2-(1H-pyrazol-1-yl)benzoic acid (CAS number 1152964-04-9; 75 mg, 0.37 mmol) except this was purified by column chromatography (silica, 40-100% ethyl acetate / petrol) to afford the title compound.

25

1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 75 mg, 0.27 mmol) and 5-methyl-2-(1*H*-pyrazol-1-yl)benzoic acid (CAS number 1214622-46-4; 74 mg, 0.37 mmol) except this was purified by column chromatography (silica, 40-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.37 - 1.51 (m, 1 H), 1.53 - 1.70 (m, 1 H), 1.71 - 1.95 (m, 2 H), 2.01 - 2.13 (m, 1 H), 2.26 - 2.38 (m, 1 H), 2.47 (s, 3 H), 3.75 - 3.86 (m, 1 H), 4.13 - 4.25 (m, 1 H), 6.36 - 6.41 (m, 1 H), 6.75 - 6.81 (m, 1 H), 7.27 - 7.34 (m, 1 H), 7.37 - 7.42 (m, 1 H), 7.55 - 7.60 (m, 1 H), 7.62 - 7.68 (m, 2 H), 8.16 - 8.20 (m, 1 H), 8.24 (s, 1 H)
MS ES⁺: 431


Example 49: 2-Bromo-6-methoxy-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide



Prepared according to the procedure for 2-methoxy-5-methyl-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 250 mg, 0.88 mmol) and 2-bromo-6-methoxybenzoic acid (CAS number 31786-45-5; 245 mg, 1.06 mmol) except this was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.55 - 1.74 (m, 2 H), 1.80 - 2.00 (m, 2 H), 2.19 - 2.43 (m, 2 H), 3.69 (s, 3 H), 4.14 - 4.27 (m, 1 H), 4.30 - 4.41 (m, 1 H), 6.33 - 6.39 (m, 1 H), 6.84 - 6.91 (m, 1 H), 7.11 - 7.17 (m, 1 H), 7.18 - 7.26 (m, 1 H), 8.16 (s, 1 H), 8.23 - 8.27 (m, 1 H)
MS ES⁺: 559

Example 50: 2-Methoxy-6-(1*H*-pyrazol-1-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 3-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]pyridine-2-carboxamide (**Example 43**) from 2-bromo-6-methoxy-N-[(1S,2S)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]benzamide (**Example 49**; 100 mg, 0.218 mmol) and 1H-pyrazole (30 mg, 0.435 mmol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.34 - 1.59 (m, 2 H), 1.69 - 1.90 (m, 2 H), 2.04 - 2.18 (m, 1 H), 2.24 - 2.39 (m, 1 H), 3.75 (s, 3 H), 3.81 - 3.93 (m, 1 H), 4.14 - 4.28 (m, 1 H), 6.12 - 6.18 (m, 1 H), 6.28 - 6.37 (m, 2 H), 6.89 - 6.99 (m, 1 H), 7.06 - 7.13 (m, 1 H), 7.37 - 7.48 (m, 2 H), 7.68 - 7.73 (m, 1 H), 7.89 (s, 1 H), 8.21 (s, 1 H)

MS ES⁺: 447

Example 51: 3-(Piperidin-1-yl)-N-[(1S,2S)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]pyridine-2-carboxamide




A solution of (1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 75 mg, 0.27 mmol), 3-(piperidin-1-yl)pyridine-2-carboxylic acid (CAS number 898289-01-5; 66 mg, 0.32 mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (54 mg, 0.40 mmol), EDC (76 mg, 0.40 mmol) and triethylamine (0.111 ml, 0.80 mmol) in DCM (1 ml) was stirred at room temperature overnight. The reaction was partitioned between DCM and a saturated solution of sodium bicarbonate, filtered through a hydrophobic frit and concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 40-100% ethyl acetate / petrol) and then further purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

^1H NMR (400 MHz, $\text{DCM}-d_2$) δ ppm 1.46 - 1.63 (m, 2 H), 1.65 - 1.79 (m, 6 H), 1.83 - 1.96 (m, 2 H), 2.17 - 2.32 (m, 1 H), 2.41 - 2.56 (m, 1 H), 2.88 - 3.05 (m, 4 H), 3.91 - 4.05 (m, 1 H), 4.35 - 4.52 (m, 1 H), 6.85 (br. s., 1 H), 7.27 - 7.37 (m, 1 H), 7.44 - 7.54 (m, 1 H), 7.94 (s, 1 H), 8.17 - 8.27 (m, 2 H), 8.86 - 8.95 (m, 1 H)

5 MS ES^+ : 435

Example 52: 5-Chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]benzamide




Prepared according to the procedure for 3-(piperidin-1-yl)-N-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]pyridine-2-carboxamide (**Example 51**) from (1*S*,2*S*)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 500 mg, 1.77 mmol) and 5-chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 38a**; CAS number 1293284-54-4; 396 mg, 1.77 mmol) except this was purified only by column chromatography (silica, 40-100% ethyl acetate / petrol) to afford the title compound.

^1H NMR (400 MHz, $\text{DCM}-d_2$) δ ppm 1.41 - 1.66 (m, 2 H), 1.69 - 1.94 (m, 2 H), 2.15 - 2.28 (m, 1 H), 2.28 - 2.41 (m, 1 H), 3.89 - 4.05 (m, 1 H), 4.12 - 4.27 (m, 1 H), 6.43 - 6.53 (m, 2 H), 7.49 - 7.58 (m, 2 H), 7.61 - 7.67 (m, 2 H), 7.73 - 7.80 (m, 1 H), 8.00 (s, 1 H), 8.19 (s, 1 H)

MS ES^+ : 452

Example 53: 3-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]benzamide




Prepared according to the procedure for 2-methoxy-5-methyl-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 126 mg, 0.45 mmol) and 3-fluoro-2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (CAS number 1293284-51-1; 111 mg, 0.54 mmol) except this was purified by column chromatography (silica, 40-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.41 - 1.56 (m, 2 H), 1.60 - 1.73 (m, 2 H), 1.88 - 2.08 (m, 2 H), 4.06-4.09 (m, 1 H), 4.15 - 4.24 (m, 1 H), 7.72 - 7.78 (m, 1 H), 7.82 - 7.86 (m, 1 H), 7.86 - 7.92 (m, 1 H), 7.94 - 8.08 (m, 3 H), 8.31 (s, 1 H), 8.39 - 8.43 (m, 1 H), 8.67 - 8.75 (m, 1 H)

MS ES⁺: 436

Example 54: 2-(1*H*-1,2,3-Triazol-1-yl)-5-(trifluoromethyl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-methoxy-5-methyl-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 126 mg, 0.45 mmol) and 2-(1*H*-1,2,3-triazol-1-yl)-5-(trifluoromethyl)benzoic acid (**Intermediate 37b**; 138 mg, 0.54 mmol) except this was purified by column chromatography (silica, 40-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.36 - 1.52 (m, 2 H), 1.58 - 1.72 (m, 2 H), 1.86 - 2.09 (m, 2 H), 3.93 - 4.07 (m, 1 H), 4.07 - 4.16 (m, 1 H), 7.33 - 7.39 (m, 1 H), 7.53 - 7.72 (m, 2 H), 7.87 - 8.03 (m, 4 H), 8.37 (s, 1 H), 8.45 - 8.53 (m, 1 H)

MS ES⁺: 486

Example 55: 5-Chloro-2-(1H-1,2,3-triazol-1-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-methoxy-5-methyl-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 126 mg, 0.45 mmol) and 5-chloro-2-(1H-1,2,3-triazol-1-yl)benzoic acid (**Intermediate 38b**; 120 mg, 0.54 mmol) except this was purified by column chromatography (silica, 40-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.39 - 1.52 (m, 2 H), 1.59 - 1.72 (m, 2 H), 1.86 - 2.13 (m, 2 H), 3.99 - 4.10 (m, 1 H), 4.10 - 4.22 (m, 1 H), 7.54 (d, *J*=2.40 Hz, 1 H), 7.63 - 7.69 (m, 1 H), 7.73 (d, *J*=2.40 Hz, 1 H), 7.79 (d, *J*=1.01 Hz, 1 H), 7.90 - 8.05 (m, 2 H), 8.31 (d, *J*=1.01 Hz, 1 H), 8.35 (s, 1 H), 8.61 - 8.66 (m, 1 H).

MS ES⁺: 452

Example 56: 2,3-Difluoro-6-(2H-1,2,3-triazol-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-methoxy-5-methyl-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 126 mg, 0.45 mmol) and 2,3-difluoro-6-(2H-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 39a**; 120 mg, 0.535 mmol) except this was purified by column chromatography (silica, 40-100% ethyl acetate / petrol) and then further purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to

afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.50 - 1.67 (m, 2 H), 1.78 - 1.96 (m, 2 H), 2.22 - 2.40 (m, 2 H), 4.03 - 4.15 (m, 1 H), 4.19 - 4.31 (m, 1 H), 6.09 - 6.37 (m, 1 H), 6.61 - 6.79 (m, 1 H), 7.30 - 7.42 (m, 1 H), 7.56 (s, 2 H), 7.66 - 7.73 (m, 1 H), 7.96 (s, 1 H), 8.13 (s, 1 H)

MS ES⁺: 454

Example 57: 5-Cyclopropyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




A solution of 5-chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 52**; 100mg, 0.22 mmol), cyclopropylboronic acid (CAS number 411235-57-9; 29 mg, 0.33 mmol), bis(triphenylphosphine)palladium(II) dichloride (3 mg, 4.43 μmol) and potassium carbonate (31 mg, 0.22 mmol) in 1,4-dioxane (1.3 ml) and water (0.13 ml) was sealed and degassed with nitrogen. The reaction was subjected to microwave irradiation at 130°C for 30 minutes. To this was then added bis(di-*tert*-butyl(4-dimethylaminophenyl)phosphine)-dichloropalladium(II) (157 mg, 0.22 mmol) and the reaction was subjected to microwave irradiation at 130°C for a further 1 hour. The reaction mixture was partitioned between ethyl acetate and water, washed with water and brine, filtered through a hydrophobic frit and concentrated *in vacuo*. The resulting residue was purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 0.68 - 0.81 (m, 2 H), 0.99 - 1.10 (m, 2 H), 1.38 - 1.59 (m, 2 H), 1.71 - 1.90 (m, 2 H), 1.93 - 2.02 (m, 1 H), 2.09 - 2.20 (m, 1 H), 2.28 - 2.39 (m, 1 H), 3.85 - 3.95 (m, 1 H), 4.15 - 4.26 (m, 1 H), 6.24 - 6.35 (m, 1 H), 6.40 - 6.58 (m, 1 H), 7.21 - 7.27 (m, 2 H), 7.57 - 7.64 (m, 3 H), 7.95 (s, 1 H), 8.22 (s, 1 H)

MS ES⁺: 458

Example 58: 3-(Trifluoromethoxy)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide




A solution of (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 70 mg, 0.25 mmol), 3-(trifluoromethoxy)pyridine-2-carboxylic acid (CAS number 1221171-81-8; 86 mg, 0.42 mmol), EDC (71 mg, 0.37 mmol), 3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (51 mg, 0.37 mmol) and triethylamine (0.104 ml, 0.74 mmol) in DCM (1 ml) was stirred at room temperature overnight. The mixture was partitioned between ethyl acetate (25 ml) and water (10 ml). The organics were washed with water (2 x 10 ml) and brine (10 ml), dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by reverse phase chromatography (C18 silica, 0-100% water (with 0.05% ammonia) / acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.46 - 1.82 (m, 4 H), 2.01 - 2.19 (m, 2 H), 4.15 - 4.42 (m, 2 H), 7.64 - 7.74 (m, 1 H), 7.88 - 8.13 (m, 3 H), 8.29 (s, 1 H), 8.55 - 8.67 (m, 1 H), 8.74 - 8.87 (m, 1 H)

MS ES⁺: 436

Example 59: 5-Chloro-2-(1H-pyrazol-1-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-methoxy-5-methyl-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 37**) from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 75 mg, 0.27 mmol) and 5-chloro-2-(1H-pyrazol-1-yl)benzoic acid (CAS

number 1214622-57-7; 120 mg, 0.54 mmol) except this was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.41 - 1.58 (m, 2 H), 1.62 - 1.74 (m, 2 H), 1.92 - 2.09 (m, 2 H), 4.07 - 4.25 (m, 2 H), 6.30 - 6.36 (m, 1 H), 7.36 - 7.42 (m, 1 H), 7.58 - 7.66 (m, 3 H), 7.90 - 7.94 (m, 1 H), 7.96 - 8.08 (m, 2 H), 8.35 (s, 1 H) and 8.52 - 8.60 (m, 1 H). MS ES⁺: 451


Example 60: 3-Ethoxy-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide



A solution of (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 150 mg, 0.53 mmol), 3-ethoxypyridine-2-carboxylic acid (CAS number 103878-09-7 ; 106 mg, 0.64 mmol), EDC (153 mg, 0.80 mmol), 3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (108 mg, 0.80 mmol) and triethylamine (0.222 ml, 1.59 mmol) in DCM (1 ml) was stirred at room temperature over the weekend. The mixture was partitioned between ethyl acetate (50 ml) and water (20 ml). The organics were washed with water (2 x 20 ml) and brine (20 ml), dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by column chromatography (basic silica, 30-100% ethyl acetate / petrol) and then by reverse phase chromatography (C18 silica, 0-100% water (with 0.05% ammonia) / acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.08 - 1.29 (m, 3 H), 1.41 - 1.63 (m, 2 H), 1.66 - 1.80 (m, 2 H), 2.01 - 2.16 (m, 2 H), 3.94 - 4.09 (m, 2 H), 4.16 - 4.34 (m, 2 H), 7.35 - 7.44 (m, 1 H), 7.46 - 7.55 (m, 1 H), 7.96 - 8.16 (m, 3 H), 8.26 - 8.46 (m, 2 H) MS ES⁺: 396

Example 61: 3,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide



Prepared according to the procedure for 3-(piperidin-1-yl)-*N*-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]pyridine-2-carboxamide (**Example 51**)


from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine

hydrochloride (**Intermediate 14**; 75 mg, 0.27 mmol) and 3,5-difluoro-2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 40a**; 60 mg, 0.27 mmol) except this was purified only by column chromatography (silica, 40-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.38 - 1.52 (m, 2 H), 1.61 - 1.73 (m, 2 H), 1.87 - 2.08 (m, 2 H), 3.94 - 4.04 (m, 1 H), 4.07 - 4.18 (m, 1 H), 7.23 - 7.31 (m, 1 H), 7.68 - 7.79 (m, 1H), 7.92 (d, *J*=7.70 Hz, 1 H), 7.97 - 8.01 (m, 3 H), 8.37 (s, 1 H) and 8.57 (d, *J*=7.71 Hz, 1 H)

MS ES⁺: 454

Example 62: 2-(Trifluoromethyl)-*N*-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]benzamide



To a solution of (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 60 mg, 0.21 mmol) in DMF (3 ml) was added 2-

(trifluoromethyl)benzoic acid (CAS number 433-97-6; 60 mg, 0.21 mmol), TBTU (0.082 g, 0.25 mmol) and DIPEA (0.1 g, 0.84 mmol) and the reaction was stirred at room

temperature for 2 hours. The reaction was diluted with water (25 ml) and extracted with ethyl acetate (30 ml x 3). The organics were washed with water (50 ml), brine (25 ml),

dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by


column chromatography (silica, 0-45% ethyl acetate / n-hexane) to afford the title compound.

^1H NMR (400 MHz, DMSO-*d*) δ ppm 1.23-1.62 (m, 2H), 1.69-1.76 (m, 2H), 2.01-2.33 (m, 2H), 4.21-4.24 (m, 2H), 7.39-7.41 (m, 1H), 7.62-7.75 (m, 3H), 8.03-8.07 (m, 2H), 8.35-8.39 (m, 1H), 8.61-8.63 (m, 1H)

MS ES⁺: 419

5

Example 63: 3-Cyclopropyl-*N*-[(1*S*,2*S*)-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]pyridine-2-carboxamide




Prepared according to the procedure for 2-(trifluoromethyl)-*N*-[(1*S*,2*S*)-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]benzamide (**Example 62**) from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 75 mg, 0.30 mmol) and 3-cyclopropylpyridine-2-carboxylic acid (**Intermediate 16**, 50 mg, 0.31 mmol) to afford the title compound.

^1H NMR (400 MHz, DMSO-*d*) δ ppm 0.62-0.67 (m, 2H), 0.80-0.89 (m, 2H), 1.53-1.77 (m, 4H), 2.06-2.10 (m, 2H), 2.51-2.52 (m, 1H), 4.23-4.36 (m, 2H), 7.33-7.38 (m, 2H), 8.02-8.09 (m, 2H), 8.32-8.34 (m, 2H), 8.68-8.70 (m, 1H)

MS ES⁺: 392

Example 64: 3,6-Difluoro-2-(2*H*-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]benzamide



Prepared according to the procedure for 2-(trifluoromethyl)-*N*-[(1*S*,2*S*)-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]benzamide (**Example 62**) from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**, 60 mg, 0.21 mmol) and 3,6-difluoro-2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 17**; 50 mg, 0.21 mmol) except this was purified by reverse phase


25

preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.43-1.44 (m, 2H), 1.61-1.68 (m, 2H), 1.87-2.00 (m, 2H), 4.00-4.07 (m, 2H), 7.56-7.69 (m, 2H), 7.92-7.94 (m, 1H), 8.00-8.02 (m, 3H), 8.37 (s, 1H), 8.76-8.78 (m, 1H)

MS ES⁺: 454

Example 65: 2-(Difluoromethyl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




To a solution of (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 100 mg, 0.35 mmol), 2-(difluoromethyl)benzoic acid (CAS number 799814-32-7; 61 mg, 0.35 mmol) and triethylamine (0.148 ml, 1.06 mmol) in DCM (2 ml) was added 1,3,5,2,4,6-trioxatriphosphorinane, 2,4,6-tripropyl-, 2,4,6-trioxide (CAS number 68957-94-8; 50% in ethyl acetate, 0.417 ml, 0.71 mmol). The reaction mixture was stirred at room temperature for 3 hours. To this was then added further 1,3,5,2,4,6-trioxatriphosphorinane, 2,4,6-tripropyl-, 2,4,6-trioxide (CAS number 68957-94-8; 50% in ethyl acetate, 0.417 ml, 0.71 mmol) and stirred at room temperature overnight. The reaction was partitioned between DCM and a saturated solution of sodium bicarbonate, filtered through a hydrophobic frit and concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) and then triturated with diethyl ether to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.62 - 1.74 (m, 2 H), 1.84 - 2.01 (m, 2 H), 2.30 - 2.50 (m, 2 H), 4.12 - 4.28 (m, 1 H), 4.28 - 4.40 (m, 1 H), 6.06 (br. s., 1 H), 6.64 - 6.86 (m, 1 H), 7.09 - 7.39 (m, 1 H), 7.46 - 7.51 (m, 1 H), 7.52 - 7.58 (m, 1 H), 7.58 - 7.65 (m, 1 H), 7.71 - 7.80 (m, 1 H), 8.03 (s, 1 H), 8.25 (s, 1 H)

MS ES⁺: 401

Example 66: 2-Cyclopropyl-6-fluoro-*N*-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]benzamide




Prepared according to the procedure for 2-(difluoromethyl)-*N*-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]benzamide (**Example 65**) from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 100 mg, 0.35 mmol) and 2-cyclopropyl-6-fluorobenzoic acid (CAS number 1603213-26-8; 64 mg, 0.35 mmol) except to this was added EDC (68 mg, 0.354 mmol), 3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (48 mg, 0.35 mmol) and triethylamine (0.1 ml, 0.71 mmol) and the reaction was stirred at room temperature for a further 1 hour. The reaction mixture was partitioned between DCM and water, filtered through a hydrophobic frit and concentrated *in vacuo*. The resulting residue was purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% formic acid) and then triturated with heptane / diethyl ether to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 0.55 - 0.69 (m, 2 H), 0.70 - 0.80 (m, 1 H), 0.81 - 0.91 (m, 1 H), 1.58 - 1.69 (m, 2 H), 1.83 - 1.94 (m, 3 H), 2.24 - 2.43 (m, 2 H), 4.06 - 4.23 (m, 1 H), 4.33 - 4.50 (m, 1 H), 6.10 (br. s., 1 H), 6.38-6.40 (m, 1 H), 6.64-6.69 (m, 1 H), 6.82 - 6.91 (m, 1 H), 7.23-7.27 (m, 1 H), 7.97 (s, 1 H), 8.20 (s, 1 H)

MS ES⁺: 409

Example 67: 5-Methyl-2-(2H-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-[[6-(trifluoromethyl)pyridin-3-yl]amino]cyclopentyl]benzamide




N-[(1*S*,2*S*)-2-aminocyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 7**; 70 mg, 0.21 mmol), 5-bromo-2-(trifluoromethyl)pyridine

(CAS number 436799-32-5; 73 mg, 0.32 mmol) and cesium carbonate (280 mg, 0.87 mmol) were suspended in toluene (3 ml). The reaction was degassed using nitrogen for 15 minutes. To this was then added BINAP (13 mg, 0.021 mmol) and tris(dibenzylideneacetone)dipalladium (0) (19 mg, 0.021 mmol) and the resulting reaction was heated to 100°C overnight. The reaction mass was poured into water (20 ml) and the organics were extracted with ethyl acetate (3 x 20 ml). The combined organics were dried over sodium sulfate and concentrated *in vacuo*. This was then purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.48-1.54 (m, 2H), 1.69-1.75 (m, 2H), 1.88-2.03 (m, 2H), 2.38 (s, 3H), 3.73-3.77 (m, 1H), 3.98-4.04 (m, 1H), 6.64-6.66 (m, 1H), 7.21-7.24 (m, 2H), 7.40-7.43 (m, 1H), 7.49-7.51 (m, 1H), 7.66-7.68 (m, 1H), 8.00 (s, 2H), 8.16 (s, 1H), 8.41-8.43 (m, 1H)

MS ES⁺: 431

Example 68: *N*-Cyclobutyl-2,6-dimethoxy-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide



To a solution of *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-*N*-cyclobutyl-2,6-dimethoxybenzamide hydrochloride (**Intermediate 18**; 200 mg, 0.56 mmol) in dry DMSO (1.9 ml) was added 2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 153 mg, 0.85 mmol) and DIPEA (295 µl, 1.69 mmol). The reaction subjected to microwave irradiation at 150°C for 2 hours and then was partitioned between ethyl acetate and water. The organics were washed with water and brine, dried over magnesium sulfate and concentrated *in vacuo*.


This was then purified using column chromatography (silica, 0-100% ethyl acetate / petrol) and then further purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.19 - 1.36 (m, 1 H), 1.39 - 1.95 (m, 7 H), 1.96 - 2.20 (m, 3 H), 2.88 - 3.10 (m, 1 H), 3.42 - 3.54 (m, 3 H), 3.59 - 3.74 (m, 3 H), 3.76 - 3.99

(m, 2 H), 4.35 - 5.12 (m, 1 H), 6.41 - 6.79 (m, 3 H), 7.21 - 7.29 (m, 1 H), 7.30 - 7.38 (m, 1 H), 7.54 - 7.65 (m, 1 H) and 8.12 - 8.29 (m, 1 H)

MS ES⁺: 464

Example 69: 2-Chloro-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide




A solution of *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-chlorobenzamide hydrochloride (**Intermediate 19**; 100 mg, 0.36 mmol), 2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 79 mg, 0.44 mmol) and DIPEA (190 μ l, 1.09 mmol) in dry DMSO (1.2 ml) was sealed and heated at 150 °C for 17 hours. The reaction mixture was filtered through cotton wool and purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.43 - 1.64 (m, 2 H), 1.65 - 1.78 (m, 2 H), 1.99 - 2.13 (m, 2 H), 4.12 - 4.32 (m, 2 H), 6.60 - 6.69 (m, 1 H), 7.25 - 7.48 (m, 5 H), 7.58 - 7.65 (m, 1 H), 8.25 (s, 1 H) and 8.44 - 8.54 (m, 1 H).

MS ES⁺: 384

Example 70: 2-Chloro-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide



Prepared according to the procedure for 2-chloro-*N*-[(1*S*,2*S*)-2-{[5-


(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 69**) from *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-chlorobenzamide hydrochloride (**Intermediate 19**; 100

mg, 0.363 mmol) and 2-chloro-5-(trifluoromethyl)pyrimidine (CAS number 69034-12-4; 80 mg, 0.436 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.51 - 1.64 (m, 2 H), 1.65 - 1.76 (m, 2 H), 1.96 - 2.10 (m, 2 H), 4.24 - 4.40 (m, 2 H), 7.27 - 7.46 (m, 4 H), 8.09 - 8.16 (m, 1 H), 8.44 - 8.50 (m, 1 H) and 8.58 (s, 2 H)

MS ES⁺: 385

Example 71: 2-Fluoro-6-methoxy-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-chloro-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 69**) from *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-fluoro-6-methoxybenzamide hydrochloride (**Intermediate 20**; 50 mg, 0.17 mmol) and 2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 38 mg, 0.21 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.42 - 1.59 (m, 2 H), 1.65 - 1.75 (m, 2 H), 1.99 - 2.11 (m, 2 H), 3.68 (s, 3 H), 4.10 - 4.21 (m, 2 H), 6.63 - 6.69 (m, 1 H), 6.74 - 6.82 (m, 1 H), 6.83 - 6.89 (m, 1 H), 7.30 - 7.39 (m, 2 H), 7.58 - 7.65 (m, 1 H), 8.24 (s, 1 H) and 8.40 - 8.47 (m, 1 H)

MS ES⁺: 398

Example 72: 2,6-Difluoro-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-chloro-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 69**) from *N*-

[(1*S*,2*S*)-2-aminocyclopentyl]-2,6-difluorobenzamide hydrochloride (**Intermediate 21**; 100 mg, 0.36 mmol) and 2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 79 mg, 0.43 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.42 - 1.58 (m, 2 H), 1.65 - 1.76 (m, 2 H), 2.01 - 2.13 (m, 2 H), 4.12 - 4.25 (m, 2 H), 6.61 - 6.67 (m, 1 H), 7.07 - 7.15 (m, 2 H), 7.38 - 7.43 (m, 1 H), 7.44 - 7.52 (m, 1 H), 7.59 - 7.64 (m, 1 H), 8.25 (s, 1 H) and 8.77 - 8.84 (m, 1 H)
MS ES⁺: 386


Example 73: *N*-[(1*S*,2*S*)-2-{Methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide



A solution of (1*S*,2*S*)-1-*N*-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 22**; 59 mg, 0.23 mmol), 2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 51.5 mg, 0.27 mmol), EDC (65.2 mg, 0.34 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (52.4 mg, 0.34 mmol) and triethylamine (0.095 ml, 0.68 mmol) in DCM (2 ml) was stirred at room temperature for 18 hours. The reaction mixture was diluted with DCM (3 ml) and washed with HCl (aq, 1M, 2 ml) then a saturated solution of sodium bicarbonate (2 ml). The organics were filtered through a hydrophobic frit and concentrated *in vacuo*. The resulting residue was purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.47 - 1.61 (m, 1 H), 1.66 - 1.78 (m, 3 H), 1.83 - 2.03 (m, 2 H), 3.03 (s, 3 H), 4.32 - 4.48 (m, 1 H), 4.69 - 4.86 (m, 1 H), 7.15 - 7.24 (m, 1 H), 7.39 - 7.48 (m, 1 H), 7.53 - 7.61 (m, 1 H), 7.65 - 7.76 (m, 1 H), 7.90 (s, 2 H), 8.29 - 8.39 (m, 2 H), 8.41 - 8.49 (m, 1 H)
MS ES⁺: 432

Example 74: 5-Fluoro-*N*-[(1*S*,2*S*)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Example 73**) from (1*S*,2*S*)-1-*N*-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate**
 5 **22**; 59 mg, 0.23 mmol) and 5-fluoro-2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (**Intermediate**
8; 56 mg, 0.27 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.48 - 1.61 (m, 1 H), 1.64 - 1.78 (m, 3 H), 1.81 - 2.03 (m, 2 H), 3.31 (s, 3 H), 4.29 - 4.45 (m, 1 H), 4.70 - 4.88 (m, 1 H), 6.95 - 7.03 (m, 1 H), 7.37 - 7.48 (m, 1 H), 7.70 - 7.80 (m, 1 H), 7.90 (s, 2 H), 8.28 - 8.34 (m, 1 H), 8.41 -
 10 8.50 (m, 2 H)

MS ES⁺: 450

Example 75: 2-Fluoro-*N*-[(1*S*,2*S*)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-6-(2*H*-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Example 73**) from (1*S*,2*S*)-1-*N*-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate**
 15 **22**; 59 mg, 0.23 mmol) and 2-fluoro-6-(2*H*-1,2,3-triazol-2-yl)benzoic acid (CAS number
 20 1186050-58-7; 56 mg, 0.27 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.43 - 1.57 (m, 1 H), 1.63 - 1.81 (m, 3 H), 1.85 - 1.94 (m, 1 H), 1.96 - 2.07 (m, 1 H), 3.07 (s, 3 H), 4.39 - 4.52 (m, 1 H), 4.66 - 4.83 (m, 1 H), 7.25 - 7.36 (m, 1 H), 7.53 - 7.64 (m, 1 H), 7.66 - 7.72 (m, 1 H), 7.95 (s, 2 H), 8.33 (s, 1 H), 8.43 (s, 1 H), 8.56 - 8.59 (m, 1 H)

25 MS ES⁺: 450

Example 76: *N*-[(1*S*,2*S*)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide




A solution of (1*S*,2*S*)-1-*N*-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 23**; 60 mg, 0.20 mmol), 3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number 1252907-86-0; 40 mg, 0.21 mmol), EDC (58 mg, 0.30 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (41 mg, 0.30 mmol) and triethylamine (0.085 ml, 0.61 mmol) in DCM (1 ml) was stirred at room temperature over the weekend. The reaction was concentrated *in vacuo* and was then purified by column chromatography (basic silica, 20 to 100% ethyl acetate / petrol) followed by column chromatography (silica, 0 to 100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.39 - 1.84 (m, 4 H), 1.95 - 2.24 (m, 2 H), 2.31 (s, 3 H), 4.17 - 4.44 (m, 2 H), 7.14 - 7.23 (m, 1 H), 7.66 - 7.75 (m, 1 H), 7.88 (s, 2 H), 8.17 - 8.33 (m, 2 H), 8.62 - 8.70 (m, 1 H), 8.71 - 8.81 (m, 1 H)

MS ES⁺: 433

Example 77: *N*-[(1*S*,2*S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide




A solution of (1*S*,2*S*)-1-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 25**; 80 mg, 0.31 mmol), 3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number 1252907-86-0; 70 mg, 0.37 mmol), EDC (177 mg, 0.92 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (126 mg, 0.922 mmol) and DIPEA (161 μ l, 0.92 mmol) in dry DCM (1 ml) was stirred at room temperature overnight. The mixture was partitioned between ethyl acetate (20 ml) and water (10 ml). The organics were washed with water (2 x 10 ml), brine (10 ml), dried over sodium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography (silica, 0 to 100% ethyl

acetate / petrol) followed by a trituration in pentane / diethyl ether to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.43 (s, 3 H), 1.66 - 1.99 (m, 4 H), 2.14 - 2.30 (m, 1 H), 2.49 - 2.68 (m, 1 H), 4.40 - 4.55 (m, 1 H), 7.38 - 7.48 (m, 1 H), 7.56 (br. s., 1 H), 7.62 - 7.67 (m, 1 H), 7.69 (br. s., 1 H), 7.84 (s, 2 H), 8.08 - 8.14 (m, 1 H), 8.23 (br. s., 1 H), 8.65 - 8.70 (m, 1 H)

MS ES⁺: 433

Example 78: *N*-[(1*S*,2*S*)-2-{{3-Methyl-5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-{{3-methyl-5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 76**) from (1*S*,2*S*)-1-*N*-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 23**; 60 mg, 0.20 mmol) and 2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 40 mg, 0.21 mmol) except this was purified only by column chromatography (silica, 0 to 100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 1.36 - 1.61 (m, 2 H), 1.79 - 1.93 (m, 2 H), 2.04 - 2.20 (m, 1 H), 2.38 (s, 3 H), 2.49 - 2.60 (m, 1 H), 3.76 - 3.88 (m, 1 H), 4.36 - 4.48 (m, 1 H), 6.04 - 6.17 (m, 1 H), 6.66 - 6.70 (m, 1 H), 7.43 - 7.52 (m, 3 H), 7.53 - 7.64 (m, 2 H), 7.77 - 7.82 (m, 1 H), 8.20 (s, 1 H)

MS ES⁺: 432

Example 79: *N*-[(1*S*,2*S*)-2-{{3-Methyl-5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 76**) from (1*S*,2*S*)-1-*N*-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 23**; 60 mg, 0.20 mmol) and 2-(pyrimidin-2-yl)benzoic acid (CAS number 400892-62-8; 41 mg, 0.20 mmol) except this was purified only by column chromatography (silica, 0 to 100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.34 - 1.77 (m, 4 H), 1.93 - 2.06 (m, 1 H), 2.09 - 2.27 (m, 4 H), 4.08 - 4.22 (m, 1 H), 4.25 - 4.39 (m, 1 H), 7.18 - 7.26 (m, 1 H), 7.29 - 7.42 (m, 2 H), 7.44 - 7.59 (m, 2 H), 7.89 - 7.99 (m, 1 H), 8.28 (s, 1 H), 8.39 - 8.48 (m, 1 H), 8.57 - 8.63 (m, 2 H)

MS ES⁺: 443

Example 80: 5-Fluoro-*N*-[(1*S*,2*S*)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 76**) from (1*S*,2*S*)-1-*N*-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 23**; 60 mg, 0.20 mmol) and 5-fluoro-2-(pyrimidin-2-yl)benzoic acid (CAS number 1293284-57-7; 41 mg, 0.20 mmol) except this was purified only by column chromatography (silica, 0 to 100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.39 - 1.82 (m, 4 H), 1.94 - 2.07 (m, 1 H), 2.09 - 2.21 (m, 1 H), 2.27 (s, 3 H), 4.10 - 4.39 (m, 2 H), 7.10 - 7.20 (m, 1 H), 7.21 - 7.32 (m, 2

H), 7.34 - 7.43 (m, 1 H), 7.96 - 8.05 (m, 1 H), 8.27 (s, 1 H), 8.45 - 8.52 (m, 1 H), 8.60 - 8.67 (m, 2 H)

MS ES⁺: 461

5 **Example 81:** *N*-[(1*S*,2*S*)-2-Methyl-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-methyl-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 77**) from (1*S*,2*S*)-1-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 25**; 510 mg, 1.96 mmol) and 2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 445 mg, 2.35 mmol) except this was then partitioned between water (20 ml) and DCM (10 ml). The organics were washed with water (2 x 20 ml) and brine (20 ml), filtered through a hydrophobic frit and concentrated *in vacuo*. The residue was purified by column chromatography (silica, 0 - 100% ethyl acetate / petrol) followed by a trituration with diethyl ether and recrystallised from IPA / water to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.38 (s, 3 H), 1.42 - 1.53 (m, 1 H), 1.71 - 2.00 (m, 3 H), 2.02 - 2.13 (m, 1 H), 2.57 - 2.66 (m, 1 H), 4.44 - 4.52 (m, 1 H), 6.17 - 6.24 (m, 1 H), 7.54 - 7.59 (m, 1 H), 7.64 - 7.72 (m, 3 H), 7.74 - 7.77 (m, 1 H), 7.80 (s, 2 H), 7.83 - 7.88 (m, 1 H) and 8.28 (s, 1 H)

MS ES⁺: 432

25 **Example 82:** *N*-(2-Methyl-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl)-2-(2*H*-1,2,3-triazol-2-yl)benzamide




To a solution of *N*-(2-amino-2-methylcyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 26**; 287 mg, 1.01 mmol) in dry DMSO (3.4 ml) was added 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 202 mg, 1.11 mmol) and DIPEA (527 μ l, 3.02 mmol). The reaction was stirred at 140 °C for 1 hour and was then
5 partitioned between ethyl acetate and water. The organics were washed with water, brine, filtered through a hydrophobic frit and concentrated *in vacuo*. This was purified by column chromatography (silica, 0-100% ethyl acetate / petrol then 0-20% methanol / ethyl acetate) and was then recrystallised from ethyl acetate to afford the title compound.

^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.37 (s, 3 H), 1.55 - 1.74 (m, 3 H), 1.91 - 2.02 (m, 2
10 H), 2.13 - 2.23 (m, 1 H), 4.57 - 4.65 (m, 1 H), 7.52 - 7.59 (m, 2 H), 7.61 - 7.67 (m, 1 H), 7.73 (s, 1 H), 7.78 - 7.82 (m, 1 H), 7.88 (s, 1 H), 7.98 (s, 2 H), 8.36 (s, 1 H) and 8.53 - 8.59 (m, 1 H)

MS ES^+ : 432


15 **Example 83:** *N*-[(1*R*,2*R*)-2-Methyl-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide



Prepared according to the procedure for *N*-(2-methyl-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide (**Example 82**) from *N*-(2-amino-2-methylcyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 26**; 287 mg, 1.01 mmol) and 2-chloro-5-(trifluoromethyl)pyrazine (CAS
20 number 799557-87-2; 202 mg, 1.11 mmol) except this was then chirally separated using SFC (Waters prep30/MS system using 20% Ethanol, column AY) to afford the title
25 compound.

^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.56 - 1.75 (m, 4 H), 1.92 - 2.03 (m, 4 H), 2.14 - 2.24 (m, 1 H), 4.56 - 4.66 (m, 1 H), 7.52 - 7.59 (m, 2 H), 7.61 - 7.68 (m, 1 H), 7.75 (s, 1
H), 7.79 - 7.83 (m, 1 H), 7.88 (s, 1 H), 7.99 (s, 2 H), 8.37 (s, 1 H), 8.55 - 8.62 (m, 1 H)
MS ES^+ : 432

Example 84: 5-Fluoro-*N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




5 Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 77**) from (1*S*,2*S*)-1-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 25**; 80 mg, 0.31 mmol) and 5-fluoro-2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 8**; 76 mg, 0.37 mmol) except this was
 10 purified by column chromatography (0 to 50% ethyl acetate / petrol) followed by a trituration in pentane / diethyl ether to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.36 (s, 3 H), 1.53 - 1.75 (m, 3 H), 1.87 - 2.02 (m, 2 H), 2.17 - 2.30 (m, 1 H), 4.60 - 4.63 (m, 1 H), 7.38 - 7.46 (m, 1 H), 7.46 - 7.56 (m, 1 H), 7.65 (s, 1 H), 7.80 - 7.87 (m, 1 H), 7.90 (s, 1 H), 7.99 (s, 2 H), 8.36 (s, 1 H), 8.54 - 8.63 (m,
 15 1 H)

MS ES⁺: 450

Example 85: *N*-[(1*S*,2*S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(1*H*-pyrazol-1-yl)pyridine-2-carboxamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 77**) from (1*S*,2*S*)-1-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 25**; 80 mg, 0.31 mmol) and 3-(1*H*-pyrazol-1-yl)pyridine-2-carboxylic acid (CAS number 1521232-19-8; 70 mg, 0.37 mmol) except this
 25

was purified by column chromatography (silica, 50 - 100% ethyl acetate / petrol then 0 - 10% methanol / ethyl acetate) followed by reverse phase chromatography (C18 silica, 0-100% water (with 0.05% ammonia) / acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.33 (s, 3 H), 1.54 - 1.78 (m, 3 H), 1.83 - 2.04 (m, 2 H), 2.18 - 2.31 (m, 1 H), 4.64 - 4.78 (m, 1 H), 6.43 - 6.51 (m, 1 H), 7.61 - 7.71 (m, 3 H), 7.91 (s, 1 H), 8.06 - 8.13 (m, 2 H), 8.37 (s, 1 H), 8.58 - 8.63 (m, 1 H), 8.64 - 8.70 (m, 1 H)
MS ES⁺: 432

Example 86: 3-Ethoxy-*N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 77**) from (1*S*,2*S*)-1-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 25**; 80 mg, 0.31 mmol) and 3-ethoxypyridine-2-carboxylic acid (CAS number 103878-09-7; 51 mg, 0.31 mmol) except this was purified by column chromatography (silica, 0 - 100% ethyl acetate / petrol) followed by reverse phase chromatography (C18 silica, 0-100% water (with 0.05% ammonia) / acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.24 - 1.34 (m, 3 H), 1.40 (s, 3 H), 1.54 - 1.78 (m, 3 H), 1.85 - 1.96 (m, 1 H), 2.00 - 2.11 (m, 1 H), 2.22 - 2.36 (m, 1 H), 4.05 - 4.14 (m, 2 H), 4.69 - 4.77 (m, 1 H), 7.41 - 7.47 (m, 1 H), 7.52 - 7.58 (m, 1 H), 7.82 (s, 1 H), 8.01 (s, 1 H), 8.12 - 8.17 (m, 1 H), 8.30 - 8.46 (m, 2 H)

MS ES⁺: 410

Example 87: 2-Chloro-*N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-6-(2*H*-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-methyl-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 77**) from (1*S*,2*S*)-1-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 25**; 63 mg, 0.24 mmol) and 2-chloro-6-(2*H*-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 15**; 65 mg, 0.29 mmol) except this was purified by column chromatography (silica, 0 - 30% ethyl acetate / petrol) followed by trituration with diethyl ether / pentane to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.43 (s, 3 H), 1.44 - 1.57 (m, 1 H), 1.68 - 2.18 (m, 4 H), 2.52 - 2.67 (m, 1 H), 4.45 - 4.58 (m, 1 H), 6.06 - 6.16 (m, 1 H), 7.47 - 7.56 (m, 2 H), 7.75 (s, 2 H), 7.83 (br. s., 1 H), 7.89 - 8.01 (m, 1 H), 8.25 (s, 1 H)


MS ES⁺: 466

Example 88: 2,6-Difluoro-*N*-[(1*S*,2*S*)-2-methyl-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-methyl-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 77**) from (1*S*,2*S*)-1-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 25**; 63 mg, 0.24 mmol) and 2,6-difluorobenzoic acid (CAS number 385-00-2; 46 mg, 0.29 mmol) except this was purified by column chromatography (silica, 0 - 20% ethyl acetate / petrol) followed by reverse phase chromatography (C18 silica, 0-100% water (with 0.05% ammonia) / acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.39 (s, 3 H), 1.50 - 1.87 (m, 4 H), 1.98 - 2.15 (m, 1 H), 2.30 - 2.44 (m, 1 H), 4.80 - 4.90 (m, 1 H), 7.12 - 7.22 (m, 2 H), 7.52 (s, 1 H), 7.70 (s, 1 H), 8.00- 8.06 (m, 1 H), 8.38 (s, 1 H), 8.69 - 8.76 (m, 1 H)

MS ES⁺: 401**Example 89: 3-Cyclopropyl-*N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide**

Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 77**) from (1*S*,2*S*)-1-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 25**; 48 mg, 0.15 mmol), 3-cyclopropylpyridine-2-carboxylic acid (**Intermediate 16**; 33 mg, 0.20 mmol) and triethylamine (0.077 ml, 0.55 mmol) except this was purified by column chromatography (silica, 0 - 50% ethyl acetate / petrol) followed by column chromatography (silica, 0 - 2.5% methanol / DCM) to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 0.58 - 0.80 (m, 2 H), 1.05 - 1.17 (m, 2 H), 1.39 (s, 3 H), 1.61 - 2.08 (m, 4 H), 2.12 - 2.24 (m, 1 H), 2.63 (s, 1 H), 3.28 - 3.43 (m, 1 H), 4.46 - 4.59 (m, 1 H), 7.31 - 7.37 (m, 2 H), 7.78 - 7.89 (m, 2 H), 8.23 - 8.33 (m, 2 H), 8.33 - 8.38 (m, 1 H)


MS ES⁺: 406**Example 90: *N*-[(1*S*,2*S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(trifluoromethoxy)pyridine-2-carboxamide**

Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 77**) from (1*S*,2*S*)-1-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 25**; 48 mg, 0.15 mmol), 3-(trifluoromethoxy)pyridine-2-carboxylic acid (CAS number 1221171-81-8; 42 mg, 0.20

mmol) and triethylamine (0.077 ml, 0.55 mmol) except this was purified by column chromatography (silica, 0 - 50% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 1.38 (s, 3 H), 1.60 - 2.04 (m, 4 H), 2.14 - 2.27 (m, 1 H), 2.56 - 2.70 (m, 1 H), 4.46 - 4.62 (m, 1 H), 7.48 - 7.62 (m, 2 H), 7.74 - 7.80 (m, 1 H), 7.83 - 7.89 (m, 1 H), 7.92 - 8.01 (m, 1 H), 8.25 (s, 1 H), 8.54 - 8.60 (m, 1 H)
MS ES⁺: 450


Example 91: *N*-[(1*S*,2*S*)-2-Methyl-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide



Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-methyl-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 77**) from (1*S*,2*S*)-1-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 25**; 48 mg, 0.15 mmol), 2-(pyrimidin-2-yl)benzoic acid (CAS number 400892-62-8; 41 mg, 0.20 mmol) and triethylamine (0.077 ml, 0.55 mmol) except this was purified by column chromatography (silica, 0 - 100% ethyl acetate / petrol) followed by reverse phase chromatography (C18 silica, 0-100% water (with 0.05% ammonia) / acetonitrile) to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 1.45 (s, 3 H), 1.48 - 1.57 (m, 1 H), 1.72 - 1.99 (m, 3 H), 2.04 - 2.12 (m, 1 H), 2.63 - 2.70 (m, 1 H), 4.46 - 4.58 (m, 1 H), 6.16 - 6.26 (m, 1 H), 7.14 - 7.22 (m, 1 H), 7.49 - 7.70 (m, 4 H), 7.87 (s, 1 H), 8.09 - 8.17 (m, 1 H), 8.27 (s, 1 H), 8.64 - 8.70 (m, 2 H)
MS ES⁺: 443

Example 92: 5-Chloro-*N*-[(1*S*,2*S*)-2-methyl-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-methyl-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 77**) from (1*S*,2*S*)-1-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 25**; 90 mg, 0.35 mmol) and 5-chloro-2-(2*H*-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 38a**, CAS number 1293284-54-4; 93 mg, 0.42 mmol) except this was purified by column chromatography (silica, 0 - 50% ethyl acetate / petrol) followed by recrystallisation from diethyl ether / pentane to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.37 (s, 3 H), 1.51 - 1.77 (m, 3 H), 1.86 - 2.04 (m, 2 H), 2.19 - 2.31 (m, 1 H), 4.63 - 4.66 (m, 1 H), 7.57 - 7.76 (m, 3 H), 7.81 - 7.88 (m, 1 H), 7.91 (s, 1 H), 8.03 (s, 2 H), 8.37 (s, 1 H), 8.58 - 8.68 (m, 1 H)

MS ES⁺: 466

Example 93: *N*-(2-Methyl-2-{{5-(trifluoromethyl)pyrimidin-2-yl}amino}cyclopentyl)-2-(2*H*-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-(2-methyl-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl)-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Example 82**) from *N*-(2-amino-2-methylcyclopentyl)-2-(2*H*-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 26**; 200 mg, 0.70 mmol) and 2-chloro-5-(trifluoromethyl)pyrimidine (CAS number 69034-12-4; 141 mg, 0.77 mmol) except this was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) followed by reverse phase chromatography (C18 silica, 0-100% water (with 0.05% ammonia) / acetonitrile) to afford the title compound.

^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.33 (s, 3 H), 1.58 - 1.74 (m, 3 H), 1.84 - 2.01 (m, 2 H), 2.25 - 2.34 (m, 1 H), 4.42 - 4.51 (m, 1 H), 7.52 - 7.59 (m, 2 H), 7.62 - 7.68 (m, 1 H), 7.81 - 7.85 (m, 1 H), 7.90 (s, 1 H), 7.95 (s, 2 H), 8.54 - 8.66 (m, 2 H) and 8.68 - 8.73 (m, 1 H)

5 MS ES⁺: 432

Example 94: *N*-(2-Methyl-2-{{5-(trifluoromethyl)pyrimidin-2-yl}amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide




10 Prepared according to the procedure for *N*-(2-methyl-2-{{5-(trifluoromethyl)pyrimidin-2-yl}amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide (**Example 93**) from *N*-(2-amino-2-methylcyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 26**; 200 mg, 0.70 mmol) and 2-chloro-5-(trifluoromethyl)pyrimidine (CAS number 69034-12-4; 141 mg, 0.77 mmol) except this was then chirally separated using SFC (acetonitrile with diethylamine modifier, column Lux A2) to afford the title compound as a single enantiomer.

^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.34 (s, 3 H), 1.58 - 1.77 (m, 3 H), 1.84 - 2.03 (m, 2 H), 2.25 - 2.36 (m, 1 H), 4.42 - 4.53 (m, 1 H), 7.50 - 7.61 (m, 2 H), 7.62 - 7.70 (m, 1 H), 7.81 - 7.85 (m, 1 H), 7.91 (s, 1 H), 7.96 (s, 2 H), 8.54 - 8.67 (m, 2 H), 8.68 - 8.73 (m, 1 H)

20 MS ES⁺: 432

Example 95: *N*-(2-Methyl-2-{{5-(trifluoromethyl)pyridin-2-yl}amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide




25 Prepared according to the procedure for *N*-(2-methyl-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide (**Example 82**) from *N*-(2-amino-2-methylcyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride

(**Intermediate 26**; 95 mg, 0.30 mmol) and 2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 100 mg, 0.55 mmol) except this was heated at 140 °C for 17 hours and then purified by column chromatography (basic silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.34 (s, 3 H), 1.37 - 1.51 (m, 1 H), 1.68 - 1.90 (m, 2 H), 1.90 - 2.00 (m, 1 H), 2.02 - 2.14 (m, 1 H), 2.39 - 2.52 (m, 1 H), 4.37 - 4.47 (m, 1 H), 6.19 (br. s., 1 H), 6.34 - 6.55 (m, 1 H), 6.92 - 7.23 (m, 1 H), 7.44 - 7.56 (m, 2 H), 7.57 - 7.69 (m, 2 H), 7.76 (s, 2 H), 7.78 - 7.84 (m, 1 H), 8.24 (s, 1 H)

MS ES⁺: 431

Example 96: *N*-(2-Methyl-2-[[5-(trifluoromethoxy)pyridin-2-yl]amino]cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide




A solution of *N*-(2-amino-2-methylcyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide

hydrochloride (**Intermediate 26**; 150 mg, 0.47 mmol), 2-bromo-5-(trifluoromethoxy)pyridine (CAS number 888327-36-4; 118 mg, 0.49 mmol), BINAP (29 mg, 0.047 mmol), tris(dibenzylideneacetone)dipalladium(0) (21.34 mg, 0.023 mmol) and sodium *tert*-butoxide (63 mg, 0.65 mmol) in dry toluene (1.6 ml) was sealed, evacuated and purged with nitrogen. The reaction was heated at 140 °C for 17 hours and was then partitioned between ethyl acetate and water, washing with water, brine, dried over sodium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography (silica, 0-70% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.31 (s, 3 H), 1.45 - 1.78 (m, 3 H), 1.80 - 2.14 (m, 3 H), 4.39 - 4.50 (m, 1 H), 6.39 - 6.47 (m, 1 H), 6.78 (s, 1 H), 7.35 - 7.44 (m, 1 H), 7.49 - 7.59 (m, 2 H), 7.59 - 7.70 (m, 1 H), 7.77 - 7.85 (m, 1 H), 7.92 - 8.02 (m, 3 H), 8.47 - 8.58 (m, 1 H)

MS ES⁺: 447

Example 97: 5-Chloro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyridin-2-yl]amino]cyclopentyl]benzamide




To a solution of (*1S,2S*)-1-*N*-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 1**; 50 mg, 0.20 mmol) in DMF (3 ml) was added 5-chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 38a**; CAS number 1293284-54-4; 45 mg, 0.204 mmol), TBTU (78 mg, 0.245 mmol) and DIPEA (40 mg, 0.306 mmol). The reaction was stirred at room temperature for 2 hours and was then diluted with water (25 ml) and extracted with ethyl acetate (3 x 30 ml). The organics were washed with water (25 ml), brine (20 ml), dried over sodium sulfate and concentrated *in vacuo*. The residue was then purified by column chromatography (silica, 0 - 45% ethyl acetate / n-hexane) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.50-1.60 (m, 4H), 1.66-2.08 (m, 2H), 4.03-4.10 (m, 1H), 4.18-4.22 (m, 1H), 6.65-6.67 (m, 1H), 7.33-7.35 (m, 1H), 7.43-7.44 (m, 1H) 7.62-7.70 (m, 2H) 7.80-7.82 (m, 1H), 7.99 (s, 2H), 8.29 (s, 1H), 8.53-8.55 (m, 1H)

MS ES⁺: 451

Example 98: 3-Fluoro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 5-chloro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 97**) from (*1S,2S*)-1-*N*-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 1**; 50 mg, 0.20 mmol) and 3-fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1293284-51-1; 42 mg, 0.20 mmol) to afford the title compound.

^1H NMR (400 MHz, DMSO-*d*) δ ppm 1.41-1.44 (m, 2H), 1.61-1.68 (m, 2H), 1.89-2.03 (m, 2H), 3.93-3.96 (m, 1H), 4.02-4.06 (m, 1H), 6.59-6.62 (m, 1H) 7.31-7.36 (m, 2H) 7.59-7.68 (m, 3H), 8.01 (s, 2H), 8.28 (s, 1H), 8.49-8.51 (m, 1H)

MS ES⁺: 435

5

Example 99: 3,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide



10

Prepared according to the procedure for 5-chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 97**) from (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 1**; 50 mg, 0.20 mmol) and 3,5-difluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (**Intermediate 40a**; 46 mg, 0.20 mmol) except this was purified by column chromatography (silica, 0-30% ethyl acetate / n-hexane) to afford the title compound.


15

^1H NMR (400 MHz, DMSO-*d*) δ ppm 1.41-1.48 (m, 2H), 1.61-1.69 (m, 2H), 1.88-1.93 (m, 2H), 3.91-3.96 (m, 1H), 4.04-4.08 (m, 1H), 7.58-7.61 (m, 1H), 7.24-7.31 (m, 2H) 7.62-7.64 (m, 1H) 7.72-7.77 (m, 1H), 8.02 (s, 2H), 8.28 (s, 1H), 8.56-8.58 (m, 1H)

20

MS ES⁺: 453

Example 100: 3-(2H-1,2,3-Triazol-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide



25


Prepared according to the procedure for 5-chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 97**) from

(*1S,2S*)-1-*N*-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 1**; 50 mg, 0.20 mmol) and 3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number 1252907-86-0; 39 mg, 0.20 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*) δ ppm 1.46-1.77 (m, 4H), 2.01-2.09 (m, 2H), 4.07-4.21 (m, 2H), 6.65-6.67 (m, 1H), 7.38-7.40 (m, 1H), 7.62-7.65 (m, 1H), 7.71-7.73 (m, 1H), 8.04 (s, 2H), 8.23-8.28 (m, 2H), 8.66-8.68 (m, 1H), 8.68-8.76 (m, 1H)

MS ES⁺: 418

Example 101: 3-(1*H*-Pyrazol-1-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide




Prepared according to the procedure for 5-chloro-2-(2*H*-1,2,3-triazol-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide (**Example 97**) from (*1S,2S*)-1-*N*-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 1**; 50 mg, 0.20 mmol) and 3-(1*H*-pyrazol-1-yl)pyridine-2-carboxylic acid (CAS number 1521232-19-8; 38 mg, 0.20 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*) δ ppm 1.41-1.71 (m, 4H), 1.99-2.05 (m, 2H), 4.11-4.23 (m, 2H), 6.35-6.36 (m, 1H), 6.64-6.66 (m, 1H), 7.42-7.44 (m, 1H), 7.63-7.68 (m, 3H), 7.96-7.96 (m, 1H), 8.08-8.10 (m, 1H), 8.27 (s, 1H), 8.57-8.58 (m, 1H), 8.80-8.82 (m, 1H)

MS ES⁺: 417

Example 102: 2-Fluoro-6-(2*H*-1,2,3-triazol-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide




To a solution of (*1S,2S*)-1-*N*-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 1**; 1.09 g, 3.87 mmol) in DCM (13 ml) was added 2-fluoro-6-(2*H*-1,2,3-triazol-2-yl)benzoic acid (CAS number 1186050-58-7; 0.802 g, 3.87 mmol),
 5 DIPEA (2.027 ml, 11.61 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (0.579 g, 4.26 mmol) and EDC (0.816 g, 4.26 mmol). The reaction was stirred at room temperature for 17 hours and was then partitioned between DCM and a saturated solution of sodium bicarbonate, filtered through a hydrophobic frit and concentrated *in vacuo*. The residue was purified by column chromatography (basic silica, 0-100% ethyl acetate / petrol) and re-
 10 crystallised from IPA to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.41 - 1.59 (m, 2 H), 1.59 - 1.76 (m, 2 H), 1.95 - 2.10 (m, 2 H), 4.06 - 4.20 (m, 2 H), 6.68 (d, *J*=8.8 Hz, 1 H), 7.29 - 7.41 (m, 2 H), 7.57 - 7.66 (m, 2 H), 7.71 - 7.75 (m, 1 H), 8.00 (s, 2 H), 8.25 - 8.28 (m, 1 H), 8.63 (d, *J*=6.8 Hz, 1 H)

15 MS ES⁺: 435

Example 103: *N*-(2-([3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino)-2-methylcyclopentyl)-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide




A solution of 1-*N*-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]-1-methylcyclopentane-1,2-diamine (**Intermediate 28**; 57 mg, 0.21 mmol), 3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number 1252907-86-0; 51 mg, 0.27 mmol), EDC (51 mg, 0.27
 25 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (36 mg, 0.27 mmol) and triethylamine (0.086 ml, 0.62 mmol) in DCM (3 ml) was stirred at room temperature for 18 hours. The reaction was then diluted with DCM (20 ml) and a saturated solution of sodium bicarbonate (10 ml), filtered through a hydrophobic frit and concentrated *in vacuo*. The residue was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title
 30 compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.47 (s, 3 H), 1.62 - 1.74 (m, 1 H), 1.78 - 1.89 (m, 2 H), 1.91 - 2.01 (m, 1 H), 2.15 - 2.26 (m, 1 H), 2.68 - 2.78 (m, 1 H), 4.45 - 4.55 (m, 1 H), 7.23 - 7.28 (m, 1 H), 7.38 (br. s., 1 H), 7.41 - 7.49 (m, 1 H), 7.61 - 7.66 (m, 1 H), 8.08 - 8.11 (m, 1 H), 8.13 (s, 1 H) and 8.65 - 8.70 (m, 1 H).

MS ES⁺: 450

Example 105: *N*-[(1*S*,2*S*)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




A solution of *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 4**; 100 mg, 0.33 mmol), 2,3-difluoro-5-(trifluoromethyl)pyridine (CAS number 89402-42-6; 65 mg, 0.36 mmol) and DIPEA (42 mg, 0.33 mmol) in dry DMSO (1.1 ml) was subjected to microwave irradiation at 140 °C for 1 hour. The reaction was filtered through cotton wool before being purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.41 - 1.77 (m, 4 H), 1.91 - 2.15 (m, 2 H), 4.17 - 4.40 (m, 2 H), 7.32 - 7.44 (m, 2 H), 7.44 - 7.54 (m, 1 H), 7.54 - 7.66 (m, 1 H), 7.68 - 7.81 (m, 2 H), 7.82 - 7.92 (m, 2 H), 8.14 - 8.22 (m, 1 H), 8.35 - 8.46 (m, 1 H)

MS ES⁺: 435

Example 106: *N*-[(1*S*,2*S*)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Example 105**) from *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 4**; 100 mg, 0.33 mmol) and 3-chloro-2-fluoro-5-

(trifluoromethyl)pyridine (CAS number 72537-17-8; 71 mg, 0.36 mmol) except this was then further purified using column chromatography (basic silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.46 - 1.63 (m, 2 H), 1.63 - 1.77 (m, 2 H), 1.91 - 2.05 (m, 1 H), 2.11 - 2.23 (m, 1 H), 4.15 - 4.25 (m, 1 H), 4.26 - 4.39 (m, 1 H), 7.17-7.20 (m, 1 H), 7.38 - 7.45 (m, 1 H), 7.46 - 7.52 (m, 1 H), 7.56 - 7.64 (m, 1 H), 7.77 (d, *J*=7.6 Hz, 1 H), 7.82 (s, 2 H), 7.95 - 7.99 (m, 1 H), 8.32 - 8.37 (m, 1 H), 8.48 (d, *J*=7.6 Hz, 1 H)

MS ES⁺: 451

Example 107: *N*-[(1*S*,2*S*)-2-{[3-Bromo-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Example 105**) from *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 4**; 100 mg, 0.33 mmol) and 3-bromo-2-chloro-5-(trifluoromethyl)pyridine (CAS number 71701-92-3; 93 mg, 0.36 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.40 - 1.62 (m, 2 H), 1.62 - 1.78 (m, 2 H), 1.91 - 2.03 (m, 1 H), 2.14 - 2.27 (m, 1 H), 4.08 - 4.19 (m, 1 H), 4.27 - 4.39 (m, 1 H), 7.01 - 7.03 (m, 1 H), 7.39 - 7.45 (m, 1 H), 7.46 - 7.52 (m, 1 H), 7.57 - 7.65 (m, 1 H), 7.75 - 7.79 (m, 1 H), 7.81 (s, 2 H), 8.08 - 8.12 (m, 1 H), 8.36 - 8.40 (m, 1 H), 8.47 - 8.50 (m, 1 H)

MS ES⁺: 495, 497

Example 108: *N*-[(1*S*,2*S*)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




A mixture of *N*-[(1*S*,2*S*)-2-{[3-bromo-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Example 107**; 67 mg, 0.14 mmol), methylboronic acid (CAS number 13061-96-6; 24 mg, 0.41 mmol), tetrakis(triphenylphosphine)palladium (16 mg, 0.014 mmol) and potassium carbonate (aq. 2 M, 271 μ l, 0.54 mmol) in 1,4-dioxane (450 μ l) was sealed, evacuated and purged with nitrogen and then subjected to microwave irradiation at 140 $^{\circ}$ C for 30 minutes. The reaction was partitioned between ethyl acetate and water, washing with water, brine, dried over magnesium sulfate and concentrated *in vacuo*. This was then purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.38 - 1.51 (m, 1 H), 1.52 - 1.62 (m, 1 H), 1.63 - 1.76 (m, 2 H), 1.91 - 2.03 (m, 1 H), 2.05 (s, 3 H), 2.14 - 2.27 (m, 1 H), 4.06 - 4.18 (m, 1 H), 4.21 - 4.33 (m, 1 H), 6.60 - 6.64 (m, 1 H), 7.37 - 7.45 (m, 1 H), 7.45 - 7.55 (m, 2 H), 7.57 - 7.65 (m, 1 H), 7.71 - 7.80 (m, 3 H), 8.19 - 8.22 (m, 1 H), 8.49 - 8.52 (m, 1 H)

MS ES $^+$: 431

Example 109: *N*-[(1*S*,2*S*)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




A mixture of *N*-[(1*S*,2*S*)-2-{[3-chloro-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Intermediate 29**; 170 mg, 0.38 mmol), cyclopropylboronic acid (CAS number 411235-57-9; 97 mg, 1.13 mmol), potassium carbonate (aq. 2 M, 752 μ l, 1.51 mmol) and tetrakis(triphenylphosphine)palladium (44 mg, 0.038 mmol) in 1,4-dioxane (1.3 ml) was sealed, purged and evacuated with nitrogen and then subjected to microwave irradiation 120 $^{\circ}$ C for 1 hour. The reaction was partitioned

between ethyl acetate and water, washed with water, brine, dried over magnesium sulfate and concentrated *in vacuo*. This was then purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% ammonia) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.81 - 0.89 (m, 1 H), 0.89 - 1.05 (m, 3 H), 1.45 - 1.64 (m, 2 H), 1.65 - 1.77 (m, 2 H), 1.96 - 2.07 (m, 1 H), 2.10 - 2.23 (m, 2 H), 4.15 - 4.25 (m, 1 H), 4.29 - 4.40 (m, 1 H), 7.41 - 7.46 (m, 1 H), 7.47 - 7.54 (m, 2 H), 7.57 - 7.64 (m, 1 H), 7.74 - 7.78 (m, 1 H), 7.81 (s, 2 H), 8.20 (s, 1 H), 8.50 - 8.53 (m, 1 H)

MS ES⁺: 458

Example 110: *N*-[(1*S*,2*S*)-2-[[3-(Propan-2-yl)-5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-[[3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Example 109**) from *N*-[(1*S*,2*S*)-2-[[3-chloro-5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Intermediate 29**; 170 mg, 0.38 mmol) and 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (CAS number 126726-62-3; 190 mg, 1.13 mmol) except this was then dissolved in methanol (1.4 ml) and to this was then added palladium on carbon (10% wt, 50% wet) (15 mg, 0.014 mmol) and the resulting mixture was stirred under a balloon of hydrogen gas for 2 hours. The reaction was filtered through diatomaceous earth (commercially sold under the trade mark "Celite") and concentrated *in vacuo* to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.11 - 1.15 (m, 3 H), 1.14 - 1.17 (m, 3 H), 1.42 - 1.63 (m, 2 H), 1.63 - 1.77 (m, 2 H), 1.93 - 2.05 (m, 1 H), 2.10 - 2.22 (m, 1 H), 3.11 - 3.22 (m, 1 H), 4.14 - 4.26 (m, 1 H), 4.30 - 4.41 (m, 1 H), 7.27 - 7.29 (m, 1 H), 7.36 - 7.43 (m, 1 H), 7.44 - 7.52 (m, 1 H), 7.56 - 7.65 (m, 1 H), 7.73 - 7.82 (m, 3 H), 8.27 (s, 1 H), 8.48 - 8.51 (m, 1 H)

MS ES⁺: 460

Example 111: *N*-[(1*S*,2*S*)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-{[3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Example 109**) from *N*-[(1*S*,2*S*)-2-{[3-chloro-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Intermediate 29**; 170 mg, 0.38 mmol) and 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (CAS number 75927-49-0; 174 mg, 1.13 mmol) except this was then dissolved in methanol (1.4 ml) and to this was then added palladium on carbon (10% wt, 50% wet) (15 mg, 0.014 mmol) and the resulting mixture was stirred under a balloon of hydrogen gas for 2 hours. The reaction was filtered through diatomaceous earth (commercially sold under the trade mark "Celite") and concentrated *in vacuo* to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.15 – 1.19 (m, 3 H), 1.42 – 1.65 (m, 2 H), 1.64 – 1.77 (m, 2 H), 1.93 – 2.05 (m, 1 H), 2.10 – 2.22 (m, 1 H), 2.55 – 2.70 (m, 2 H), 4.12 – 4.23 (m, 1 H), 4.28 – 4.40 (m, 1 H), 7.21 – 7.25 (m, 1 H), 7.40 – 7.45 (m, 1 H), 7.46 – 7.53 (m, 1 H), 7.57 – 7.65 (m, 1 H), 7.72 – 7.80 (m, 3 H), 8.28 (s, 1 H), 8.51 – 8.55 (m, 1 H)

MS ES⁺: 446

Example 112: *N*-[(1*S*,2*S*)-2-{[5-Cyclopropylpyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




A mixture of *N*-[(1*S*,2*S*)-2-{[5-bromopyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide and *N*-[(1*S*,2*S*)-2-{[5-chloropyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Intermediate 30a and 30b**; 100 mg, 0.23 mmol),

cyclopropylboronic acid (CAS number 411235-57-9; 60 mg, 0.70 mmol), sodium carbonate (aq. 2 M, 350 μ l, 0.70 mmol) and tetrakis(triphenylphosphine)palladium (27 mg, 0.023 mmol) in 1,4-dioxane (778 μ l) was sealed, purged and evacuated with nitrogen and then subjected to microwave irradiation at 100 °C for 1 hour. To this was then added
 5 further cyclopropylboronic acid (CAS number 411235-57-9; 60 mg, 0.70 mmol) and tetrakis(triphenylphosphine)palladium (27 mg, 0.023 mmol). The reaction was sealed, purged and evacuated with nitrogen and again subjected to microwave irradiation at 140 °C for 20 minutes. The reaction was partitioned between ethyl acetate and water, washed with water, brine, dried over magnesium sulfate and concentrated *in vacuo*. The resulting
 10 residue was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) and then purified by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% formic acid) and further purified by column chromatography (basic silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 0.77 - 0.92 (m, 4 H), 1.40 - 1.60 (m, 2 H), 1.68 - 1.94
 15 (m, 3 H), 2.14 - 2.29 (m, 2 H), 3.80 - 3.91 (m, 1 H), 3.99 - 4.10 (m, 1 H), 6.65 - 6.73 (m, 1 H), 7.43 - 7.59 (m, 4 H), 7.64 (s, 2 H), 7.68 - 7.72 (m, 1 H), 7.74 - 7.78 (m, 1 H) and 7.84 (br. s., 1 H).

MS ES⁺: 390

20 **Example 113:** *N*-[(1*S*,2*S*)-2-[[5-(Propan-2-yl)pyrazin-2-yl]amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-[(5-cyclopropylpyrazin-2-yl)amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Example 112**) from *N*-
 25 [(1*S*,2*S*)-2-[(5-bromopyrazin-2-yl)amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide and *N*-[(1*S*,2*S*)-2-[(5-chloropyrazin-2-yl)amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Intermediate 30a and 30b**; 100 mg, 0.23 mmol) and 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (CAS number 126726-62-3; 165 mg, 0.98 mmol) except this was purified only by column chromatography (silica, 0-100% ethyl acetate /
 30 petrol) and then was dissolved in ethanol (2.5 ml). To this was then added palladium on

carbon (10% wt, 50% wet) (26 mg, 0.025 mmol) and the resulting mixture was stirred under a balloon of hydrogen gas for 2 hours. The reaction was filtered through diatomaceous earth (commercially sold under the trade mark "Celite") and concentrated *in vacuo*. This was purified by column chromatography (basic silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.13 - 1.20 (m, 6 H), 1.37 - 1.57 (m, 2 H), 1.58 - 1.72 (m, 2 H), 1.93 - 2.07 (m, 2 H), 2.81 - 2.91 (m, 1 H), 3.95 - 4.09 (m, 2 H), 6.72 - 6.78 (m, 1 H), 7.40 - 7.44 (m, 1 H), 7.46 - 7.51 (m, 1 H), 7.57 - 7.62 (m, 1 H), 7.75 - 7.78 (m, 1 H), 7.80 - 7.82 (m, 1 H), 7.92 - 7.93 (m, 1 H), 7.94 (s, 2 H), 8.35 - 8.39 (m, 1 H).

MS ES⁺: 392

Example 114: *N*-[(1*S*,2*S*)-2-[(5-Ethylpyrazin-2-yl)amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-[(5-cyclopropylpyrazin-2-yl)amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Example 112**) from *N*-[(1*S*,2*S*)-2-[(5-bromopyrazin-2-yl)amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide and *N*-[(1*S*,2*S*)-2-[(5-chloropyrazin-2-yl)amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Intermediate 30a and 30b**; 100 mg, 0.23 mmol) and 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (CAS number 75927-49-0; 151 mg, 0.98 mmol) except this was purified only by column chromatography (silica, 0-100% ethyl acetate / petrol) and then was dissolved in ethanol (1.4 ml). To this was then added palladium on carbon (10% wt, 50% wet) (15 mg, 0.014 mmol) and the resulting mixture was stirred under a balloon of hydrogen gas for 2 hours. The reaction was filtered through diatomaceous earth (commercially sold under the trade mark "Celite") and concentrated *in vacuo*. This was purified by column chromatography (basic silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.17 - 1.25 (m, 3 H), 1.42 - 1.67 (m, 2 H), 1.68 - 1.94 (m, 3 H), 2.15 - 2.29 (m, 2 H), 2.59 - 2.68 (m, 2 H), 3.95 (br. s., 1 H), 4.02 - 4.13 (m, 1 H), 6.77 (br. s., 1 H), 7.43 - 7.69 (m, 6 H), 7.74 - 7.80 (m, 1 H) and 8.07 (br. s., 1 H).

MS ES⁺: 378

Example 115: 2-(2H-1,2,3-Triazol-2-yl)-N-[(1*S*,2*S*)-2-{{5-(trifluoromethoxy)pyridin-2-yl}amino}cyclopentyl]benzamide




A mixture of *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 4**; 75 mg, 0.24 mmol), 2-bromo-5-(trifluoromethoxy)pyridine (CAS number 888327-36-4; 59 mg, 0.24 mmol), BINAP (15 mg, 0.024 mmol), tris(dibenzylideneacetone)dipalladium(0) (11 mg, 0.012 mmol) and sodium *tert*-butoxide (33 mg, 0.34 mmol) in dry toluene (2.4 ml) was sealed, evacuated and purged with nitrogen and heated at 110 °C for 17 hours. The reaction was partitioned between ethyl acetate and water, washing with water, brine, filtered through a hydrophobic frit and concentrated *in vacuo*. The residue was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.37 - 1.58 (m, 2 H), 1.59 - 1.73 (m, 2 H), 1.92 - 2.08 (m, 2 H), 3.96 - 4.08 (m, 2 H), 6.58 - 6.65 (m, 1 H), 6.81 - 6.90 (m, 1 H), 7.40 - 7.46 (m, 2 H), 7.46 - 7.53 (m, 1 H), 7.56 - 7.65 (m, 1 H), 7.74 - 7.81 (m, 1 H), 7.93 - 8.01 (m, 3 H), 8.33 - 8.42 (m, 1 H)

MS ES⁺: 433

Example 117: 5-Chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1*S*,2*S*)-2-{{5-(trifluoromethoxy)pyridin-2-yl}amino}cyclopentyl]benzamide




A solution of *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-5-chloro-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 31**; 120 mg, 0.35 mmol), 2-bromo-5-

(trifluoromethoxy)pyridine (CAS number 888327-36-4; 127 mg, 0.53 mmol) and potassium *tert*-butoxide (118 mg, 1.05 mmol) in toluene (10 ml) was degassed under a nitrogen atmosphere for 15 minutes. To this was then added BINAP (22 mg, 0.035 mmol) and tris(dibenzylideneacetone)dipalladium(0) (32 mg, 0.035 mmol) and the reaction mixture was again degassed for 15 minutes. The reaction mixture was heated at 120°C for 15 hours and then was diluted with water, filtered through diatomaceous earth (commercially sold under the trade mark "Celite") and extracted with ethyl acetate. The organics were washed with water, brine, dried over sodium sulfate and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0 - 2.5% methanol / DCM) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.42-1.57 (m, 2H), 1.64-1.67 (m, 2H), 1.96-2.04 (m, 2H), 4.00-4.07 (m, 2H), 6.60-6.63 (m, 1H), 6.91-6.92 (m, 1H), 7.44-7.48 (m, 2H), 7.67-7.70 (m, 1H), 7.81-7.83 (m, 1H), 7.99-8.01 (m, 3H), 8.56-8.57 (m, 1H)
MS ES⁺: 468

Example 118: *N*-[(1*S*,2*S*)-2-[(5-Bromopyridin-2-yl)amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




A mixture of *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 4**; 300 mg, 0.98 mmol), 5-bromo-2-chloropyridine (CAS number 53939-30-3; 225 mg, 1.17 mmol), sodium *tert*-butoxide (150 mg, 1.56 mmol), BINAP (24 mg, 0.039 mmol) and tris(dibenzylideneacetone)dipalladium(0) (18 mg, 0.019 mmol) in toluene (4 ml) was heated at 85°C overnight. The mixture was partitioned between ethyl acetate (10 ml) and water (10 ml). The aqueous layer was further extracted with ethyl acetate (3 x 20 ml). The combined organics were washed with water (2 x 20 ml), filtered through a hydrophobic frit and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (300 MHz, DCM-*d*₂) δ ppm 1.40 - 1.52 (m, 2 H), 1.66 - 1.88 (m, 2 H), 2.08 - 2.30 (m, 2 H), 3.72 - 3.90 (m, 1 H), 3.94 - 4.12 (m, 1 H), 5.00 - 5.19 (m, 1 H), 6.34 - 6.45 (m, 1

H), 6.59 - 6.79 (m, 1 H), 7.39 - 7.61 (m, 4 H), 7.66 (s, 2 H), 7.73 - 7.79 (m, 1 H), 7.92 - 7.96 (m, 1 H).

MS ES⁺: 427, 429

5 **Example 119:** *N*-[(1*S*,2*S*)-2-[(5-Bromo-3-methoxypyridin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-[(5-bromopyridin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide (**Example 118**) from *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 4**; 300 mg, 0.98 mmol) and 5-bromo-2-chloro-3-methoxypyridine (CAS number 286947-03-3; 260 mg, 1.17 mmol) except after heating overnight, to this was then added further 5-bromo-2-chloro-3-methoxypyridine (CAS number 286947-03-3; 260 mg, 1.17 mmol), sodium *tert*-butoxide (150 mg, 1.56 mmol), BINAP (24 mg, 0.039 mmol) and tris(dibenzylideneacetone)dipalladium(0) (18 mg, 0.019 mmol) and the reaction was heated at 100°C for 3 hours. The mixture was partitioned between ethyl acetate (10 ml) and water (10 ml). The aqueous layer was further extracted with ethyl acetate (3 x 10 ml). The combined organics were washed with brine, filtered through a hydrophobic frit and concentrated *in vacuo*. The crude product was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.43 - 1.52 (m, 1 H), 1.55 - 1.60 (m, 1 H), 1.73 - 1.84 (m, 2 H), 2.12 - 2.23 (m, 1 H), 2.29 - 2.40 (m, 1 H), 3.82 (s, 3 H), 3.84 - 3.94 (m, 1 H), 3.97 - 4.09 (m, 1 H), 5.23 - 5.30 (m, 1 H), 6.90 - 6.94 (m, 1 H), 7.25 - 7.35 (m, 1 H), 7.41 - 7.49 (m, 3 H), 7.51 - 7.59 (m, 1 H), 7.65 (s, 2 H), 7.73 - 7.78 (m, 1 H)

MS ES⁺: 457, 459

Example 121: 2-(2H-1,2,3-Triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[4-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-[(5-bromopyridin-2-yl)amino]cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Example 118**) from *N*-[(1*S*,2*S*)-2-aminocyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide hydrochloride

(**Intermediate 4**; 200 mg, 0.65 mmol) and 2-bromo-4-(trifluoromethyl)pyridine (CAS number 175205-81-9; 147 mg, 0.650 mmol) except this was heated to 140°C for 17 hours to afford the title compound.

¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.38 - 1.59 (m, 2 H), 1.60 - 1.73 (m, 2 H), 1.92 - 2.10 (m, 2 H), 3.96 - 4.15 (m, 2 H), 6.71 (d, *J*=5.20 Hz, 1 H), 6.85 (s, 1 H), 7.03 - 7.11 (m, 1 H), 7.39 - 7.54 (m, 2 H), 7.55 - 7.64 (m, 1 H), 7.73 - 7.80 (m, 1 H), 7.94 (s, 2 H), 8.17 (d, *J*=5.20 Hz, 1 H), 8.33 - 8.43 (m, 1 H)

MS ES⁺: 417

Example 122: *N*-[(1*S*,2*S*)-2-[[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino]cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide




A solution of (1*S*,2*S*)-1-*N*-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 33**; 100 mg, 0.32 mmol), 3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number 1252907-86-0; 66 mg, 0.35 mmol), EDC (91 mg, 0.47 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (65 mg, 0.47 mmol) and triethylamine (0.132 ml, 0.95 mmol) in DCM (1 ml) was stirred at room temperature overnight. The reaction was partitioned between water (5 ml) and DCM (5 ml), filtered through a hydrophobic frit and concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) to afford the title compound.

^1H NMR (400 MHz, $\text{DCM}-d_2$) δ ppm 1.49 - 1.73 (m, 2 H), 1.80 - 1.91 (m, 2 H), 2.26 - 2.44 (m, 2 H), 4.11 - 4.21 (m, 1 H), 4.26 - 4.37 (m, 1 H), 6.04 - 6.12 (m, 1 H), 7.54 - 7.60 (m, 1 H), 7.61 - 7.64 (m, 1 H), 7.76 (s, 2 H), 7.97 - 8.02 (m, 1 H), 8.07 - 8.14 (m, 1 H), 8.21 - 8.25 (m, 1 H), 8.62 - 8.66 (m, 1 H)

5 MS ES^+ : 452

Example 123: *N*-[(1*S*,2*S*)-2-[[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino]cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide



10

Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-[[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino]cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 122**) from (1*S*,2*S*)-1-*N*-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 34**; 100 mg, 0.33 mmol) and 3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number 1252907-86-0; 66 mg, 0.35 mmol) to afford the title compound.

15


^1H NMR (400 MHz, $\text{DCM}-d_2$) δ ppm 1.48 - 1.73 (m, 2 H), 1.77 - 1.93 (m, 2 H), 2.23 - 2.47 (m, 2 H), 4.11 - 4.21 (m, 1 H), 4.26 - 4.35 (m, 1 H), 5.75 - 5.84 (m, 1 H), 7.27 - 7.34 (m, 1 H), 7.55 - 7.62 (m, 1 H), 7.77 (s, 2 H), 7.97 - 8.03 (m, 1 H), 8.03 - 8.09 (m, 1 H), 8.12 (s, 1 H), 8.61 - 8.66 (m, 1 H)

20

MS ES^+ : 436

Example 124: *N*-[(1*S*,2*S*)-2-[[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino]cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide

25




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 122**) from (1*S*,2*S*)-1-*N*-[3-methyl-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 35**; 100 mg, 0.34 mmol) and 3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number 1252907-86-0; 71 mg, 0.37 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.34 - 1.55 (m, 1 H), 1.57 - 1.79 (m, 3 H), 1.94 - 2.10 (m, 4 H), 2.15 - 2.28 (m, 1 H), 4.15 - 4.37 (m, 2 H), 6.52 - 6.65 (m, 1 H), 7.42 - 7.58 (m, 1 H), 7.67 - 7.78 (m, 1 H), 7.87 (s, 2 H), 8.15 - 8.31 (m, 2 H), 8.60 - 8.72 (m, 1 H), 8.77 - 8.89 (m, 1 H)

MS ES⁺: 432

Example 125: *N*-[(1*S*,2*S*)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide (**Example 122**) from (1*S*,2*S*)-1-*N*-[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 41**; 266 mg, 0.86 mmol) and 3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number 1252907-86-0; 179 mg, 0.94 mmol) except this was further purified by reverse phase chromatography (C18 silica, 5-100% water (with 0.05% ammonia) / acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.20 - 1.27 (m, 3 H), 1.39 - 1.52 (m, 1 H), 1.63 - 1.76 (m, 1 H), 1.81 - 1.92 (m, 2 H), 2.18 - 2.29 (m, 1 H), 2.42 - 2.59 (m, 3 H), 4.00 - 4.11 (m, 1 H), 4.26 - 4.37 (m, 1 H), 6.38 - 6.47 (m, 1 H), 7.55 - 7.61 (m, 1 H), 7.70 (s, 2 H), 7.75 - 7.83 (m, 1 H), 7.97 - 8.02 (m, 1 H), 8.15 (s, 1 H), 8.61 - 8.67 (m, 1 H).

MS ES⁺: 447

Example 126: *N*-(4,4-Difluoro-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide




A microwave vial was charged with *N*-(2-amino-4,4-difluorocyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 42**; 65 mg, 0.19 mmol), 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 38 mg, 0.21 mmol) and DIPEA (99 μ l, 0.57 mmol) in dry DMSO (630 μ l). The reaction was subjected to microwave irradiation at 140°C for 30 minutes. The reaction was partitioned between ethyl acetate and water. The organics were washed with water and brine, dried over magnesium sulfate, filtered and concentrated *in vacuo*. The crude material was purified by column chromatography (basic silica, 0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.00 - 2.22 (m, 2 H), 2.56 - 2.76 (m, 2 H), 4.35 - 4.53 (m, 2 H), 7.38 - 7.42 (m, 1 H), 7.47 - 7.52 (m, 1 H), 7.59 - 7.65 (m, 1 H), 7.76 - 7.81 (m, 1 H), 7.93 (s, 2 H), 8.05 - 8.08 (m, 1 H), 8.16 - 8.25 (m, 1 H), 8.40 (s, 1 H), 8.62 - 8.69 (m, 1 H).

MS ES⁺: 454

Example 127: *N*-(4,4-Difluoro-2-{{5-(trifluoromethyl)pyrimidin-2-yl}amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide




To a solution of *N*-(2-amino-4,4-difluorocyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 42**; 120 mg, 0.39 mmol) in dry DMSO (1.2 ml) was added 2-chloro-5-(trifluoromethyl)pyrimidine (CAS number 69034-12-4; 70 mg, 0.384 mmol) and DIPEA (183 μ l, 1.047 mmol). The reaction mixture was heated in a sealed vial at 140 °C

for 17 hours then partitioned between ethyl acetate and water. The organics were washed with water, filtered through a hydrophobic frit and concentrated *in vacuo*. The crude material was purified by column chromatography (basic silica, 0-100% ethyl acetate / petrol) then was chirally separated using SFC (Waters prep30/MS system using 20% Isopropanol, Daicel AD 10mm id x 250mm long columns at 30ml/min, 40°C and 100bar) to afford the title compound as a single enantiomer.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.06 - 2.25 (m, 2 H), 2.56 - 2.70 (m, 2 H), 4.42 - 4.59 (m, 2 H), 7.36 - 7.42 (m, 1 H), 7.46 - 7.52 (m, 1 H), 7.58 - 7.65 (m, 1 H), 7.76 - 7.81 (m, 1 H), 7.93 (s, 2 H), 8.20-8.24 (m, 1 H), 8.60 - 8.70 (m, 3 H)

MS ES⁺: 454

Example 128: *N*-(4,4-Difluoro-2-{{5-(trifluoromethyl)pyridin-2-yl}amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide




To a solution of *N*-(2-amino-4,4-difluorocyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 42**; 120 mg, 0.349 mmol) in dry DMSO (1.2 ml) was added 2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 70 mg, 0.38 mmol) and DIPEA (183 μl, 1.05 mmol). The reaction mixture was heated in a sealed vial at 140 °C for 17 hours then partitioned between ethyl acetate and water. The organics were washed with water, filtered through a hydrophobic frit and concentrated *in vacuo*. The crude material was purified by column chromatography (basic silica, 0-100% ethyl acetate in petrol) and then was chirally separated using SFC (Waters prep30/MS system using 10% Ethanol, Daicel AD 10mm id x 250mm long columns at 30ml/min, 40°C and 100bar) to afford the title compound as a single enantiomer.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 2.02 - 2.23 (m, 2 H), 2.73 - 2.94 (m, 2 H), 4.23 - 4.39 (m, 2 H), 5.90 (br. s, 1 H), 6.56 - 6.63 (m, 1 H), 6.84 - 6.96 (m, 1 H), 7.42 - 7.53 (m, 2 H), 7.53 - 7.67 (m, 4 H), 7.78 - 7.83 (m, 1 H), 8.21 (s, 1 H)

MS ES⁺: 453

Example 129: *N*-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide




Prepared according to the procedure for *N*-(4,4-difluoro-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide (**Example 128**) from *N*-(2-amino-4,4-difluorocyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 42**; 120 mg, 0.349 mmol) and 2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 70 mg, 0.38 mmol) and this was then chirally separated using SFC to afford the title compound as a single enantiomer.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 2.01 - 2.22 (m, 2 H), 2.74 - 2.92 (m, 2 H), 4.25 - 4.39 (m, 2 H), 6.06 (br. s, 1 H), 6.54 - 6.65 (m, 1 H), 6.81 - 6.94 (m, 1 H), 7.42 - 7.53 (m, 2 H), 7.54 - 7.67 (m, 4 H), 7.77 - 7.83 (m, 1 H), 8.20 (s, 1 H)

MS ES⁺: 453

Example 130: *N*-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide



Method 1:

Prepared according to the procedure for *N*-(4,4-difluoro-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide (**Example 126**) from *N*-(2-amino-4,4-difluorocyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride (**Intermediate 42**; 65 mg, 0.19 mmol) and 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 38 mg, 0.21 mmol) and this was then chirally separated using SFC (Waters prep30/MS system using 16% Isopropanol, Phenomenex Lux-C-4 10mm id x

250mm long columns at 30ml/min, 40°C and 100bar) to afford the title compound as a single enantiomer.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.98 - 2.27 (m, 2 H), 2.58 - 2.78 (m, 2 H), 4.32 - 4.57 (m, 2 H), 7.36 - 7.45 (m, 1 H), 7.46 - 7.54 (m, 1 H), 7.58 - 7.69 (m, 1 H), 7.75 - 7.84 (m, 1 H), 7.94 (s, 2 H), 8.03 - 8.12 (m, 1 H), 8.16 - 8.29 (m, 1 H), 8.41 (s, 1 H), 8.67 (s, 1 H)

MS ES⁺: 454


Method 2:

To a mixture of 4,4-difluoro-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 45**; 35 mg, 0.12 mmol) in dry DCM (400 μl) was added 2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 28 mg, 0.15 mmol), EDC (71 mg, 0.37 mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (51 mg, 0.38 mmol) and DIPEA (65 μl, 0.37 mmol). The reaction was stirred at room temperature for 72 hours then partitioned between ethyl acetate and water. The organics were washed with water and brine, dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 0-100% ethyl acetate in petrol) then this was then chirally separated using SFC (Waters prep30/MS system using 16% Isopropanol, Phenomenex Lux-C-4 10mm id x 250mm long columns at 30ml/min, 40°C and 100bar) to afford the title compound as a single enantiomer.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.98 - 2.27 (m, 2 H), 2.58 - 2.78 (m, 2 H), 4.32 - 4.57 (m, 2 H), 7.36 - 7.45 (m, 1 H), 7.46 - 7.54 (m, 1 H), 7.58 - 7.69 (m, 1 H), 7.75 - 7.84 (m, 1 H), 7.94 (s, 2 H), 8.03 - 8.12 (m, 1 H), 8.16 - 8.29 (m, 1 H), 8.41 (s, 1 H), 8.67 (s, 1 H)

MS ES⁺: 454

Example 131: *N*-[(1*S*,2*S*)-4,4-Difluoro-2-[[5-(trifluoromethoxy)pyridin-2-yl]amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide




To a solution of *N*-[(1*S*,2*S*)-2-amino-4,4-difluorocyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Intermediate 46**; 50 mg, 0.16 mmol) in dry toluene (1.6 ml) was added 2-bromo-5-(trifluoromethoxy)pyridine (CAS number 888327-36-4; 40 mg, 0.17 mmol), BINAP (10 mg, 0.016 mmol), tris(dibenzylideneacetone)dipalladium(0) (8 mg, 8.74 μ mol) and sodium *tert*-butoxide (22 mg, 0.23 mmol). The reaction was placed under an atmosphere of nitrogen, sealed and heated at 120°C for 17 hours then partitioned between ethyl acetate and water. The organics were washed with water and brine, dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 10-70% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.87 - 2.22 (m, 2 H), 2.53 - 2.78 (m, 2 H), 4.23 - 4.43 (m, 2 H), 6.52 - 6.66 (m, 1 H), 7.07 - 7.16 (m, 1 H), 7.34 - 7.41 (m, 1 H), 7.45 - 7.53 (m, 2 H), 7.57 - 7.64 (m, 1 H), 7.77 - 7.82 (m, 1 H), 7.95 (s, 2 H), 8.00 - 8.06 (m, 1 H), 8.58 - 8.66 (m, 1 H)

MS ES⁺: 469

Example 132: *N*-[(1*S*,2*S*)-4,4-Difluoro-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




A microwave vial was charged with *N*-[(1*S*,2*S*)-2-amino-4,4-difluorocyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Intermediate 46**; 50 mg, 0.15 mmol), 2,3-difluoro-5-(trifluoromethyl)pyridine (CAS number 89402-42-6; 29 mg, 0.16 mmol) and DIPEA (26 μ l, 0.15 mmol) in dry DMSO (485 μ l). The reaction mixture was subjected to microwave irradiation at 120°C for 30 minutes then partitioned between ethyl acetate and water. The organics were washed with water and brine, dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 0-60% ethyl acetate / petrol) to afford the title compound.

^1H NMR (400 MHz, DMSO-*d*6) δ ppm 2.06 - 2.28 (m, 2 H), 2.53 - 2.76 (m, 2 H), 4.46 - 4.69 (m, 2 H), 7.32 - 7.38 (m, 1 H), 7.42 - 7.51 (m, 1 H), 7.55 - 7.65 (m, 2 H), 7.74 - 7.85 (m, 2 H), 7.89 (s, 2 H), 8.21 (s, 1 H), 8.60 - 8.68 (m, 1 H)

MS ES⁺: 471

5

Example 135: 2-(5-Ethoxypyrimidin-2-yl)-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide



A solution of (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 116 mg, 0.41 mmol), 2-(5-ethoxypyrimidin-2-yl)benzoic acid (**Intermediate 47**; 100 mg, 0.41 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (84 mg, 0.61 mmol), EDC (118 mg, 0.61 mmol) and triethylamine (0.171 ml, 1.23 mmol) in dry DCM (4 ml) was stirred at room temperature for 4 hours. The reaction was partitioned


between DCM and water, filtered through a hydrophobic frit and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC (eluted with acetonitrile / water with 0.1 % ammonia) and then by reverse phase preparative HPLC (eluted with acetonitrile / water containing 0.1% formic acid) to afford the title compound.

^1H NMR (400 MHz, DCM-*d*2) δ ppm 1.40-1.43 (m, 3 H), 1.46 - 1.91 (m, 4 H), 2.14 - 2.23 (m, 1 H), 2.35 - 2.44 (m, 1 H), 3.86 - 4.06 (m, 3 H), 4.25 - 4.34 (m, 1 H), 6.38 - 6.42 (m, 1 H), 6.67 - 6.72 (m, 1 H), 7.40 - 7.55 (m, 3 H), 7.83 - 7.87 (m, 1 H), 7.98 - 8.02 (m, 1 H), 8.16 - 8.25 (m, 3 H)

MS ES⁺: 473

Example 136: 2-Fluoro-6-methoxy-N-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

25




A solution of (1*S*,2*S*)-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 14**; 14 mg, 0.05 mmol), 2-fluoro-6-methoxybenzoic acid (CAS number 137654-21-8; 8.5 mg, 0.05 mmol), TOTU (20 mg, 0.06 mmol) and 4-methylmorpholine (0.008 ml, 0.075 mmol) in DMF (0.25 ml) was stirred at room temperature for 1 hour. The reaction was then diluted with methanol and concentrated *in vacuo*. The resulting residue was purified by reverse phase preparative HPLC (eluted with acetonitrile / water with 0.1 % ammonia) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.51 - 1.67 (m, 2 H), 1.82 - 1.95 (m, 2 H), 2.20 - 2.32 (m, 1 H), 2.32 - 2.43 (m, 1 H), 3.70 (s, 3 H), 4.05 - 4.17 (m, 1 H), 4.28 - 4.45 (m, 1 H), 6.20 (br. s., 1 H), 6.35 - 6.53 (m, 1 H), 6.66 - 6.76 (m, 2 H), 7.24 - 7.36 (m, 1H), 7.98 (s, 1 H), 8.21 (s, 1 H)

MS ES⁺: 399

Example 137: *N*-[(1*S*,2*S*)-2-[[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino]cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide




To a solution of 3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7; 155 mg, 0.77 mmol), DIPEA (0.27 ml, 1.54 mmol) and (1*S*,2*S*)-1-*N*-[3-methyl-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 35**; 200 mg, 0.68 mmol) in DCM (3 ml) and acetonitrile (5 ml) was added HATU (293 mg, 0.77 mmol). The reaction was stirred at room temperature for 16 hours and then concentrated *in vacuo*. The residue was purified by reverse phase column chromatography (C18 silica, 0 - 100 % water (0.1 % formic acid) / acetonitrile) and then by reverse phase

column chromatography (C18 silica, 5 - 95 % water (0.05 % ammonia) / acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.41 - 1.55 (m, 1 H), 1.59 - 1.77 (m, 3 H), 1.99 (s, 3 H), 2.00 - 2.11 (m, 1 H), 2.13 - 2.27 (m, 1 H), 4.12 - 4.35 (m, 2 H), 6.60 - 6.68 (m, 1 H), 7.31 - 7.38 (m, 1 H), 7.47 - 7.53 (m, 1 H), 7.59 - 7.67 (m, 1 H), 8.15 - 8.26 (m, 2 H), 8.62 - 8.71 (m, 3 H), 8.78 - 8.86 (m, 1 H)

MS ES⁺: 443

Example 138: *N*-[(1*S*,2*S*)-2-{{3-Fluoro-5-(trifluoromethyl)pyridin-2-yl}amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide




Prepared according to the procedure for 2-(5-Ethoxypyrimidin-2-yl)-*N*-[(1*S*,2*S*)-2-{{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]benzamide (**Example 135**) from (1*S*,2*S*)-1-*N*-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 34**: 263 mg, 1.00 mmol) and 2-(pyrimidin-2-yl)benzoic acid (CAS number 400892-62-8; 200 mg, 1.00 mmol) except after the reaction was complete it was concentrated *in vacuo* and the residue was purified by column chromatography (silica, 0 - 50% ethyl acetate / petrol) and then was purified by reverse phase column chromatography (C18 silica, 0 - 100 % water (0.05 % ammonia) / methanol) and triturated with DCM / petrol. The product was further purified by reverse phase column chromatography (C18 silica, 0 - 100 % water (0.1 % ammonia) / acetonitrile) to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 1.49 - 1.66 (m, 2 H), 1.73 - 1.92 (m, 2 H), 2.29 - 2.48 (m, 2 H), 4.09 - 4.30 (m, 2 H), 5.80 - 5.97 (m, 1 H), 6.68 - 6.80 (m, 1 H), 6.99 - 7.11 (m, 1 H), 7.28 - 7.33 (m, 1 H), 7.40 - 7.58 (m, 3 H), 7.95 - 8.03 (m, 1 H), 8.03 - 8.10 (m, 1 H), 8.54 - 8.65 (m, 2 H)

MS ES⁺: 446

Example 139: 5-Fluoro-*N*-[(1*S*,2*S*)-2-{{3-fluoro-5-(trifluoromethyl)pyridin-2-yl}amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide




Prepared according to the procedure for 2-(5-Ethoxypyrimidin-2-yl)-N-[(1S,2S)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]benzamide (**Example 135**) from (1S,2S)-1-N-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 34**: 200 mg, 0.76 mmol) and 5-fluoro-2-(pyrimidin-2-yl)benzoic acid (CAS number 1293284-57-7; 166 mg, 0.76 mmol) except after the reaction was complete it was concentrated *in vacuo* and the residue was purified by reverse phase column chromatography (C18 silica, 0 - 100 % water (0.05 % ammonia) / methanol), then by column chromatography (silica, 0 - 50% ethyl acetate / petrol) and then triturated with DCM / petrol to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 1.50 - 1.66 (m, 2 H), 1.77 - 1.94 (m, 2 H), 2.27 - 2.46 (m, 2 H), 4.05 - 4.23 (m, 2 H), 5.64 - 5.81 (m, 1 H), 6.89 - 6.98 (m, 1 H), 7.02 - 7.07 (m, 1 H), 7.11 - 7.17 (m, 1 H), 7.18 - 7.24 (m, 1 H), 7.24 - 7.30 (m, 1 H), 7.94 - 8.00 (m, 1H), 8.09 - 8.17 (m, 1 H), 8.56 - 8.62 (m, 2 H)

MS ES⁺: 464

Example 140: N-[(1S,2S)-2-[[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino]cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide




Prepared according to the procedure for 2-(5-Ethoxypyrimidin-2-yl)-N-[(1S,2S)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]benzamide (**Example 135**) from (1S,2S)-1-N-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 34**: 450 mg, 1.71 mmol) and 2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid

(CAS number 475105-77-2; 349 mg, 1.71 mmol) except after the reaction was complete it was partitioned between DCM and a saturated solution of sodium bicarbonate, filtered through a hydrophobic frit. The organics were loaded directly on to a cation / anion mixed mode cartridge, eluted with DCM and concentrated *in vacuo*. The resulting residue was
 5 purified by column chromatography (silica, 0 – 100% ethyl acetate / petrol) and then purified by reverse phase column chromatography (C18 silica, 0 - 100 % water (0.05 % ammonia) / acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.57 - 1.72 (m, 2 H), 1.82 - 1.94 (m, 2 H), 2.27 - 2.46 (m, 5 H), 4.10 - 4.37 (m, 2 H), 5.69 - 5.82 (m, 1 H), 7.18 - 7.27 (m, 1 H), 7.28 - 7.37
 10 (m, 1 H), 7.40 - 7.50 (m, 1 H), 7.53 - 7.64 (m, 2 H), 7.88 - 8.00 (m, 2 H)

MS ES⁺: 450

Example 141: 2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1*S*,2*S*)-2-[[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide




Prepared according to the procedure for 2-(5-Ethoxypyrimidin-2-yl)-N-[(1*S*,2*S*)-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 135**) from (1*S*,2*S*)-1-*N*-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride
 20 (**Intermediate 23**; 452 mg, 1.74 mmol) and 2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid (CAS number 475105-77-2; 355 mg, 1.74 mmol) except after the reaction was complete it was partitioned between DCM and a saturated solution of sodium bicarbonate, filtered through a hydrophobic frit. The organics were loaded directly on to a cation / anion mixed mode cartridge, eluted with DCM and concentrated *in vacuo*. The resulting residue was
 25 purified by column chromatography (silica, 0 – 100% ethyl acetate / petrol) and then recrystallised from MTBE / heptane to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 1.48 - 1.70 (m, 2 H), 1.82 - 1.95 (m, 2 H), 2.24 (s, 3 H), 2.26 - 2.37 (m, 1 H), 2.42 (s, 3 H), 2.49 - 2.62 (m, 1 H), 3.98 - 4.12 (m, 1 H),

4.38 - 4.52 (m, 1 H), 6.43 - 6.52 (m, 1 H), 6.65 - 6.74 (m, 1 H), 7.50 - 7.65 (m, 3 H), 7.97 - 8.05 (m, 1 H), 8.12 (s, 1 H)

MS ES⁺: 447

5 **Example 142:** *N*-[(1*S*,2*S*)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide




10 Prepared according to the procedure for 2-(5-Ethoxypyrimidin-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 135**) from (1*S*,2*S*)-1-*N*-[3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 48**; 105 mg, 0.33 mmol) and 3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number 1252907-86-0; 74 mg, 0.39 mmol) except after work-up, the organics were loaded directly on to a cation / anion mixed mode
15 cartridge, eluted with DCM, then methanol and 2M ammonia in methanol and concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0 – 100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.79 - 1.05 (m, 4 H), 1.45 - 1.80 (m, 4 H), 2.00 - 2.24 (m, 3 H), 4.24 - 4.43 (m, 2 H), 7.48 - 7.54 (m, 1 H), 7.68 - 7.73 (m, 1 H), 7.90 (s, 2
20 H), 8.18 - 8.21 (m, 1 H), 8.22 - 8.26 (m, 1 H), 8.65 - 8.69 (m, 1 H), 8.72 - 8.83 (m, 1 H)

MS ES⁺: 459

Example 143: *N*-[(1*S*,2*S*)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide




Prepared according to the procedure for 2-(5-Ethoxypyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide (**Example 135**) from (1S,2S)-1-N-[3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 48**; 105 mg, 0.33 mmol) and 3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7; 79 mg, 0.39 mmol) except after work-up, the organics were loaded directly on to a cation / anion mixed mode cartridge, eluted with DCM, then methanol and 2M ammonia in methanol and concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0 – 100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.81 - 1.03 (m, 4 H), 1.47 - 1.59 (m, 1 H), 1.63 - 1.79 (m, 3 H), 2.02 - 2.15 (m, 2 H), 2.16 - 2.26 (m, 1 H), 4.28 - 4.39 (m, 2 H), 7.34 - 7.38 (m, 1 H), 7.53 - 7.59 (m, 1 H), 7.61 - 7.66 (m, 1 H), 8.19 - 8.21 (m, 1 H), 8.22 - 8.26 (m, 1 H), 8.64 - 8.68 (m, 1 H), 8.68 - 8.71 (m, 2 H), 8.72 - 8.77 (m, 1 H)

MS ES⁺: 470

Example 144: N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide




A solution of (1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 25**; 50 mg, 0.192 mmol), 3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7; 46 mg, 0.231 mmol), triethylamine (80 ul, 0.576 mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (34 mg, 0.250 mmol) and EDC (48 mg, 0.250 mmol) in DCM (5 ml) was stirred at room temperature for 18 hours. The reaction was partitioned between DCM (20 ml) and a saturated solution of sodium bicarbonate (10 ml). The aqueous layer was further extracted with DCM (20 ml) and the combined organics were filtered through a hydrophobic frit and concentrated *in vacuo*. The resulting residue was purified by column chromatography (silica, 0 - 100% ethyl acetate / petrol) to afford the title compound.

^1H NMR (400 MHz, $\text{DCM}-d_2$) δ ppm 1.42 (s, 3 H), 1.64 - 1.99 (m, 4 H), 2.13 - 2.23 (m, 1 H), 2.52 - 2.60 (m, 1 H), 4.41 - 4.49 (m, 1 H), 7.30 - 7.34 (m, 1 H), 7.55 - 7.67 (m, 4 H), 8.08 - 8.12 (m, 1 H), 8.22 (s, 1 H), 8.64 - 8.67 (m, 1 H), 8.73 - 8.76 (m, 2 H)

MS ES^+ : 444

5

Example 145: 2-(3-Methyl-1,2,4-oxadiazol-5-yl)-*N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide



Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-methyl-2-{[5-


(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide (**Example 144**) from (1*S*,2*S*)-1-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 25**; 190 mg, 0.73 mmol) and 2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid (CAS number 475105-77-2; 179 mg, 0.88 mmol). After work-up, the crude material was loaded directly on to a cation / anion mixed mode cartridge, eluted with DCM and concentrated *in vacuo*. This was then recrystallised from MTBE to afford the title compound.

^1H NMR (400 MHz, $\text{DCM}-d_2$) δ ppm 1.41 (s, 3 H), 1.50 - 1.63 (m, 1 H), 1.72 - 2.04 (m, 3 H), 2.10 - 2.24 (m, 1 H), 2.31 (s, 3 H), 2.56 - 2.66 (m, 1 H), 4.46 - 4.65 (m, 1 H), 6.34 - 6.52 (m, 1 H), 7.59 - 7.74 (m, 4 H), 7.82 (br. s., 1 H), 8.01 - 8.09 (m, 1 H), 8.21 - 8.31 (m, 1 H)

20

MS ES^+ : 447

Example 146: *N*-(2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide




25

To a solution of 1-*N*-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]-1-methylcyclopentane-1,2-diamine (**Intermediate 28**; 0.225 g, 0.81 mmol) and 4-methylmorpholine (0.134 ml, 1.217 mmol) in acetonitrile (5 ml) was added TOTU (0.399 g, 1.23 mmol) and 3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7; 0.163 g, 0.81 mmol). The reaction was stirred at room temperature for 1 hour and then was diluted with DCM and washed with brine. The organics were dried over magnesium sulfate, concentrated *in vacuo* and purified by SCX chromatography (2M ammonia in methanol). The resulting residue was purified by column chromatography (silica, 0 - 10% methanol / DCM) and further purified by reverse phase chromatography (C18 silica, 5 - 95 % water (0.05 % ammonia) / acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.45 (s, 3 H), 1.65 - 1.98 (m, 5 H), 2.52 - 2.59 (m, 1 H), 4.38 - 4.48 (m, 1 H), 7.36 - 7.41 (m, 1 H), 7.64 - 7.70 (m, 2 H), 7.78 - 7.83 (m, 1 H), 8.19 (s, 1 H), 8.34 - 8.39 (m, 1 H), 8.67 - 8.73 (m, 3 H), 8.94 - 9.00 (m, 1 H)

MS ES⁺: 461

Example 147: *N*-[(1*S*,2*S*)-2-{{3-Fluoro-5-(trifluoromethyl)pyridin-2-yl}amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide




A solution of (1*S*,2*S*)-1-*N*-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 34**; 379 mg, 1.44 mmol), 3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7; 290 mg, 1.44 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (34 mg, 0.250 mmol) (294 mg, 2.16 mmol), EDC (415 mg, 2.16 mmol) and triethylamine (0.604 ml, 4.32 mmol) in DCM (1 ml) was stirred at room temperature for 16 hours. The reaction was added partitioned between DCM and as saturated solution of sodium bicarbonate. The organics were filtered through a hydrophobic frit and loaded directly on to a cation / anion mixed mode cartridge, eluted with DCM and concentrated *in vacuo*. The resulting residue was purified by reverse phase chromatography (C18 silica, 0 - 100 % water (0.1 % ammonia) / acetonitrile) to afford the title compound.

^1H NMR (400 MHz, DCM- d_2) δ ppm 1.42 - 1.74 (m, 2 H), 1.76 - 1.94 (m, 2 H), 2.21 - 2.33 (m, 1 H), 2.33 - 2.49 (m, 1 H), 4.06 - 4.34 (m, 2 H), 5.93 (br. s., 1 H), 7.18 - 7.34 (m, 2 H), 7.47 - 7.58 (m, 1 H), 7.94 - 8.04 (m, 1 H), 8.11 - 8.31 (m, 2 H), 8.57 - 8.67 (m, 1 H), 8.66 - 8.76 (m, 2 H).

5 MS ES⁺: 447

Example 148: *N*-[(1*S*,2*S*)-2-{{3-Chloro-5-(trifluoromethyl)pyridin-2-yl}amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide



10 A solution of (1*S*,2*S*)-1-*N*-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 33**; 327 mg, 1.03 mmol), 3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7; 250 mg, 1.24 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (211 mg, 1.55 mmol), EDC (297 mg, 1.55 mmol) and triethylamine (0.432 ml, 3.10 mmol) in DCM (4 ml) was stirred at room temperature for 18


15 hours. The reaction was partitioned between DCM (10 ml) and water (10 ml), filtered through a hydrophobic frit and concentrated *in vacuo*. The resulting residue was purified by column chromatography (0 - 100% ethyl acetate / petrol) and was then by reverse phase chromatography (C18 silica, 5 - 95 % water (0.05 % ammonia) / acetonitrile) to afford the title compound.

20 ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.44 - 1.57 (m, 1 H), 1.63 - 1.78 (m, 3 H), 1.95 - 2.10 (m, 1 H), 2.14 - 2.27 (m, 1 H), 4.27 - 4.36 (m, 2 H), 7.21 - 7.25 (m, 1 H), 7.36 - 7.40 (m, 1 H), 7.61 - 7.66 (m, 1 H), 7.95 - 7.97 (m, 1 H), 8.21 - 8.24 (m, 1 H), 8.34 - 8.37 (m, 1 H), 8.64 - 8.67 (m, 1 H), 8.69-8.72 (m, 3 H)

MS ES⁺: 463, 465

25


Example 149: *N*-[(1*S*,2*S*)-2-{{3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide



A solution of (*1S,2S*)-1-*N*-[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 41**; 450 mg, 1.64 mmol), 2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid (CAS number 475105-77-2; 335 mg, 1.64 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (335 mg, 2.46 mmol), EDC (472 mg, 2.46 mmol) and triethylamine (0.687 ml, 4.92 mmol) in DCM (5 ml) was stirred at room temperature for 16 hours. The reaction was partitioned between DCM and a saturated solution of sodium bicarbonate, filtered through a hydrophobic frit and loaded directly on to a cation / anion mixed mode cartridge, eluted with DCM and concentrated *in vacuo*. The resulting residue was purified by reverse phase chromatography (C18 silica, 0 - 100 % water (0.1 % ammonia) / acetonitrile) and recrystallised from MTBE / heptane to afford the title compound.

¹H NMR - (400 MHz, METHANOL-*d*₄) δ ppm 1.25 - 1.32 (m, 3 H), 1.55 - 1.96 (m, 4 H), 2.14 - 2.28 (m, 4 H), 2.32 - 2.44 (m, 1 H), 2.64 - 2.75 (m, 2 H), 4.23 - 4.34 (m, 1 H), 4.40 - 4.51 (m, 1 H), 7.45 - 7.51 (m, 1 H), 7.61 - 7.71 (m, 2 H), 7.99 - 8.06 (m, 1 H), 8.11 (s, 1 H). MS ES⁺: 461

Example 150: *N*-[(*1S,2S*)-2-[[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide




Prepared according to the procedure for *N*-[(*1S,2S*)-2-[[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide (**Example 149**) from (*1S,2S*)-1-*N*-[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 41**; 450 mg, 1.64 mmol) and 3-(pyrimidin-2-yl)pyridine-2-

carboxylic acid (CAS number 1228431-21-7; 330 mg, 1.64 mmol) to afford the title compound.

^1H NMR - (400 MHz, METHANOL- d_4) δ ppm 1.18 - 1.28 (m, 3 H), 1.54 - 1.95 (m, 4 H), 2.17 - 2.30 (m, 1 H), 2.32 - 2.45 (m, 1 H), 2.49 - 2.70 (m, 2 H), 4.23 - 4.42 (m, 2 H), 7.29 - 7.36 (m, 1 H), 7.62 - 7.71 (m, 1 H), 8.17 (s, 1 H), 8.28 - 8.35 (m, 1 H), 8.62 - 8.75 (m, 3 H).

MS ES^+ : 458

Example 151: *N*-[(1*S*,2*S*)-2-{{3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide




Prepared according to the procedure for *N*-[(1*S*,2*S*)-2-{{3-ethyl-5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide (**Example 149**) from (1*S*,2*S*)-1-*N*-[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 41**; 450 mg 1.64 mmol) and 2-(pyrimidin-2-yl)benzoic acid (CAS number 400892-62-8; 328 mg, 1.64 mmol) to afford the title compound.

^1H NMR (400 MHz, METHANOL- d_4) δ ppm 1.19 - 1.29 (m, 3 H), 1.52 - 1.96 (m, 4 H), 2.12 - 2.23 (m, 1 H), 2.29 - 2.44 (m, 1 H), 2.47 - 2.71 (m, 2 H), 4.16 - 4.28 (m, 1 H), 4.28 - 4.42 (m, 1 H), 7.11 - 7.20 (m, 1 H), 7.40 - 7.47 (m, 1 H), 7.50 - 7.64 (m, 2 H), 8.00 - 8.06 (m, 1 H), 8.14 (s, 1 H), 8.50 - 8.59 (m, 2 H).

MS ES^+ : 457

Example 153: *N*-(2-Methyl-2-{{5-(trifluoromethyl)pyrimidin-2-yl}amino}cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide




A solution of 3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7; 80 mg, 0.40 mmol), 1-methyl-1-N-[5-(trifluoromethyl)pyrimidin-2-yl]cyclopentane-1,2-diamine (**Intermediate 50**; 103 mg, 0.40 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (81 mg, 0.60 mmol), EDC (114 mg, 0.60 mmol) and DIPEA (0.208 ml, 1.19 mmol) in DCM (4 ml) was stirred at room temperature for 4 days. The reaction was diluted with DCM (5 ml) and a saturated solution of sodium bicarbonate (5 ml), filtered through a hydrophobic frit and concentrated *in vacuo*. The crude product was purified by reverse phase chromatography (C18 silica, 5 - 95 % water (0.05 % ammonia) / acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.40 (s, 3 H), 1.61 - 1.84 (m, 3 H), 1.87 - 2.00 (m, 2 H), 2.29 - 2.42 (m, 1 H), 4.43 - 4.54 (m, 1 H), 7.38 - 7.43 (m, 1 H), 7.63 - 7.69 (m, 1 H), 7.99 (s, 1 H), 8.34 - 8.39 (m, 1 H), 8.51 - 8.66 (m, 2 H), 8.68 - 8.71 (m, 1 H), 8.72 - 8.75 (m, 2 H), 8.80 - 8.86 (m, 1 H)

MS ES⁺: 444

Example 154: *N*-(2-Methyl-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]cyclopentyl)-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide




Prepared according to the procedure for *N*-(2-methyl-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide (**Example 153**) from 1-methyl-1-N-[5-(trifluoromethyl)pyrimidin-2-yl]cyclopentane-1,2-diamine (**Intermediate 50**; 150 mg, 0.58 mmol) and 3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number 1252907-86-0; 110 mg, 0.58 mmol) and then triturated with heptane to afford the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.36 (s, 3 H), 1.62 - 1.79 (m, 3 H), 1.88 - 2.05 (m, 2 H), 2.24 - 2.35 (m, 1 H), 4.47 - 4.58 (m, 1 H), 7.72 - 7.76 (m, 1 H), 7.83 (s, 1 H), 8.04 (s, 2 H), 8.30 - 8.34 (m, 1 H), 8.53 - 8.67 (m, 2 H), 8.68 - 8.72 (m, 1 H), 8.86 - 8.92 (m, 1 H)

MS ES⁺: 433

Example 155: *N*-(2-Methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]amino]cyclopentyl)-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide




Prepared according to the procedure for *N*-(2-methyl-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide (**Example 153**) from 1-methyl-1-*N*-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine (**Intermediate 51**; 85 mg, 0.33 mmol), 3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number 1252907-86-0; 75 mg, 0.33 mmol) and triethylamine (0.14 ml, 0.98 mmol) except this was then recrystallised from diisopropyl ether / pentane and then triturated with diethyl ether to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.44 (s, 3 H), 1.59 - 1.73 (m, 1 H), 1.74 - 2.05 (m, 3 H), 2.13 - 2.27 (m, 1 H), 2.49 (br. s., 1 H), 4.43 - 4.52 (m, 1 H), 6.33 (br. s., 1 H), 6.85 (br. s., 1 H), 7.39 - 7.52 (m, 2 H), 7.60 - 7.66 (m, 1 H), 7.84 (s, 2 H), 8.07 - 8.12 (m, 1 H), 8.25 (br. s., 1 H), 8.65 - 8.70 (m, 1 H)

MS ES⁺: 432

Example 156: *N*-(2-Methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]amino]cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide




Prepared according to the procedure for *N*-(2-methyl-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide (**Example 153**) from 1-methyl-1-*N*-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine (**Intermediate 51**; 91 mg, 0.35 mmol), 3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7; 85 mg, 0.42 mmol) and triethylamine (0.147 ml, 1.06 mmol) except after work-up the organics were loaded directly on to a cation / anion mixed mode cartridge, eluted with DCM then with 2M ammonia in methanol and concentrated *in vacuo*. The resulting residue was purified by reverse phase chromatography (C18 silica, 5 - 100 % water (0.05 %

ammonia) / acetonitrile) then recrystallised from MTBE / heptane to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.44 (s, 3 H), 1.60 - 1.74 (m, 1 H), 1.75 - 2.02 (m, 3 H), 2.12 - 2.23 (m, 1 H), 2.47 - 2.58 (m, 1 H), 4.38 - 4.48 (m, 1 H), 6.23 (br. s., 1 H), 6.97 (br. s., 1 H), 7.24 - 7.29 (m, 1 H), 7.40 - 7.47 (m, 1 H), 7.53 - 7.60 (m, 2 H), 8.08 - 8.12 (m, 1 H), 8.25 (br. s., 1 H), 8.63 - 8.66 (m, 1 H), 8.71 - 8.75 (m, 2 H)

MS ES⁺: 443

Example 157: *N*-[(1*S*,2*S*)-2-[[5-(Difluoromethoxy)pyridin-2-yl]amino]-4,4-difluorocyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide




To a solution of *N*-[(1*S*,2*S*)-2-amino-4,4-difluorocyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide (**Intermediate 46**; 100 mg, 0.33 mmol) in dry toluene (3 ml) was added 2-bromo-5-(difluoromethoxy)pyridine (CAS number 845827-14-7; 89 mg, 0.33 mmol), BINAP (20 mg, 0.033 mmol), tris(dibenzylideneacetone)dipalladium(0) (15 mg, 0.016 mmol) and sodium *tert*-butoxide (44 mg, 0.46 mmol). The reaction was placed under an atmosphere of nitrogen, sealed and heated at 110°C for 2.5 hours then filtered through a thiol cartridge, eluting with ethyl acetate and water. The filtrate was diluted with further ethyl acetate and water and then partitioned. The organics were washed with water, dried over magnesium sulfate, filtered and concentrated *in vacuo*. The crude material was purified by column chromatography (silica, 0-100% ethyl acetate / petrol) then triturated with heptane and diethyl ether to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.88 - 2.23 (m, 2 H), 2.71 - 2.95 (m, 2 H), 4.07 - 4.32 (m, 2 H), 6.19 - 6.69 (m, 2 H), 7.12 - 7.20 (m, 1 H), 7.23 - 7.31 (m, 1 H), 7.43 - 7.53 (m, 2 H), 7.55 - 7.61 (m, 1 H), 7.64 (s, 2 H), 7.75 - 7.82 (m, 2 H)

MS ES⁺: 451

Example 158: *N*-[(1*S*,2*S*)-2-[[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-5-fluoro-2-(pyrimidin-2-yl)benzamide




To a solution of 5-fluoro-2-(pyrimidin-2-yl)benzoic acid (CAS number 1293284-57-7; 53 mg, 0.24 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (33 mg, 0.24 mmol), EDC (46.3 mg, 0.241 mmol) and triethylamine (0.067 ml, 0.48 mmol) in DCM (5 ml) was added (1*S*,2*S*)-1-*N*-[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 41**; 50 mg, 0.161 mmol). The reaction mixture was stirred at room temperature for 88 hours and then partitioned between DCM and a saturated solution of sodium bicarbonate, passing through a hydrophobic frit. The organics were loaded directly on to a cation / anion mixed mode cartridge, eluted with DCM and concentrated *in vacuo*. This was then purified by reverse phase chromatography (C18 silica, 0-100% acetonitrile / water with 0.1% ammonia). The resulting aqueous was concentrated *in vacuo* and extracted with DCM. The organics were concentrated *in vacuo* to afford the title compound.

¹H NMR (400 MHz, METHANOL-*d*₄) δ ppm 1.18 - 1.29 (m, 3 H), 1.55 - 1.73 (m, 2 H), 1.77 - 1.90 (m, 2 H), 2.07 - 2.26 (m, 1 H), 2.29 - 2.41 (m, 1 H), 2.45 - 2.72 (m, 2 H), 4.16 - 4.42 (m, 2 H), 6.99 - 7.05 (m, 1 H), 7.08 - 7.20 (m, 2 H), 7.22 - 7.36 (m, 1 H), 8.03 - 8.18 (m, 2 H), 8.42 - 8.57 (m, 2 H)

MS ES⁺: 475

Example 159: *N*-[(1*S*,2*S*)-2-[[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide




To a solution of (*1S,2S*)-1-*N*-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine hydrochloride (**Intermediate 23**; 100 mg, 0.34 mmol) in DCM (1.2 ml) was added 3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7; 81 mg, 0.40 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (69 mg, 0.51 mmol), EDC (97 mg, 0.51 mmol) and triethylamine (0.14 ml, 1.01 mmol). The reaction was stirred at room temperature for 18 hours and then partitioned between water and DCM, passing through a hydrophobic frit. The organics were concentrated *in vacuo* and then purified by column chromatography (0-100% ethyl acetate / petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.42 - 1.54 (m, 1 H), 1.72 - 1.85 (m, 1 H), 1.86 - 1.97 (m, 2 H), 2.20 (s, 3 H), 2.21 - 2.31 (m, 1 H), 2.52 - 2.64 (m, 1 H), 3.95 - 4.09 (m, 1 H), 4.26 - 4.42 (m, 1 H), 6.66 - 6.76 (m, 1 H), 7.24 - 7.31 (m, 1 H), 7.52 - 7.62 (m, 1 H), 7.98 - 8.08 (m, 2 H), 8.21 (s, 1 H), 8.64 - 8.72 (m, 3 H)

MS ES⁺: 444

Example 160: 2-(5-Methyl-1,3,4-oxadiazol-2-yl)-*N*-[(*1S,2S*)-2-methyl-2-{5-(trifluoromethyl)pyrazin-2-yl}amino}cyclopentyl]benzamide



A solution of 2-(5-methyl-1,3,4-oxadiazol-2-yl)benzoic acid (CAS number 898289-64-0; 82 mg, 0.40 mmol), (*1S,2S*)-1-methyl-1-*N*-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine (**Intermediate 25**; 80 mg, 0.31 mmol), 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (54 mg, 0.40 mmol), EDC (77 mg, 0.40 mmol) and triethylamine (0.13 ml, 0.92 mmol) in DCM (3 ml) was stirred at room temperature for 72 hours. The reaction was diluted with DCM and washed with a saturated solution of sodium bicarbonate, passing through a hydrophobic frit and concentrated *in vacuo*. The crude product was purified by reverse phase chromatography (C18 silica, 5-100% acetonitrile / water with 0.05% ammonia) to afford the title compound.

¹H NMR (400 MHz, DCM-*d*₂) δ ppm 1.36 (s, 3 H), 1.51 - 1.65 (m, 1 H), 1.71 - 1.92 (m, 2 H), 1.94 - 2.05 (m, 1 H), 2.10 - 2.20 (m, 1 H), 2.49 - 2.53 (m, 3 H), 2.55 - 2.65 (m, 1 H),

4.55 - 4.64 (m, 1 H), 6.46 - 6.58 (m, 1 H), 7.51 (br. s., 1 H), 7.59 - 7.67 (m, 3 H), 7.90 - 7.95 (m, 1 H), 7.96 - 7.99 (m, 1 H), 8.23 (s, 1 H)

MS ES⁺: 447

3. Biological efficacy of compounds of the invention

Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca²⁺ sensitive fluorescent dye. The changes in fluorescent signal were monitored by Fluorescent Imaging Plate Reader (FLIPRTM) technology available from Molecular Devices, LLC, U.S.A. Orexin mediated increases in intracellular Ca²⁺ concentration were readily detected upon activation with orexin-A. Twenty-four hours prior to the assay, RBL-2H3 cells stably expressing either human orexin receptor 1 or human orexin receptor 2 were seeded in cell culture medium in black, clear-bottom 384-well plates (commercially available from Corning Inc., U.S.A.) and grown overnight at 37 °C, 5% CO₂. On the day of the assay, cell culture media was removed and cells were loaded with Calcium 5 Dye (commercially sold by Molecular Devices, LLC, U.S.A.) for 1 hour at 37 °C, 5% CO₂. Test compounds (at 10 point half log concentration response curves from 10 μM) were added to cells for 15 minutes prior to the addition of orexin-A to all wells, to achieve a final concentration that produces approximately an 80% maximal response. The IC₅₀ values were determined from ten point concentration response curves. Curves were generated using the average of two wells for each data point. The results obtained are shown in the table below.

Results

Example Number	Human Orexin1R IC ₅₀ (nM)	Human Orexin2R IC ₅₀ (nM)
1	240	>10,000
2	870	>10,000
3	58	>10,000
4	520	>10,000
5	270	>10,000
6	51	>10,000

Example Number	Human Orexin1R IC ₅₀ (nM)	Human Orexin2R IC ₅₀ (nM)
7	51	>10,000
8	110	>10,000
9	340	>10,000
10	59	>10,000
11	170	>10,000
12	65	>10,000
13	99	>10,000
14	89	>10,000
15	49	>10,000
16	54	>10,000
17	53	>10,000
18	57	>10,000
19	757	6105
20	875	>10,000
21	576	6421
22	665	6160
23	792	3800
24	766	>10,000
25	472	>10,000
26	622	>10,000
27	726	2000
28	776	>10,000
29	279	>10,000
30	370	>10,000
31	122	>10,000
32	32	>10,000
33	890	>10,000
34	523	>10,000
35	693	>10,000

Example Number	Human Orexin1R IC ₅₀ (nM)	Human Orexin2R IC ₅₀ (nM)
36	207	>10,000
37	340	>10,000
38	49	>10,000
39	81	>10,000
40	35	>10,000
41	644	>10,000
42	261	>10,000
43	289	>10,000
44	199	>10,000
45	241	>10,000
46	172	>10,000
47	445	>10,000
48	88	>10,000
49	367	>10,000
50	80	>10,000
51	301	>10,000
52	69	>10,000
53	93	>10,000
54	950	>10,000
55	761	>10,000
56	166	>10,000
57	38	>10,000
58	934	>10,000
59	161	>10,000
60	852	>10,000
61	321	>10,000
62	457	>10,000
63	450	>10,000
64	57	>10,000

Example Number	Human Orexin1R IC ₅₀ (nM)	Human Orexin2R IC ₅₀ (nM)
65	797	>10,000
66	180	>10,000
67	891	>10,000
68	297	1610
69	321	>10,000
70	678	>10,000
71	722	7600
72	479	>10,000
73	248	>10,000
74	308	>10,000
75	279	>10,000
76	33	>10,000
77	12	>10,000
78	19	>10,000
79	35	>10,000
80	35	>10,000
81	7	>10,000
82	21	7541
83	2500	1400
84	22	>10,000
85	18	>10,000
86	129	>10,000
87	8	>10,000
88	166	>10,000
89	140	>10,000
90	68	>10,000
91	6	>10,000
92	8	5569
93	35	>10,000


Example Number	Human Orexin1R IC ₅₀ (nM)	Human Orexin2R IC ₅₀ (nM)
94	28	>10,000
95	19	1067
96	86	1356
97	122	>10,000
98	160	>10,000
99	153	>10,000
100	128	>10,000
101	310	>10,000
102	46	>10,000
103	8	7897
105	39	>10,000
106	29	>10,000
107	27	>10,000
108	24	>10,000
109	21	>10,000
110	43	3549
111	34	>10,000
112	476	>10,000
113	67	>10,000
114	997	>10,000
115	175	>10,000
117	406	>10,000
118	368	>10,000
119	22	7800
121	822	>10,000
122	32	>10,000
123	18	>10,000
124	21	>10,000
125	14	>10,000

Example Number	Human Orexin1R IC ₅₀ (nM)	Human Orexin2R IC ₅₀ (nM)
126	119	>10,000
127	68	>10,000
128	33	>10,000
129	633	8753
130	77	>10,000
131	39	>10,000
132	12	>10,000
135	94	>10,000
136	830	>10,000
137	34	>10,000
138	30	>10,000
139	32	>10,000
140	35	>10,000
141	62	>10,000
142	12	8827
143	49	>10,000
144	13	>10,000
145	11	>10,000
146	7	>10,000
147	24	>10,000
148	19	>10,000
149	25	>10,000
150	43	>10,000
151	29	>10,000
153	66	>10,000
154	42	>10,000
155	8	>10,000
156	11	>10,000
157	236	>10,000

Example Number	Human Orexin1R IC₅₀ (nM)	Human Orexin2R IC₅₀ (nM)
158	5	>10,000
159	25	>10,000
160	29	>10,000

CLAIMS

1. A compound of formula



5 wherein

R^1 represents a 5- or 6-membered heteroaryl group optionally substituted by at least one substituent selected from halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkoxy carbonyl, C₁-C₃ alkoxy carbonylamino, C₁-C₃ haloalkyl, C₁-C₃ haloalkoxy, -NR⁴R⁵, C₃-C₆ cycloalkylamino, C₁-C₃ alkylcarbonyloxy, C₁-C₃ alkylcarbonylamino, sulphonamido, C₁-C₃ alkylsulphonyl, C₁-C₃ alkylsulphonylamino and -C(O)NR⁶R⁷;

L represents a bond, CH₂, O or NR¹²;

R^a represents a hydrogen atom or a C₁-C₃ alkyl or C₁-C₃ haloalkyl group;

R^b represents a hydrogen atom or a C₁-C₃ alkyl or C₁-C₃ haloalkyl group;

15 X represents CH₂, CHF or CF₂;

R^2 represents a hydrogen atom or a C₁-C₆ alkyl or C₃-C₆ cycloalkyl group;

R^3 represents a phenyl group or a 5- or 6-membered heteroaryl group, all optionally substituted by at least one substituent independently selected from halogen, hydroxyl, cyano, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ hydroxyalkyl, C₁-C₃ alkoxy,

20 C₁-C₃ haloalkoxy, C₂-C₄ alkenyl, C₁-C₃ alkylcarbonyloxy, C₁-C₃ alkoxy carbonyl, -NR⁸R⁹, -C(O)NR¹⁰R¹¹, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyloxy,

C₃-C₆ cycloalkylmethyl or a 5- or 6-membered heteroaryl group, the heteroaryl group

itself being optionally substituted by at least one substituent independently selected from C₁-C₆ alkyl, C₁-C₆ alkoxy and C₁-C₆ haloalkoxy;

R⁴ and R⁵ each independently represent a hydrogen atom or a C₁-C₃ alkyl or C₃-C₆ cycloalkyl group, or R⁴ and R⁵ may together with the nitrogen atom to which they are
5 attached form a 4- to 7-membered saturated heterocyclic ring optionally substituted by at least one substituent independently selected from halogen, hydroxyl and C₁-C₃ alkoxy;

R⁶ and R⁷ each independently represent a hydrogen atom or a C₁-C₃ alkyl or C₃-C₆ cycloalkyl group, or R⁶ and R⁷ may together with the nitrogen atom to which they are
10 attached form a 4- to 7-membered saturated heterocyclic ring optionally substituted by at least one substituent independently selected from halogen and hydroxyl;

R⁸ and R⁹ each independently represent a hydrogen atom or a C₁-C₃ alkyl or C₃-C₆ cycloalkyl group, or R⁸ and R⁹ may together with the nitrogen atom to which they are
attached form a 4- to 7-membered saturated heterocyclic ring optionally substituted by at least one substituent independently selected from halogen, hydroxyl and C₁-C₃ alkoxy;

15 R¹⁰ and R¹¹ each independently represent a hydrogen atom or a C₁-C₃ alkyl or C₃-C₆ cycloalkyl group, or R¹⁰ and R¹¹ may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring optionally substituted by at least one substituent independently selected from halogen and hydroxyl; and

R¹² represents a hydrogen atom, methyl group or a C₂-C₃ alkylene chain that links to
20 R¹ to form a 5- or 6-membered ring;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein R¹ represents a 5- or 6-membered
25 heteroaryl group containing one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the heteroaryl group being optionally substituted by one or two substituents independently selected from halogen, C₁-C₃ alkyl and C₁-C₃ haloalkyl.

3. A compound according to claim 1, wherein R¹ represents a 5- or 6-membered heteroaryl group selected from pyridinyl, pyrimidinyl and pyrazinyl, all optionally substituted as defined in claim 1.

5

4. A compound according to claim 3, wherein R¹ represents a group selected from:

- (i) 4-(trifluoromethyl)pyridin-2-yl,
- (ii) 5-(trifluoromethyl)pyridin-2-yl,
- (iii) 5-(trifluoromethoxy)pyridin-2-yl,
- 10 (iv) 6-(trifluoromethyl)pyridin-2-yl,
- (v) 6-(trifluoromethyl)pyridin-3-yl,
- (vi) 5-chloropyridin-2-yl,
- (vii) 5-bromopyridin-2-yl,
- (viii) 3-fluoro-5-(trifluoromethyl)pyridin-2-yl,
- 15 (ix) 3-chloro-5-(trifluoromethyl)pyridin-2-yl,
- (x) 3-bromo-5-(trifluoromethyl)pyridin-2-yl,
- (xi) 5-bromo-3-methoxypyridin-2-yl,
- (xii) 3-methyl-5-(trifluoromethyl)pyridin-2-yl,
- (xiii) 5-(trifluoromethyl)pyrimidin-2-yl,
- 20 (xiv) 5-ethylpyrimidin-2-yl,
- (xv) 5-(trifluoromethyl)pyrazin-2-yl,
- (xvi) 5-chloropyrazin-2-yl,
- (xvii) 5-(ethyl)pyrazin-2-yl,
- (xviii) 5-(cyclopropyl)pyrazin-2-yl,
- 25 (xix) 5-(isopropyl)pyrazin-2-yl,
- (xx) 3-methyl-5-(trifluoromethyl)pyrazin-2-yl,
- (xxi) 3-ethyl-5-(trifluoromethyl)pyrazin-2-yl,
- (xxii) 3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl, and
- (xxiii) 3-isopropyl-5-(trifluoromethyl)pyrazin-2-yl.

30

5. A compound according to any one of the preceding claims, wherein X represents CH₂.

6. A compound according to any one of the preceding claims, wherein L represents NH.

7. A compound according to any one of the preceding claims, wherein R² represents
5 a hydrogen atom.

8. A compound according to any one of claims 1 to 7, wherein R³ represents a 5- or 6-
membered heteroaryl group selected from pyridinyl, pyrimidinyl and pyrazinyl, all
optionally substituted as defined in claim 1.

9. A compound according to any one of claims 1 to 7, wherein R³ represents a phenyl
group optionally substituted by at least one substituent independently selected from
fluorine, chlorine, C₁-C₃ alkyl, C₁-C₃ alkoxy or a 5- or 6-membered heteroaryl group,
the heteroaryl group itself being optionally substituted by one or two substituents
15 independently selected from C₁-C₂ alkyl, C₁-C₂ alkoxy and C₁-C₂ haloalkoxy.

10. A compound according to any one of claims 1 to 7, wherein R³ represents a group
selected from:

- (i) 2-fluorophenyl,
- 20 (ii) 2-chlorophenyl,
- (iii) 2-methylphenyl,
- (iv) 2-cyclopropylphenyl,
- (v) 2-methoxyphenyl,
- (vi) 2-ethoxyphenyl,
- 25 (vii) 2-(difluoromethoxy)phenyl,
- (viii) 3-methylphenyl,
- (ix) 3-methoxyphenyl,
- (x) 2,6-difluorophenyl,
- (xi) 2,6-dichlorophenyl,
- 30 (xii) 2,6-dimethoxyphenyl,

- (xiii) 2,6-diethoxyphenyl,
- (xiv) 2-ethoxy-5-methylphenyl,
- (xv) 2,5-dimethoxyphenyl,
- (xvi) 2-fluoro-6-methoxyphenyl,
- 5 (xvii) 5-fluoro-2-methoxyphenyl,
- (xviii) 3-fluoro-2-methoxyphenyl,
- (xix) 2-(1*H*-1,2,4-triazol-1-yl)phenyl,
- (xx) 2-(2*H*-1,2,3-triazol-2-yl)phenyl,
- (xxi) 5-methyl-2-(1*H*-1,2,3-triazol-1-yl)phenyl,
- 10 (xxii) 5-methyl-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
- (xxiii) 5-fluoro-2-(1*H*-1,2,3-triazol-1-yl)phenyl,
- (xxiv) 5-fluoro-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
- (xxv) 2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl,
- (xxvi) 2-(pyrimidin-2-yl)phenyl,
- 15 (xxvii) 5-fluoro-2-(pyrimidin-2-yl)phenyl,
- (xxviii) 2-(1*H*-pyrazol-1-yl)phenyl,
- (xxix) 2-(1*H*-imidazol-1-yl)phenyl,
- (xxx) 2-(1*H*-1,2,3-triazol-1-yl)phenyl,
- (xxxi) 2-(pyrimidin-2-yl)-5-fluorophenyl,
- 20 (xxxii) 2-fluoro-6-(2*H*-1,2,3-triazol-2-yl)phenyl,
- (xxxiii) 2-methoxy-5-methylphenyl,
- (xxxiv) 2-chloro-6-(2*H*-1,2,3-triazol-2-yl)phenyl,
- (xxxv) 2-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl,
- (xxxvi) 5-trifluoromethyl-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
- 25 (xxxvii) 2-fluoro-6-(pyrazol-1-yl)phenyl,
- (xxxviii) 5-fluoro-2-(pyrazol-1-yl)phenyl,
- (xxxix) 5-methyl-2-(pyrazol-1-yl)phenyl,
- (xl) 2-bromo-6-methoxyphenyl,
- (xli) 2-methoxy-6-(pyrazol-1-yl)phenyl,
- 30 (xlii) 5-chloro-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
- (xliii) 3-fluoro-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
- (xliv) 5-trifluoromethyl-2-(1*H*-1,2,3-triazol-1-yl)phenyl,

- (xlv) 5-chloro-2-(1*H*-1,2,3-triazol-1-yl)phenyl,
- (xlvi) 2,3-difluoro-6-(2*H*-1,2,3-triazol-2-yl)phenyl,
- (xlvii) 5-cyclopropyl-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
- (xlviii) 5-chloro-2-(pyrazol-1-yl)phenyl,
- 5 (xlix) 3,5-difluoro-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
 - (l) 2-(difluoromethyl)phenyl,
 - (li) 2-(trifluoromethyl)phenyl,
 - (lii) 3,6-difluoro-2-(2*H*-1,2,3-triazol-2-yl)phenyl,
 - (liii) 2-cyclopropyl-6-fluorophenyl,
- 10 (liv) 2-(5-ethoxypyrimidin-2-yl)phenyl,
 - (lv) 3-(pyrimidin-2-yl)pyridin-2-yl,
 - (lvi) 3-ethoxy-6-methylpyridin-2-yl,
 - (lvii) 3-(pyrazol-1-yl)pyridin-2-yl,
 - (lviii) 3-(piperidin-1-yl)pyridin-2-yl,
- 15 (lix) 3-(trifluoromethoxy)pyridin-2-yl,
 - (lx) 3-(ethoxy)pyridin-2-yl,
 - (lxi) 3-(cyclopropyl)pyridin-2-yl,
 - (lxii) 3-chloropyridin-2-yl,
 - (lxiii) 3-bromopyridin-2-yl,
- 20 (lxiv) 3-methoxypyridin-2-yl,
 - (lxv) 3-(propan-2-yloxy)pyridin-2-yl,
 - (lxvi) 6-bromo-3-methoxypyridin-2-yl,
 - (lxvii) 3-methoxy-6-methylpyridin-2-yl, and
 - (lxviii) 3-(2*H*-1,2,3-triazol-2-yl)pyridin-2-yl.

25

11. A compound of formula (I) as defined in claim 1 selected from the group consisting of:

2,6-Dimethoxy-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

30

2,6-Dimethoxy-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;

5-Methyl-2-(2H-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;

N-[(1*S*,2*S*)-2-{(5-Ethylpyrimidin-2-yl)amino}cyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

5 *N*-[(1*S*,2*S*)-2-{(5-Chloropyridin-2-yl)amino}cyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

5-Methyl-2-(2H-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

10 5-Methyl-2-(2H-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-(3-Methyl-1,2,4-oxadiazol-5-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

N-[(1*S*,2*S*)-2-{(5-Chloropyrazin-2-yl)amino}cyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

15 5-Fluoro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

2-(1H-Pyrazol-1-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

20 2-(2H-1,2,3-Triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

2-(Pyrimidin-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

5-Fluoro-2-(pyrimidin-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

25 2-(3-Methyl-1,2,4-oxadiazol-5-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-(3-Methyl-1,2,4-oxadiazol-5-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;

30 2-(2H-1,2,3-Triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-(2H-1,2,3-Triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;

2-(2H-1,2,3-Triazol-2-yl)-*N*-[(*1S,2R*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]oxy}cyclopentyl]benzamide;

2-(2H-1,2,3-Triazol-2-yl)-*N*-[(*1S,2S*)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopentyl]benzamide;

5 2,6-Dimethoxy-*N*-[(*1S,2S*)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopentyl]benzamide;

2-(2H-1,2,3-Triazol-2-yl)-*N*-(2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide;

10 2-(2H-1,2,3-Triazol-2-yl)-*N*-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide;

5-Methyl-2-(2H-1,2,3-triazol-2-yl)-*N*-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide;

2,6-Dimethoxy-*N*-[(*1S,2S*)-2-{[6-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

15 3-Bromo-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

2-Ethoxy-5-methyl-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

20 3-Ethoxy-6-methyl-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

2-(1H-Pyrazol-1-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-Fluoro-6-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

25 2,6-Difluoro-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2,6-Dimethoxy-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

30 2-(1H-1,2,3-Triazol-1-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5-Fluoro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-Methoxy-5-methyl-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-(Pyrimidin-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5 5-Fluoro-2-(pyrimidin-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-Chloro-6-(2*H*-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

10 5-Fluoro-2-(1*H*-1,2,3-triazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5-Methyl-2-(1*H*-1,2,3-triazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

3-(1*H*-Pyrazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

15 2-(5-Methyl-1,3,4-oxadiazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-(2*H*-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

20 2-Fluoro-6-(1*H*-pyrazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5-Fluoro-2-(1*H*-pyrazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5-Methyl-2-(1*H*-pyrazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

25 2-Bromo-6-methoxy-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-Methoxy-6-(1*H*-pyrazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

30 3-(Piperidin-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

5-Chloro-2-(2*H*-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

3-Fluoro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-(1H-1,2,3-Triazol-1-yl)-5-(trifluoromethyl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

5 5-Chloro-2-(1H-1,2,3-triazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2,3-Difluoro-6-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

10 5-Cyclopropyl-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

3-(Trifluoromethoxy)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

5-Chloro-2-(1H-pyrazol-1-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

15 3-Ethoxy-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

3,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

20 2-(Trifluoromethyl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

3-Cyclopropyl-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

3,6-Difluoro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

25 2-(Difluoromethyl)-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-Cyclopropyl-6-fluoro-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

30 5-Methyl-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S*,2*S*)-2-{[6-(trifluoromethyl)pyridin-3-yl]amino}cyclopentyl]benzamide;

N-Cyclobutyl-2,6-dimethoxy-*N*-[(*1S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

2-Chloro-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

2-Chloro-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;

5 2-Fluoro-6-methoxy-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

2,6-Difluoro-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

10 *N*-[(*1S,2S*)-2-{Methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

5-Fluoro-*N*-[(*1S,2S*)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

2-Fluoro-*N*-[(*1S,2S*)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-6-(2H-1,2,3-triazol-2-yl)benzamide;

15 *N*-[(*1S,2S*)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

N-[(*1S,2S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

20 *N*-[(*1S,2S*)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-[(*1S,2S*)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;

5-Fluoro-*N*-[(*1S,2S*)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;

25 *N*-[(*1S,2S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-(2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;

30 *N*-[(*1R,2R*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

5-Fluoro-*N*-[(*1S,2S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-[(1*S*,2*S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(1*H*-pyrazol-1-yl)pyridine-2-carboxamide;

3-Ethoxy-*N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide,

5 2-Chloro-*N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-6-(2*H*-1,2,3-triazol-2-yl)benzamide;

2,6-Difluoro-*N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

3-Cyclopropyl-*N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(trifluoromethoxy)pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;

15 5-Chloro-*N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

20 *N*-(2-Methyl-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl)-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

5-Chloro-2-(2*H*-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

25 3-Fluoro-2-(2*H*-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

3,5-Difluoro-2-(2*H*-1,2,3-triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

3-(2*H*-1,2,3-Triazol-2-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

3-(1*H*-Pyrazol-1-yl)-*N*-[(1*S*,2*S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;

2-Fluoro-6-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

N-(2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopentyl)-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

5 *N*-[(*1S,2S*)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-[(*1S,2S*)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

10 *N*-[(*1S,2S*)-2-{[3-Bromo-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-[(*1S,2S*)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-[(*1S,2S*)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

15 *N*-[(*1S,2S*)-2-{[3-(Propan-2-yl)-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-[(*1S,2S*)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

20 *N*-[(*1S,2S*)-2-[(5-Cyclopropylpyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-[(*1S,2S*)-2-{[5-(Propan-2-yl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-[(*1S,2S*)-2-[(5-Ethylpyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

25 2-(2H-1,2,3-Triazol-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]benzamide;

5-Chloro-2-(2H-1,2,3-triazol-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]benzamide;

30 *N*-[(*1S,2S*)-2-[(5-Bromopyridin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-[(*1S,2S*)-2-[(5-Bromo-3-methoxypyridin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

2-(2H-1,2,3-Triazol-2-yl)-*N*-[(*1S,2S*)-2-{[4-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;

N-[(*1S,2S*)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

5 *N*-[(*1S,2S*)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

N-[(*1S,2S*)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

10 *N*-[(*1S,2S*)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;

15 *N*-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;

N-[(*1S,2S*)-4,4-Difluoro-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

20 *N*-[(*1S,2S*)-4,4-Difluoro-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;

2-(5-Ethoxypyrimidin-2-yl)-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

2-Fluoro-6-methoxy-*N*-[(*1S,2S*)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

25 *N*-[(*1S,2S*)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

N-[(*1S,2S*)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;

30 5-Fluoro-*N*-[(*1S,2S*)-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;

N-[(*1S,2S*)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide;

2-(3-Methyl-1,2,4-oxadiazol-5-yl)-*N*-[(1*S*,2*S*)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

N-[(1*S*,2*S*)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

5 *N*-[(1*S*,2*S*)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

10 2-(3-Methyl-1,2,4-oxadiazol-5-yl)-*N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;

N-(2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

15 *N*-[(1*S*,2*S*)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide;

20 *N*-[(1*S*,2*S*)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;

N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

25 *N*-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-3-(2*H*-1,2,3-triazol-2-yl)pyridine-2-carboxamide;

30 *N*-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

N-[(1*S*,2*S*)-2-{[5-(Difluoromethoxy)pyridin-2-yl]amino}-4,4-difluorocyclopentyl]-2-(2*H*-1,2,3-triazol-2-yl)benzamide;

N-[(1*S*,2*S*)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-5-fluoro-2-(pyrimidin-2-yl)benzamide;


N-[(1*S*,2*S*)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;

2-(5-Methyl-1,3,4-oxadiazol-2-yl)-*N*-[(1*S*,2*S*)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;


enantiomers thereof and pharmaceutically acceptable salts of any of the foregoing.

12. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in any one of the preceding claims, which comprises

(i) reacting a compound of formula




wherein L, X, R^a, R^b, R¹ and R² are as defined in formula (I), with a compound of formula



wherein R²⁰ represents a halogen atom or a hydroxyl group and R³ is as defined in formula (I), or a salt thereof; or

(ii) when L represents NH or N(CH₃), reacting a compound of formula



wherein R^{25} represents a hydrogen atom or methyl group and X, R^a , R^b , R^2 and R^3 are as defined in formula (I), with a compound of formula (V), $R^1 - LG^1$, wherein LG^1 represents a leaving group and R^1 is as defined in formula (I);

- 5 and optionally thereafter carrying out one or more of the following procedures:
- converting a compound of formula (I) into another compound of formula (I)
 - removing any protecting groups
 - forming a pharmaceutically acceptable salt.
- 10 13. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 11, in association with a pharmaceutically acceptable adjuvant, diluent or carrier, and optionally one or more other therapeutic agents.
- 15 14. A composition according to claim 13, wherein the one or more other therapeutic agents are selected from carbamazepine, olanzapine, quetiapine, verapamil, lamotrigine, oxcarbazepine, risperidone, aripiprazole, ziprasidone and lithium.
- 20 15. A compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 11 for use in treating schizophrenia, schizophreniform disorder, schizoaffective disorder, cognitive disorders or pain.
- 25 16. A compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 11 for use in treating post-traumatic stress disorder, panic disorders or addiction.

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2015/050480

A. CLASSIFICATION OF SUBJECT MATTER INV. C07D213/74 C07D239/42 C07D249/06 C07D271/07 C07D231/12 A61K31/44 A61K31/506 A61P25/18 ADD. According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07D C07C Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, CHEM ABS Data, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PALOMBA, MICHELE ET AL: "Anti-inflammatory and analgesic amides. New developments", XP002724962, retrieved from STN Database accession no. 2000:45655 abstract -/--	1-16
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 12 May 2015		Date of mailing of the international search report 26/05/2015
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Panday, Narendra

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2015/050480

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	& PALOMBA, MICHELE ET AL: "Anti-inflammatory and analgesic amides. New developments", ARCHIV DER PHARMAZIE (WEINHEIM, GERMANY) , 333(1), 17-26 CODEN: ARPMAS; ISSN: 0365-6233, 2000, DOI: 10.1002/(SICI)1521-4184(200001)333:1<17::A ID-ARDP17>3.0.CO;2-0 10.1002/(SICI)1521-4184(200001)333:1<17::A ID-ARDP17>3.0.CO;2-0 -----	
A	WO 2008/038841 A1 (JAPAN TOBACCO INC [JP]; KIKUCHI SHINICHI [JP]; MATSUI TAKUYA [JP]; INO) 3 April 2008 (2008-04-03) page 219 - page 366; table 1 -----	1-16
A	RONG JIANG ET AL: "Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 22, no. 12, 27 April 2012 (2012-04-27), pages 3890-3894, XP028509301, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2012.04.122 [retrieved on 2012-05-04] the whole document -----	1-16
A	SIFFERLEN THIERRY ET AL: "Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Pa", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24, no. 4, 30 December 2013 (2013-12-30), pages 1201-1208, XP028606685, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2013.12.092 the whole document -----	1-16
A	C J WINROW ET AL: "Discovery and development of orexin receptor antagonists as therapeutics for insomnia", BRITISH JOURNAL OF PHARMACOLOGY, vol. 171, no. 2, 23 December 2013 (2013-12-23), pages 283-293, XP055120026, ISSN: 0007-1188, DOI: 10.1111/bph.12261 Almorexant, SB-649868 -----	1-16
	----- -/--	

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2015/050480

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHRISTOPHER, JOHN A: "Orexin receptor antagonist", PHARM. PAT. ANALYST, vol. 1, no. 3, 2012, XP009178221, page 330; figure 1; compounds 1,2 page 335 - page 336; figures 5, 6; compounds 38, 40, 41, 43-54 -----	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2015/050480

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2008038841	A1	03-04-2008	NONE
